Document:

Document

Exhibit 10.2

ANYWHERE REAL ESTATE INC.
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is hereby entered into as of August 4, 2022, by and between  Anywhere Real Estate Inc.(the “Company”) and Ryan M. Schneider (“Executive”) (hereinafter collectively referred to as the “Parties”).
In consideration of the respective agreements of the Parties contained herein, it is agreed as follows:
1. Term. The term of employment commenced on March 11, 2020 (the “Effective Date”) and shall end on the date of termination of employment pursuant to Section 5 (the “Term”).
2. Employment. During the Term:
(a) Executive shall be assigned with the duties and responsibilities of President and Chief Executive Officer, including the duties and responsibilities of such office as may reasonably be assigned to Executive from time to time by the Board of Directors of the Company (the “Board”). Executive shall perform such duties, undertake the responsibilities, and exercise the authorities customarily performed, undertaken and exercised by persons situated in a similar executive capacity at a similar company. In performing Executive’s duties hereunder, Executive shall report solely and directly to the Board. Executive shall serve as a member of the Board and as a director and/or officer of certain of the Company’s Affiliates and will fulfill his duties as such director or officer without additional compensation. During the Term, the Company shall cause Executive to be nominated to the Board and support his reelection.
(b) Executive shall devote Executive’s full-time business attention to the business and affairs of the Company and its Affiliates and shall use Executive’s best efforts to faithfully and diligently serve the business and affairs of the Company and its Affiliates. Notwithstanding the foregoing, Executive may, subject to the Company’s policy as in effect from time to time, (i) serve on civic, charitable or non-profit boards or committees, (ii) serve on for-profit boards or committees, subject to the approval of the Nominating and Corporate Governance Committee or with respect to service on public boards, the Board, which approval shall not be unreasonably withheld or delayed, and (iii) manage personal and family investments and affairs, participate in industry organizations and deliver lectures at educational institutions, in each case so long as such service and activity does not materially interfere, individually or in the aggregate, with the performance of his responsibilities hereunder and subject to the code of conduct and other applicable policies of the Company and its Affiliates as in effect from time to time.
(c) Executive shall be subject to and shall abide by each of the personnel and compliance policies of the Company and its Affiliates applicable and communicated in writing to senior executives, including, without limitation, the Company’s Clawback Policy as in effect from time to time.
3. Annual Compensation.
(a) Base Salary. The Company agrees to pay or cause to be paid to Executive during the Term a base salary at the rate of $1,000,000 per annum or such increased amount as the Compensation Committee of the Board (the “Committee”) may from time to time determine (the “Base Salary”); provided, however, Executive’s Base Salary may be reduced up to 10% in connection with a broader compensation reduction that applies similarly to all senior executives of the Company, following 
1

consultation with Executive. Such Base Salary shall be payable in accordance with the Company’s customary practices applicable to its executives, but no less frequently than monthly.
(b) Incentive Compensation. For each successive fiscal year of the Company ending during the Term, Executive shall be eligible to receive annual cash incentive compensation (the “Incentive Compensation”) subject to and in accordance with the terms of the applicable annual cash bonus plan as in effect from time to time, as approved by the Committee, which may include payments based upon Company performance measures and/or Executive’s relative individual performance. For 2022 and each successive fiscal year of the Company ending during the Term, Executive shall be eligible to receive a target annual cash bonus of 200% of “eligible earnings” (as defined below), as may hereafter be increased (the “Target Bonus”), with the opportunity to receive a maximum annual cash bonus subject to and in accordance with the terms of the applicable annual cash bonus plan as in effect from time to time. For purposes of this Agreement, “eligible earnings” in respect of such bonus year shall be calculated in accordance with the applicable annual cash bonus plan as in effect from time to time. Such annual cash bonus shall be paid in no event later than March 15th of the taxable year following the end of the taxable year to which the performance targets relate, provided that Executive is employed by the Company or one of its Affiliates through the date specified in the annual cash bonus plan (or, if earlier, the expiration of the Term) and any performance targets established by the Committee for the applicable fiscal year have been achieved.
(c) Long-Term Incentive Compensation. Executive may be eligible for long-term incentive compensation awards as determined by the Committee, including with respect to composition and terms of the grants. Executive’s long-term incentive award may be allocated across various equity vehicles. In the event that the Committee determines to provide an alternative incentive program to the senior executive team, Executive will be treated under that program in a manner commensurate with his position with the Company.
4. Other Benefits.
(a) Employee Benefits. During the Term, Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company or its Affiliates and made available to employees of the Company generally, including, without limitation, all retirement, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit, and vacation/paid time-off plans and policies, to the extent Executive is eligible under the terms of such plans. Executive’s participation in such plans, practices and programs shall be commensurate with Executive’s position at the Company. Executive shall also be entitled to participate in a death and dismemberment benefit plan that shall provide death and dismemberment insurance in the amount of two and a half times Executive’s Base Salary at the time of death or dismemberment up to $2 million, subject to Executive’s eligibility of insurability. For the avoidance of doubt, Executive shall not be entitled to any excise tax gross-up under Section 280G or 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (or any successor provision) or any other tax gross-up.
(b) Business Expenses. Upon submission of proper invoices in accordance with the Company’s normal procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by Executive in connection with the performance of Executive’s duties hereunder that have been incurred in accordance with the Company’s business expense and travel and entertainment policies in effect from time to time. Such reimbursement shall be made as soon as practicable and in no event later than the end of the calendar year following the calendar year in which the expenses were incurred.
2

5. Termination. The Term and Executive’s employment hereunder may be terminated under the circumstances set forth below; provided, however, that notwithstanding anything contained herein to the contrary, Executive shall not have any duties or responsibilities to the Company after Executive’s termination of employment that would preclude Executive from having a “separation from service” from the Company within the meaning of Section 409A of the Code, upon such termination of employment.
(a) Disability. The Company may terminate Executive’s employment, on written notice to Executive after having reasonably established Executive’s Disability (as defined below). For purposes of this Agreement, “Disability” means (i) Executive’s inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) Executive is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident or health plan covering employees of the Company. Whether Executive has incurred a “Disability” shall be determined by a physician selected by the Company or its insurers. Executive shall be entitled to the compensation and benefits provided for under this Agreement for any period prior to Executive’s termination by reason of Disability during which Executive is unable to work due to a physical or mental infirmity in accordance with the Company’s policies for similarly-situated executives (without duplication of compensation and benefits payable under any applicable disability policies).
(b) Death. Executive’s employment shall be terminated as of the date of Executive’s death.
(c) Cause. The Company may terminate Executive’s employment for “Cause” by providing a Notice of Termination (as defined in Section 7 below) that notifies Executive of his termination for Cause (as defined below), effective as of the date of such notice. For purposes of this Agreement, “Cause” shall mean (i) Executive’s willful failure to substantially perform his duties as an employee of the Company or any subsidiary (other than any such failure resulting from incapacity due to physical or mental illness), (ii) any act of fraud, misappropriation, dishonesty, embezzlement or similar conduct against the Company or any subsidiary, (iii) Executive’s conviction of, or plea of guilty or nolo contendere to a charge of commission of, a felony or crime involving moral turpitude, (iv) Executive’s indictment for a charge of commission of a felony or any crime involving moral turpitude, (v) Executive’s gross negligence in the performance of his duties, (vi) Executive purposefully or negligently makes (or has been found to have made) a false certification to the Company pertaining to its financial statements, (vii) the habitual use of drugs or habitual, excessive use of alcohol to the extent that any of such uses in the Board’s good faith determination materially interferes with the performance of Executive’s duties under this Agreement, (viii) a breach of fiduciary duty and/or (ix) a material breach by Executive of any of the terms and conditions of this Agreement or a material breach of any of Executive’s representations in this Agreement. A termination will not be for “Cause” pursuant to clause (i), (ii), (v) or (ix), to the extent such conduct is curable, unless the Company shall have notified Executive in writing describing such conduct and Executive shall have failed to cure such conduct within ten (10) business days after his receipt of such written notice. Executive may only be terminated for Cause by a resolution of the Board.
(d) Without Cause; Disability; Death. The Company may terminate Executive’s employment other than for Cause, Disability or death. The Company shall deliver to Executive a Notice of Termination and the Company may, in its sole discretion, select any date within 60 days of such notice as the effective date for Executive’s termination of employment other than for Cause, Disability or death.
3

(e) Termination by Executive Without Good Reason. Executive may voluntarily terminate Executive’s employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive’s employment, and the Company may, in its sole discretion, select any date within such notice period as the effective date for Executive’s termination of employment without Good Reason.
(f) Termination by Executive for Good Reason. Executive may terminate employment with the Company for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive’s employment for Good Reason. The Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration of such thirty-day notice period. For purposes of this Agreement, “Good Reason” means voluntary resignation after any of the following actions taken by the Company or any of its subsidiaries without Executive’s consent: (i) a material reduction of Executive’s duties and responsibilities to the Company or Executive’s title or position or reporting (other than any such material reduction resulting from incapacity due to physical or mental illness); (ii) a reduction in Base Salary or Target Bonus opportunity (not including any diminution in Base Salary permitted by Section 3(a) of this Agreement); (iii) a material breach by the Company of a material provision of this Agreement; (iv) the Executive’s removal from, or failure to be nominated or re-elected to, the Board; or (v) if occurring on or after a Change in Control, the relocation of Executive’s primary office to a location more than twenty (20) miles from the prior location and Executive’s commute increases as a result of such relocation. Executive shall provide notice of the existence of the Good Reason condition within ninety (90) days of the date Executive learns of the condition, and the Company shall have a period of thirty (30) days during which it may remedy the condition, and in case of full remedy such condition shall not be deemed to constitute Good Reason hereunder. In the event the Company is unable to remedy the Good Reason condition in all material respects within the thirty (30) day period, Executive may terminate employment with the Company for Good Reason within thirty (30) days following the expiration of such thirty (30) day period.
(g) Termination by Executive for Retirement. Executive may voluntarily terminate Executive’s employment due to Retirement (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive’s employment, and the Company may, in its sole discretion, select any date within such notice period as the effective date for Executive’s termination of employment due to Retirement. For purposes of this Agreement, “Retirement” means a termination of employment (other than for Cause) after attaining eligibility for Retirement. Executive attains eligibility for Retirement upon the earlier of (i) age 65 or (ii) age 55 with at least ten (10) whole years of consecutive service with the Company and all Affiliates. For the avoidance of doubt, the phrase “consecutive service” in the preceding sentence shall not include time spent by Executive (x) as a consultant or advisor to the Company or its Affiliates following a “separation from service” within the meaning of Section 409A of the Code; or (y) engaged as an independent sales agent affiliated with one of the Company’s or its Affiliates’ real estate brands.
6. Notice of Termination. Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination (as defined below) to the other Party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice that indicates a termination date, the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated. For purposes of this Agreement, no such purported termination of Executive’s employment hereunder shall be effective without such Notice of Termination (unless waived by the Party entitled to receive such notice, in the manner described in Section 12(j) below).
4

7. Compensation Upon Termination. Upon Executive’s termination of employment pursuant to Section 5, Executive shall be eligible to receive the compensation under this Section 7.
(a) Termination by the Company for Cause or by Executive Other Than for Good Reason. If Executive’s employment is terminated (A) by the Company for Cause or (B) by Executive for any reason, other than for Good Reason, in either case, during the Term, the Company shall provide Executive with the following payments and benefits:
(i) any accrued and unpaid Base Salary;
(ii) except in the event a termination of employment by the company for Cause, any annual bonus earned but unpaid in respect of any completed fiscal year preceding the termination date;
(iii) reimbursement for any and all monies advanced or expenses incurred in connection with Executive’s employment for reasonable expenses incurred by Executive on behalf of the Company for the period ending on the termination date in accordance with the Company’s expense reimbursement and travel and entertainment policies in effect from time to time;
(iv) any accrued and unpaid vacation pay in accordance with the terms of the Company’s vacation policy as in effect from time to time;
(v) any previous compensation that Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect, to the extent vested as of Executive’s termination date; and
(vi) any amount or benefit as provided under any plan, program, agreement or corporate governance document of the Company or its Affiliates that are then-applicable, in accordance with the terms thereof.
(the foregoing items in Sections 7(a)(i) through 7(a)(vi) being collectively referred to as the “Accrued Compensation”).
(b) Termination by the Company for Disability. If Executive’s employment is terminated by the Company for Disability during the Term, the Company shall pay or provide to Executive:
(i) the Accrued Compensation; and
(ii) an amount equal to the Incentive Compensation that Executive would have been entitled to receive in respect of the fiscal year in which Executive’s termination date occurs, had Executive continued in employment through the date the payment is made, which amount, determined based on the Company’s actual performance for such year relative to the performance goals applicable to Executive shall be multiplied by a fraction (A) the numerator of which is the number of days in such fiscal year through termination date and (B) the denominator of which is 365 (the “Pro-Rata Bonus”) and shall be payable in a lump sum payment at the time such bonus or incentive awards are payable to other participants.
(c) Termination By Reason of Death. If Executive’s employment is terminated by reason of Executive’s death during the Term, the Company shall pay or provide to Executive’s beneficiaries:
(i) the Accrued Compensation;
5

(ii) the Pro-Rata Bonus payable in a lump sum at the time such bonus or incentive awards are payable to other participants; and
(iii) a death insurance benefit in the amount of two and a half times Executive’s Base Salary at the time of death (which shall be inclusive of any Company provided life insurance policy applicable to Executive) up to $2 million, subject to Executive’s eligibility of insurability.
(d) Termination by the Company Without Cause or by Executive for Good Reason Not In Connection With a Change in Control. If Executive’s employment is terminated by the Company without Cause (other than on account of Executive’s death or Disability) or by Executive for Good Reason, in either case, not in connection with a Change in Control (as defined in Section 7(e)) during the Term, Executive shall be entitled to the benefits provided in this Section 7(d):
(i) the Accrued Compensation;
(ii) the Pro-Rata Bonus payable in a lump sum at the time such bonus or incentive awards are payable to other participants;
(iii) subject to Executive’s compliance with Sections 9 and 12(h) hereof, a payment equal to two times the sum of Executive’s Base Salary and Target Bonus (as defined below) as in effect immediately prior to Executive’s termination of employment (or if greater, the Base Salary as in effect immediately preceding the occurrence of the Good Reason condition) and such payment shall be made in twenty-four equal monthly installments, with the first installment payable in the first regular payroll occurring following the sixtieth (60th) day following such termination of employment;
(iv) subject to Executive’s compliance with Sections 9 and 12(h) hereof, the Company shall provide Executive and Executive’s dependents, if applicable, with continued coverage under the terms of the medical or dental program or policy as in effect from time to time at the Company for eighteen (18) months following such termination (which such 18 month period shall run concurrently with the COBRA period and which coverage shall become secondary to any Medicare coverage for which Executive becomes eligible) and Executive shall pay for such benefits at the same cost that active employees of the Company are required to pay for such benefits from time to time; provided, however, the Parties agree to cooperate such that the continued coverage is, to the extent practicable, provided in a manner so as to minimize adverse tax consequences to the Company under Section 4980D of the Code; provided, further, continued coverage shall cease at such time as Executive becomes eligible for coverage with a subsequent employer; and
(v) subject to Executive’s compliance with Sections 9 and 12(h) hereof, the Company shall provide for the 12-month period beginning on the date on which Executive’s employment terminates, or until Executive begins other full-time employment with a new employer, whichever occurs first, outplacement services that are directly related to the type of services Executive provided to the Company and are actually provided by an outplacement services firm, paid by the Company; provided, however, the cost of the outplacement services may not exceed $50,000.
(e) Termination by the Company Without Cause or by Executive for Good Reason Following a Change in Control. If, during the Term, (i) Executive’s employment is terminated by the Company without Cause (other than on account of Executive’s death or Disability) within twenty-four (24) calendar months following a Change in Control, (ii) Executive’s employment is terminated by Executive for Good Reason within twenty-four (24) months following a Change in Control, (iii) Executive’s employment is terminated by the Company without Cause (other than on account of 
6

Executive’s death or Disability) prior to a Change in Control (but, only if a Change in Control occurs) and such termination is otherwise in connection with or in anticipation of a Change in Control or is at the request or direction of a Person who has entered into an agreement with the Company the consummation of which would constitute a Change in Control, or (iv) Executive’s employment is terminated by Executive for Good Reason prior to a Change in Control (but, only if a Change in Control occurs) and such termination is otherwise in connection with or in anticipation of a Change in Control or the circumstance or event which constitutes Good Reason occurs at the request or direction of a Person who has entered into an agreement with the Company the consummation of which would constitute a Change in Control, Executive shall be entitled to the benefits provided in this Section 7(e):
(i) the Accrued Compensation;
(ii) the Pro-Rata Bonus payable in a lump sum at the time such bonus or incentive awards are payable to other participants;
(iii) subject to Executive’s compliance with Sections 9 and 12(h) hereof, a payment equal to two times the sum of Executive’s Base Salary and Target Bonus as in effect immediately prior to Executive’s termination of employment (or if greater, the Base Salary as in effect immediately preceding the occurrence of the Good Reason condition) payable in a lump sum in the first regular payroll occurring following the sixtieth (60th) day following such termination of employment; provided, however, if the Change in Control is not a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company under Section 409A of the Code, then the payments shall be made in twenty-four equal monthly installments;
(iv) subject to Executive’s compliance with Sections 9 and 12(h) hereof, the Company shall provide Executive and Executive’s dependents, if applicable, with continued coverage under the terms of the medical or dental program or policy as in effect from time to time at the Company for eighteen (18) months following such termination (which such 18 month period shall run concurrently with the COBRA period and which coverage shall become secondary to any Medicare coverage for which Executive becomes eligible) and Executive shall pay for such benefits at the same cost that active employees of the Company are required to pay for such benefits from time to time; provided, however, the Parties agree to cooperate such that the continued coverage is, to the extent practicable, provided in a manner so as to minimize adverse tax consequences to the Company under Section 4980D of the Code; provided, further, continued coverage shall cease at such time as Executive becomes eligible for coverage with a subsequent employer; and
(v) subject to Executive’s compliance with Sections 9 and 12(h) hereof, the Company shall provide for the 12-month period beginning on the date on which Executive’s employment terminates, or until Executive begins other full-time employment with a new employer, whichever occurs first, outplacement services that are directly related to the type of services Executive provided to the Company and are actually provided by an outplacement services firm, paid by the Company; provided, however, the cost of the outplacement services may not exceed $50,000.
For purposes of this Agreement, a “Change in Control” shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:
(I) the acquisition (other than from the Company), by any person (as such term is defined in Section 13(c) or 14(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more 
7

than fifty percent (50%) of the combined voting power of the Company’s then outstanding voting securities; or
(II) the members of the Incumbent Board (as defined herein) cease for any reason to constitute at least a majority of the Board (For purposes of this Agreement, the term “Incumbent Board” shall mean the directors who, as of the Effective Date, are members of the Board and any new director, other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of members of the Board, whose appointment or election by the Board or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least a majority of the Board then still in office who either were directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended); or
(III) there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, if (1) the shareholders of the Company, immediately before such merger or consolidation, do not, as a result of such merger or consolidation, own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the entity resulting from such merger or consolidation in substantially the same proportion as their ownership of the combined voting power of the voting securities of the Company outstanding immediately before such merger or consolidation or (2) immediately following the merger or consolidation, the individuals who comprised the Board immediately prior thereto do not constitute at least a majority of the board of directors of the entity resulting from such merger or consolidation (or, if the entity resulting from such merger or consolidation is then a subsidiary, the ultimate parent thereof); or
(IV) a complete liquidation or dissolution of the Company or the closing of an agreement for the sale or other disposition of all or substantially all of the assets of the Company.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities is acquired by (x) a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries or (y) any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the shareholders of the Company in the same proportion as their ownership of shares in the Company immediately prior to such acquisition.
(f) Termination by Executive for Retirement. If Executive’s employment is terminated due to Executive’s Retirement during the Term, the Company shall provide Executive with the following payments and benefits:
(i) the Accrued Compensation; and
(ii) the Pro-Rata Bonus payable in a lump sum at the time such bonus or incentive awards are payable to other participants.
For the avoidance of doubt, Executive’s Retirement during the Term shall not be deemed a termination of employment other than for Cause, Disability or death or a termination of employment for Good Reason.
(g) No Mitigation. Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other employment or otherwise and, except as provided in 
8

Sections 7(d)(iv) or (v) or 7(e)(iv) or (v) above, no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.
(h) Survival. The Company’s obligations under this Section 7 shall survive the termination of the Term for any termination of employment occurring prior to the expiration of the Term as used in this Section 7.
8. Certain Tax Treatment.
(a) Reduction of Payments in Certain Circumstances. Notwithstanding anything to the contrary contained herein (or any other agreement entered into by and between the Company and Executive, or any incentive arrangement or plan offered by the Company), in the event that any amount or benefit paid or distributed to Executive pursuant to this Agreement, taken together with any amounts or benefits otherwise paid to Executive by the Company or any Affiliate of the Company (collectively, the “Covered Payments”), would constitute an “excess parachute payment” as defined in Section 280G of the Code, and would thereby subject Executive to an excise tax under Section 4999 of the Code (an “Excise Tax”), the provisions of this Section 8 shall apply. If the aggregate present value (as determined for purposes of Section 280G of the Code) of the Covered Payments exceeds the amount which can be paid to Executive without Executive incurring an Excise Tax, then, solely to the extent that Executive would be better off on an after tax basis by receiving the maximum amount which may be paid hereunder without Executive becoming subject to the Excise Tax, as determined by a nationally recognized accounting firm designated by the Company (the “Accounting Firm”) with the consent of the Executive (which consent shall not be unreasonably withheld or delayed), the amounts payable to Executive under this Agreement (or any other agreement by and between the Executive and Company or any of its Affiliates or pursuant to any incentive arrangement or plan offered by the Company or any of its Affiliates) shall be reduced (but not below zero) to the maximum amount which may be paid hereunder without Executive becoming subject to the Excise Tax (such reduced payments to be referred to as the “Payment Cap”). In the event Executive receives reduced payments and benefits as a result of application of this Section 8, Executive shall have the right to designate which of the payments and benefits otherwise set forth herein (or any other agreement between the Company and Executive or any incentive arrangement or plan offered by the Company) shall be received in connection with the application of the Payment Cap, subject to the following sentence. Reduction shall be made in the following order: (i) at the discretion of Executive, payments that are valued in full under Treasury Regulation Section 1.280G-1, Q&A 24 and are not subject to Section 409A of the Code, (ii) payments that are valued in full under Treasury Regulation Section 1.280G-1, Q&A 24 and are subject to Section 409A of the Code, with the amounts that are payable last reduced first, (iii) at the discretion of Executive, payments that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24 and are not subject to Section 409A of the Code and (iv) payments that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24 and are subject to Section 409A of the Code, with the amounts that are payable last reduced first. If the Accounting Firm determines that aggregate Covered Payments should be reduced as described above, it shall promptly notify Executive and the Company to that effect. In the absence of manifest error, all determinations made by the Accounting Firm under this Section 8(a) shall be binding on Executive and the Company and shall be made as soon as reasonably practicable and in no event later than fifteen (15) days following the later of Executive’s date of termination of employment or the date of the transaction which causes the application of Section 280G of the Code. The Company shall bear all costs, fees and expenses of the Accounting Firm. To the extent requested by Executive, the Company shall cooperate with Executive in good faith in valuing, and the Accounting Firm shall take into account the value of, services to be provided by Executive (including Executive agreeing to refrain from performing services pursuant to a covenant not to compete) before, on or after the date of the transaction 
9

which causes the application of Section 280G of the Code such that payments in respect of such services may be considered to be “reasonable compensation” within the meaning of Q&A-9 and Q&A-40 to Q&A-44 of the final regulations under Section 280G of the Code and/or exempt from the definition of the term “parachute payment” within the meaning of Q&A-2(a) of such final regulations in accordance with Q&A-5(an) of such final regulations. If it is ultimately determined (by IRS private letter ruling or closing agreement, court decision or otherwise) that Executive’s Covered Payments were reduced by too much or by too little in order to accomplish the purpose of this Section 8(a), Executive and the Company shall promptly cooperate to correct such underpayment or overpayment in a manner consistent with the purpose of this Section 8(a).
(b) Section 409A. The Parties intend for the payments and benefits under this Agreement to be exempt from Section 409A of the Code or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention. Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, (i) no amounts shall be paid to Executive under Section 7 of this Agreement until Executive would be considered to have incurred a “separation from service” from the Company within the meaning of Section 409A of the Code, (ii) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive’s separation from service shall instead be paid on the first business day after the date that is six (6) months following Executive’s separation from service (or immediately following Executive’s death, if earlier), (iii) each amount to be paid or benefit to be provided under this Agreement shall be construed as a separately identified payment for purposes of Section 409A of the Code, (iv) any payments that are due within the “short term deferral period” as defined in Section 409A of the Code shall not be treated as deferred compensation unless applicable law requires otherwise and (v) amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Executive) during any one (1) year may not effect amounts reimbursable or provided in any subsequent year.
9. Restrictive Covenants.
(a) Acknowledgments. Executive acknowledges and agrees that: (i) the business in which the Company and its Affiliates are engaged is intensely competitive and that Executive’s employment by the Company has required, and will continue to require, that Executive have access to, and knowledge of, Confidential Information (as defined herein); (ii) the disclosure of any Confidential Information could place the Company at a serious competitive disadvantage and could do serious damage, financial and otherwise, to the business of the Company and its Affiliates; (iii) Executive has been given access to, and developed relationships with, customers of the Company and its Affiliates at the time and expense of the Company; (iv) by Executive’s training, experience and expertise, Executive’s services to the Company are, and will continue to be, extraordinary, special and unique; and (v) Executive has received good and valuable consideration for the restrictive covenants set forth herein, including without limitation, the right to acquire and own securities of the Company, the employment by the Company and the related compensation and benefits and other good and valuable consideration, the sufficiency of which is hereby acknowledged.
(b) Non-Solicitation; Non-Interference; No-Hire. From the Effective Date through the third anniversary of the Executive’s termination date, Executive shall not, directly or indirectly, on Executive’s own behalf or by, through or on behalf of, another Person: (i) solicit, induce, encourage or 
10

persuade, or attempt to solicit, induce, encourage or persuade, any then-current employee, consultant or independent contractor of the Company or any Affiliate of the Company to leave the employ of, or engagement with, the Company or any such Affiliate, or in any way interfere with the relationship between the Company or any such Affiliate, on the one hand, and any then-current employee, consultant or independent contractor thereof, on the other hand, (ii) hire or engage any person or entity who or which was an employee, consultant or independent contractor of the Company or any Affiliate of the Company at any time within the last one (1) year of Executive’s employment with the Company; (iii) solicit, induce, encourage or persuade, or attempt to solicit, induce, encourage or persuade any then-current customer, supplier, licensee or other business relation of the Company or any Affiliate of the Company to cease doing business with, or to reduce its current or contemplated level of business with, the Company or such Affiliate, or in any way interfere with the relationship between any such customer, supplier, licensee or business relation, on the one hand, and the Company or any such Affiliate, on the other hand; or (iv) solicit, induce, encourage or persuade, or attempt to solicit, induce, encourage or persuade any potential customer, supplier, licensee or other potential business relation of the Company or any Affiliate of the Company, whom the Company had solicited, was attempting to solicit, or had identified for solicitation during the last twelve (12) months of Executive’s employment with the Company and whom or which Executive knew to be such a potential customer, supplier, licensee or other potential business relation, in each case, to cease doing business with, or to reduce its contemplated level of business with, the Company or such Affiliate, or in any way interfere with the relationship between any such potential customer, supplier, licensee or other potential business relation, on the one hand, and the Company or any such Affiliate, on the other hand.
(c) Non-Competition. From the Effective Date through the third anniversary of the Executive’s termination date, Executive shall not, directly or indirectly, on Executive’s own behalf or by, through, or on behalf of, another Person, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or other entity, in whatever form, engaged in (1) real estate brokerage, the franchising of real estate, employee relocation business, title services, settlement services, or technology-related businesses supporting any of the foregoing, (2) any business with business assets, technology, relationships or services in residential real estate that has the ability to divert business from the residential real estate brokerage, franchising of residential real estate brokerage, employee relocation, or title or settlement services markets, (3) any businesses involved in or related to residential real estate brokerage through the use of on-line databases and listings, or (4) or any other business of the same type as any business in which the Company or any of its Affiliates is engaged on the date of termination of Executive’s employment or in which they have proposed, on or prior to such date, to be engaged in on or after such date and in which the Executive has been involved to any extent (other than de minimis) at any time during the two (2) year period ending with the date of termination of such Executive’s employment, anywhere in the world in which the Company or its Affiliates conduct business. Nothing in this Section 9(c) shall prohibit Executive from being a passive owner of not more than 4.99% of the outstanding equity interests of any entity so long as Executive has no active participation in the business of such corporation.
(d) Non-Disclosure; Non-Use of Confidential Information. Executive shall not disclose or use at any time, either during his employment with the Company and its Affiliates or thereafter, any Confidential Information (as herein defined) of which Executive is or becomes aware, whether or not such information is developed by him, except to the extent that such disclosure or use is directly related to and required by Executive’s performance in good faith of duties assigned to Executive by the Company. Executive will take all appropriate steps to safeguard Confidential Information in his possession and to 
11

protect it against disclosure, misuse, espionage, loss and theft. Executive shall deliver to the Company at the termination of his employment with the Company and its Affiliates, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer tapes and software and other documents and data (and copies thereof) relating to the Confidential Information or the Work Product (as hereinafter defined) of the business of the Company or any of its Affiliates that Executive may then possess or have under his control. Notwithstanding anything set forth in this Agreement to the contrary, Executive shall not be prohibited from disclosing Confidential Information if reasonably necessary in connection with litigation between Executive and the Company or any of its Affiliates, provided that Executive uses his best efforts to protect the confidential nature of such Confidential Information including, but not limited to, filing any Confidential Information under seal or pursuant to a protective order.
(e) Proprietary Rights. Executive recognizes that the Company and its Affiliates possess a proprietary interest in all Confidential Information and Work Product and have the exclusive right and privilege to use, protect by copyright, patent or trademark, or otherwise exploit the processes, ideas and concepts described therein to the exclusion of Executive, except as otherwise agreed between the Company and Executive in writing. Executive expressly agrees that any Work Product made or developed by Executive or Executive’s agents or Affiliates during the course of Executive’s employment, including any Work Product which is based on or arises out of Work Product, shall be the property of and inure to the exclusive benefit of the Company and its Affiliates. Executive further agrees that all Work Product developed by Executive (whether or not able to be protected by copyright, patent or trademark) during the course of Executive’s employment, or involving the use of the time, materials or other resources of the Company or any of its Affiliates, shall be promptly disclosed to the Company and shall become the exclusive property of the Company, and Executive shall execute and deliver any and all documents necessary or appropriate to implement the foregoing.
(f) Non-Disparagement. Executive covenants that during and following the Term, Executive will not disparage or encourage or induce others to disparage the Company or its Affiliates, together with all of their respective past and present directors and officers, as well as their respective past and present managers, officers, shareholders, partners, employees, agents, attorneys, servants and customers and each of their predecessors, successors and assigns (collectively, the “Company Entities and Persons”); provided that such limitation shall extend to past and present managers, officers, shareholders, partners, employees, agents, attorneys, servants and customers only in their capacities as such or in respect of their relationship with the Company and its Affiliates. The term “disparage” includes, without limitation, comments or statements adversely affecting in any manner (i) the conduct of the business of the Company Entities and Persons, or (ii) the business reputation of the Company Entities and Persons. Nothing in this Agreement is intended to or shall prevent either Party from providing, or limiting testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law or from making any statement in any document filed with the U.S. Securities and Exchange Commission. Either party shall also be permitted to refute any incorrect statements made about him or it by the other party.
(g) Cooperation in Any Investigations and Litigation. Executive agrees that Executive will reasonably cooperate at reasonable times and places with the Company and its Affiliates, and its counsel, in connection with any investigation, inquiry, administrative proceeding or litigation relating to any matter in which Executive becomes involved or of which Executive has knowledge as a result of Executive’s service with the Company by providing truthful information. The Company agrees to promptly reimburse Executive for reasonable expenses approved in writing in advance of being incurred (including travel expenses, attorneys’ fees and other expenses of counsel) by Executive, in connection with Executive’s cooperation pursuant to this Section 9(g). Such reimbursements shall be made within 
12

sixty (60) days following Executive’s submission of a written invoice to the Company describing such expenses in reasonable detail, and in no event later than the calendar year following the year in which the expenses are incurred. Executive agrees that, in the event Executive is subpoenaed by any person or entity (including, but not limited to, any government agency) to give testimony (in a deposition, court proceeding or otherwise) which in any way relates to Executive’s employment by the Company, Executive will, to the extent not legally prohibited from doing so, give prompt notice of such request to the Company’s General Counsel so that the Company may contest the right of the requesting person or entity to such disclosure before making such disclosure. Nothing in this provision shall require Executive to violate Executive’s obligation to comply with valid legal process. Executive shall also not, directly or indirectly, direct, encourage, assist, or advise any non-governmental third party to institute, commence or prosecute any claims, rights or causes of action in law or in equity in any forum or proceeding whatsoever against the Company or its Affiliates.
(h) Permitted Disclosures. Pursuant to 18 U.S.C. § 1833(b), Executive will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret of the Company that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to Executive’s attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney and use the trade secret information in the court proceeding, if Executive (I) files any document containing the trade secret under seal, and (II) does not disclose the trade secret, except pursuant to court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section. Further, nothing in any agreement Executive has with the Company shall prohibit or restrict Executive from (i) voluntarily communicating with an attorney retained by Executive, (ii) voluntarily communicating with any law enforcement, government agency, including the Equal Employment Opportunity Commission or a local commission on human rights, or any self-regulatory organization, regarding possible violations of law, including criminal conduct and unlawful employment practices, in each case without advance notice to the Company, or (iii) disclosing any Confidential Information to a court or other administrative or legislative body in response to a subpoena, court order or written request, provided that Executive first promptly notifies and provides the Company with the opportunity to seek, and join in its efforts at the sole expense of the Company, to challenge the subpoena or obtain a protective order limiting its disclosure, or other appropriate remedy. 
(i) Blue Pencil. It is the intent and desire of Executive and the Company that the provisions of this Section 9 be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of this Section 9 shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either Party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.
(j) Survival. Executive’s obligations under this Section 9 shall survive the termination of the Term.
(k) Certain Definitions.
(i) For purposes of this Agreement, “Affiliates” means:
13

(1) in the case of the Company, a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company; and
(2) in the case of an individual: (i) any member of the immediate family of Executive, including parents, siblings, spouse and children (including those by adoption); the parents, siblings, spouse, or children (including those by adoption) of such immediate family member, and in any such case any trust whose primary beneficiary is such individual or one or more members of such immediate family and/or Executive’s lineal descendants; (ii) the legal representative or guardian of the individual or of any such immediate family member in the event the individual or any such immediate family member becomes mentally incompetent; and (iii) any Person controlling, controlled by or under common control with Executive.
As used in this definition, the term “control,” including the correlative terms “controlling,” “controlled by” and “under common control with,” means possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by contract or otherwise) of a Person.
(ii) For purposes of this Agreement, “Confidential Information” means information that is not generally known to the public (except for information known to the public because of Executive’s violation of Section 9(c) of this Agreement) and that is used, developed or obtained by the Company in connection with its business, including, but not limited to, information, observations and data obtained by Executive while employed by the Company or any predecessors thereof (including those obtained prior to the date of this Agreement) concerning (i) the business or affairs of the Company (or such predecessors), (ii) products or services, (iii) fees, costs and pricing structures, (iv) designs, (v) analyses, (vi) drawings, photographs and reports, (vii) computer software, including operating systems, applications and program listings, (viii) flow charts, manuals and documentation, (ix) databases, (x) accounting and business methods, (xi) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (xii) customers and clients and customer or client lists, (xiii) other copyrightable works, (xiv) all production methods, processes, technology and trade secrets, and (xv) all similar and related information in whatever form. Confidential Information will not include any information that has been published in a form generally available to the public prior to the date Executive proposes to disclose or use such information. Confidential Information will not be deemed to have been published or otherwise disclosed merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination. For purposes of this definition, the “Company” shall mean the Company collectively with its Affiliates.
(iii) For purposes of this Agreement, “Person” shall be construed broadly and shall include, without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.
(iv) For purposes of this Agreement, “Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or unpatentable) that relates to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or services and that are conceived, developed or made by Executive (whether or not during usual business hours and whether or not alone or in conjunction with any other person) while employed by the Company or any of its 
14

Affiliates (including those conceived, developed or made prior to the date of this Agreement) together with all patent applications, letters patent, trademark,
trade name and service mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing.
10. Remedies for Breach of Obligations under Sections 9 or 10 hereof. Executive acknowledges that the Company and its Affiliates will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches Executive’s obligations under Section 9 hereof. Accordingly, Executive agrees that the Company and its Affiliates will be entitled, in addition to any other available remedies, to obtain injunctive relief in aid of arbitration against any breach or prospective breach by Executive of Executive’s obligations under Section 9 hereof in any Federal or state court sitting in the state of Delaware, or, at the Company’s election, in any other state in which Executive maintains Executive’s principal residence or Executive’s principal place of business. Executive hereby submits to the non-exclusive jurisdiction of all those courts for the purposes of any actions or proceedings instituted by the Company or its Affiliates to obtain that injunctive relief in aid of arbitration, and Executive agrees that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law.
11. Representations and Warranties.
(a) The Company represents and warrants that (i) it is fully authorized to enter into this Agreement and to perform its obligations under it, (ii) the execution, delivery and performance of this Agreement by it does not violate any applicable law, regulation, order, judgment or decree or any agreement, arrangement, plan or corporate governance document (x) to which it is a Party or (y) by which it is bound, and (iii) upon the execution and delivery of this Agreement by the Parties, this Agreement shall be a valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally.
(b) Executive represents and warrants to the Company that the execution and delivery by Executive of this Agreement do not, and the performance by Executive of Executive’s obligations hereunder will not, with or without the giving of notice or the passage of time, or both: (a) violate any judgment, writ, injunction, or order of any court, arbitrator, or governmental agency applicable to Executive; or (b) conflict with, result in the breach of any provisions of or the termination of, or constitute a default under, any agreement to which Executive is a Party or by which Executive is or may be bound.
12. Miscellaneous.
(a) Successors and Assigns.
(i) This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns and the Company shall require any successor or assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or assignment had taken place. The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company or to an affiliate of the Company. The term “the Company” as used herein shall include a corporation or other entity acquiring all or substantially all the assets and business of the Company (including this Agreement) whether by operation of law or otherwise.
15

(ii) Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive’s beneficiaries or legal representatives, except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal personal representatives.
(b) Clawback Policy. Executive acknowledges and agrees that (i) he or she is subject to the terms and conditions of the Company’s Clawback Policy as in effect from time to time, (ii) such Clawback Policy, in each case, shall apply to, among other things, all currently outstanding vested and unvested awards and all awards that have been previously exercised or paid, including any proceeds, gains or other economic benefit in respect of the award and (iii) to the extent permitted by applicable law and notwithstanding the terms and conditions of the Clawback Policy as in effect from time to time, such Clawback Policy shall apply in the event Executive breaches his covenants as set forth in Section 9 of this Agreement.
(c) Indemnification. Executive shall be indemnified by the Company as, and to the extent, provided in the certificate of incorporation and bylaws of the Company and as provided in Executive’s Director and Officer Indemnification Agreement dated October 17, 2017 and shall be provided with director and officer liability insurance on a basis no less favorable than provided to any other officer or director of the Company. The obligations under this paragraph shall survive termination of the Term.
(d) Enforcement.
(i) Arbitration. Except for the Company or its Affiliate’s right to obtain injunctive relief in aid of arbitration for violation of Section 9 of this Agreement, any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application, implementation, breach or enforcement which the parties are unable to resolve by mutual agreement, shall be settled by submission by either party of the controversy, claim or dispute to binding arbitration in New York City, in the Borough of Manhattan (unless the parties agree in writing to a different location), before a single arbitrator in accordance with the Employment Dispute Resolution Rules of the American Arbitration Association then in effect. In any such arbitration proceeding the parties agree to provide all discovery deemed necessary by the arbitrator. The decision and award made by the arbitrator shall be final, binding and conclusive on all parties hereto for all purposes, and judgment may be entered thereon in any court having jurisdiction thereof. Each party shall bear its or his costs and expenses in any such arbitration, including, but not limited to, attorneys’ fees; provided, however, if Executive prevails on substantially all material claims, the Company shall reimburse Executive for all of his reasonable attorneys’ fees and costs. It is part of the essence of this Agreement that any claims hereunder shall be resolved expeditiously and as confidentially as possible. Accordingly, the Company and Executive agree that all proceedings in any arbitration shall be conducted under seal and kept strictly confidential. In that regard, no party shall use, disclose or permit the disclosure of any information, evidence or documents produced by any other party in the arbitration proceedings or about the existence, contents or results of the proceedings except as necessary and appropriate for the preparation and conduct of the arbitration proceedings, or as may be required by any legal process, or as required in an action in aid of arbitration or for enforcement of or appeal from an arbitral award. Before making any disclosure permitted by the preceding sentence, the party intending to make such disclosure shall give the other party reasonable written notice of the intended disclosure and afford such other party a reasonable opportunity to protect its interests.
(ii) Remedies. All remedies hereunder are cumulative, are in addition to any other remedies provided for by law and may, to the extent permitted by law, be exercised concurrently or 
16

separately, and the exercise of any one remedy shall not be deemed to be an election of such remedy or to preclude the exercise of any other remedy.
(iii) Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.
(e) Right to Counsel. Executive acknowledges that Executive has had the opportunity to consult with legal counsel of Executive’s choice in connection with the drafting, negotiation and execution of this Agreement and related employment arrangements.
(f) Notice. For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by Certified mail, return receipt requested, postage prepaid, addressed to the respective addresses last given by each Party to the other, provided that all notices to the Company shall be directed to the attention of the Company’s Chief Executive Officer with a copy to the Company’s General Counsel. All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.
(g) Withholding. The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder. The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount thereof.
(h) Release of Claims. The termination benefits described in Section 7(d)(ii), (iii) and (v) and Section 7(e)(ii), (iii) and (v) of this Agreement shall be conditioned on Executive delivering to the Company, a signed release of claims in the form of Exhibit A hereto within forty-five (45) days or twenty-one (21) days, as may be applicable under the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act, following Executive’s termination date, and not revoking Executive’s consent to such release of claims within seven (7) days of such execution (a “Release Agreement”); provided, however, that Executive shall not be required to release any rights under equity-based agreements, any rights Executive may have to be indemnified by the Company under Section 12(c) of this Agreement or under any other indemnification agreement entered into between Executive and the Company or to be covered under directors and officers liability insurance, provided, further, that in no event shall the timing of Executive’s execution (and non-revocation) of the general release, directly or indirectly, result in Executive designating the calendar year of payment, and if a payment that is subject to execution (and non-revocation) of the general release could be made in more than one taxable year, payment shall be made in the later taxable year.
(i) Resignation as Officer or Director. Upon a termination of employment for any reason, Executive shall resign each position (if any) that Executive then holds as an officer or director of the Company and any of its Affiliates, as well as any positions Executive holds as a trustee or fiduciary of any employee benefit plan maintained by the Company. Executive’s execution of this Agreement shall be deemed the grant by Executive to the officers of the Company of a limited power of attorney to sign in Executive’s name and on Executive’s behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations
(j) Modification. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the 
17

Company. No waiver by either Party hereto at any time of any breach by the other Party hereto of, or noncompliance with, any condition or provision of this Agreement to be performed by such other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either Party which are not expressly set forth in this Agreement.
(k) Effect of Other Law. Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A of the Code, or other federal law applicable to the employment arrangements between Executive and the Company. Any delay in providing benefits or payments, any failure to provide a benefit or payment, or any repayment of compensation that is required under the preceding sentence shall not in and of itself constitute a breach of this Agreement, provided, however, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law.
(l) Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the state of Delaware applicable to contracts executed in and to be performed entirely within such state, without giving effect to the conflict of law principles thereof.
(m) No Conflicts. Executive represents and warrants to the Company that Executive is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive’s ability to execute this Agreement or to carry out Executive’s duties and responsibilities hereunder. 
(n) Inconsistencies. In the event of any inconsistency between any provision of this Agreement and any provision of any employee handbook, personnel manual, program, policy, or arrangement of the Company or its Affiliates (including, without limitation, any provisions relating to notice requirements and post-employment restrictions), the provisions of this Agreement shall control, unless Executive otherwise agrees in a writing that expressly refers to the provision of this Agreement whose control he is waiving.
(o) Beneficiaries/References. In the event of Executive’s death or a judicial determination of his incompetence, references in this Agreement to Executive shall be deemed, where appropriate, to refer to his beneficiary, estate or other legal representative.
(p) Survivorship. Except as otherwise set forth in this Agreement, the respective rights and obligations of the Parties hereunder shall survive the Term and any termination of Executive’s employment. Without limiting the generality of the forgoing, the provisions of Section 7, 9 and 10 shall survive the Term.
(q) Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.
(r) Entire Agreement. This Agreement constitutes the entire agreement between the Parties hereto and supersedes all prior agreements (including the Employment Agreement entered into between the Company and Executive dated March 11, 2020), understandings and arrangements, oral or written, between the Parties hereto with respect to the subject matter hereof.
18

(s) Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.
13. Certain Rules of Construction.
(a) The headings and subheadings set forth in this Agreement are inserted for the convenience of reference only and are to be ignored in any construction of the terms set forth herein.
(b) Wherever applicable, the neuter, feminine or masculine pronoun as used herein shall also include the masculine or feminine, as the case may be.
(c) The term “including” is not limiting and means “including without limitation.”
(d) References in this Agreement to any statute or statutory provisions include a reference to such statute or statutory provisions as from time to time amended, modified, reenacted, extended, consolidated or replaced (whether before or after the date of this Agreement) and to any subordinate legislation made from time to time under such statute or statutory provision.
(e) References to “writing” or “written” include any non-transient means of representing or copying words legibly, including by facsimile or electronic mail.
(f) References to “$” are to United States Dollars.

[Remainder of Page Intentionally Left Blank]

19

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and Executive has executed this Agreement as of the day and year first above written.

ANYWHERE REAL ESTATE INC.

By:      /s/ Tanya Reu-Narvaez    
Name:     Tanya Reu-Narvaez
Title:      Executive Vice President, Chief People Officer

            EXECUTIVE

By:  /s/ Ryan M. Schneider
            Name:     Ryan M. Schneider

Signature Page to CEO Employment Agreement
20

EXHIBIT A

FORM OF RELEASE AGREEMENT
THIS RELEASE AGREEMENT (the “Release”) is made by and between Ryan M. Schneider (“Executive”) and Anywhere Real Estate Inc. (the “Company”).
1. For and in consideration of the payments and benefits provided in Sections [7(d)(ii), (iii), (iv) and (v)] 7(e)(ii), (iii), (iv) and (v)] of the Amended and Restated Employment Agreement between Executive and the Company dated as of August 4, 2022 (the “Employment Agreement”), Executive, for himself, his successors and assigns, executors and administrators, now and forever hereby releases and discharges the Company, together with all of its past and present parents, subsidiaries, and affiliates, together with each of their officers, directors, stockholders, partners, employees, agents, representatives and attorneys, and each of their subsidiaries, affiliates, estates, predecessors, successors, and assigns; provided that such release shall extend to past and present officers, directors, shareholders, partners, employees, agents, representatives and attorneys only in their capacities as such or in respect of their relationship with the Company and its affiliates (hereinafter collectively referred to as the “Releasees”) from any and all rights, claims, charges, actions, causes of action, complaints, sums of money, suits, debts, covenants, contracts, agreements, promises, obligations, damages, demands or liabilities of every kind whatsoever, in law or in equity, whether known or unknown, suspected or unsuspected (collectively, “Claims”), which Executive or Executive’s executors, administrators, successors or assigns ever had, now has or may hereafter claim to have by reason of any matter, cause or thing whatsoever: (i) arising from the beginning of time up to the date upon which Executive signs the Release, including but not limited to (A) any such Claims arising out of, or relating in any way to, Executive’s employment with the Company or any of the other Releasees, or the termination of Executive’s employment relationship with the Company or any of the other Releasees, and (B) any such Claims arising under any federal, local or state law, executive order, statute or regulation, including, without limitation, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Employee Retirement Income Security Act of 1974, the Civil Rights Act of 1991, the Family and Medical Leave Act of 1993, the Fair Labor Standards Act of 1938 (but limited to the provisions prohibiting retaliation), the Equal Pay Act of 1963, and the Sarbanes-Oxley Act of 2002, any “whistleblower” or retaliation claims (to the extent permitted by applicable law), and/or the applicable federal, state or local law, executive order, statute or regulation against discrimination, each as amended; (ii) arising under or relating to the Employment Agreement or breach of a contract relating to employment; or (iii) arising under or relating to any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company and any of the Releasees and Executive; provided, however, that notwithstanding the foregoing, nothing contained in the Release shall in any way diminish or impair: (a) any rights Executive may have under Section [7(d)][7(e)] of this Employment Agreement, including any accrued benefits; (b) any rights Executive may have, from and after the date upon which Executive signs the Release; (c) any rights to indemnification that may exist from time to time under the Company’s certificate of incorporation or bylaws, or state law or any other indemnification agreement entered into between Executive and the Company or rights under any directors and officers insurance policy; (d) Executive’s ability to bring appropriate proceedings to enforce the Release; (e) any rights under applicable equity agreements and (f) any rights or claims Executive may have that cannot be waived under applicable law (collectively, the “Excluded Claims”). Executive further acknowledges and agrees that, except with respect to Excluded Claims, the Company and the Releasees have fully satisfied any and all obligations whatsoever owed to Executive arising out of 
A-1

Executive’s employment with the Company or any of the Releasees, and that no further payments or benefits are owed to Executive by the Company or any of the Releasees.
2. Executive understands and agrees that, except for the Excluded Claims, Executive has knowingly relinquished, waived and forever released any and all rights to any personal recovery in any action or proceeding that may be commenced on Executive’s behalf arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for back pay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys’ fees.
3. Executive understands that nothing contained in this Agreement limits Executive’s ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). Executive further understands that this Agreement does not limit Executive’s ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit Executive’s right to receive an award for information provided to any Government Agencies. 
4. Executive acknowledges and agrees that Executive has been advised of Executive’s right to consult with an attorney of Executive’s choosing prior to signing the Release. Executive understands and agrees that Executive has the right and has been given the opportunity to review the Release with an attorney of Executive’s choice should Executive so desire. Executive also agrees that Executive has entered into the Release knowingly, freely and voluntarily. Executive further acknowledges and agrees that Executive has twenty-one (21) calendar days, or in the event of a group termination, forty-five (45) calendar days, to consider the Release, and any exhibits hereto, although Executive may sign it sooner if Executive wishes. In addition, once Executive has signed the Release, Executive shall have seven (7) additional days from the date of execution to revoke Executive’s consent and may do so by writing to the Company’s Chief Human Resources Officer, which must be received by the Company within such seven (7) day revocation period. The Release shall not be effective, and no payments shall be due hereunder, earlier than the eighth (8th) day after Executive shall have executed the Release and returned it to the Company, assuming that Executive had not revoked Executive’s consent to the Release prior to such date.
5. It is understood and agreed by Executive that any payment made to Executive is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.
6. The Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of Executive’s claims. Executive acknowledges that Executive has had a full and reasonable opportunity to consider the Release and that Executive has not been pressured or in any way coerced into executing the Release. Executive further acknowledges and agrees that he is executing this Release in exchange for good and valuable consideration in addition to anything of value to which Executive is otherwise entitled.
7. The exclusive venue for any disputes arising hereunder shall be the state or federal courts located in the State of Delaware, and each of the parties hereto irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such proceeding brought in such a court has been brought in an inconvenient forum. Each of the parties hereto also agrees that any final and 
A-2

unappealable judgment against a party hereto in connection with any action, suit or other proceeding may be enforced in any court of competent jurisdiction, either within or outside of the United States. A certified or exemplified copy of such award or judgment shall be conclusive evidence of the fact and amount of such award or judgment.
8. The Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the state of Delaware. If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.
9. The Release shall inure to the benefit of and be binding upon the Company and its successors and assigns.
IN WITNESS WHEREOF, Executive and the Company have executed the Release as of the below-written dates.

IMPORTANT NOTICE: BY SIGNING BELOW YOU RELEASE AND GIVE UP ANY AND ALL LEGAL CLAIMS, KNOWN AND UNKNOWN, THAT YOU MAY HAVE AGAINST THE COMPANY AND RELATED PARTIES.

__________________________________  ______________________
ANYWHERE REAL ESTATE INC.       Ryan M. Schneider

Dated: ____________________           Dated:  __________________
A-3Document

EXECUTION COPY

PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT
BY AND BETWEEN
CODEXIS, INC.
AND
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

EFFECTIVE AS OF

10 July 2014

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.    Definitions
	1

	1.1    “Affiliate”
	1

	1.2    “Alliance Manager”
	2

	1.3    “Applicable Law”
	2

	1.4    “Arising Codexis Enzyme Technology”
	2

	1.5    “Arising Codexis Enzyme Technology IP”
	2

	1.6    “Arising Codexis Process Technology”
	2

	1.7    “Arising Codexis Process Technology IP”
	2

	1.8    “Arising GSK Enzyme Technology”
	2

	1.9    “Arising GSK Enzyme Technology IP”
	2

	1.10    “Arising GSK Process Technology”
	2

	1.11    “Arising GSK Process Technology IP”
	3

	1.12    “Background IP”
	3

	1.13    “Business Day”
	3

	1.14    “Calendar Quarter”
	3

	1.15    “Calendar Year”
	3

	1.16    “Change of Control”
	3

	1.17    “Clinical Proof of Concept”
	3

	1.18    “Codexis Core Patents”
	3

	1.19    “Codexis Core Technology”
	3

	1.20    “Codexis Core Technology Improvements”
	4

	1.21    “Codexis Core Technology Improvements IP”
	4

	1.22    “Codexis Documentation”
	4

	1.23    “Codexis Enzymes”
	4

    - i -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.24    “Codexis Enzyme Patents”
	4

	1.25    “Codexis Exclusive Field”
	4

	1.26    “Codexis Initial Enzyme(s)”
	5

	1.27    “Codexis Initial Enzyme IP”
	5

	1.28    “Codexis Library”
	5

	1.29    “Codexis Materials”
	5

	1.30    “Codexis Mayflower Patents”
	5

	1.31    “Codexis Methods”
	5

	1.32    “Codexis Senior Management”
	5

	1.33    “Codexis Software”
	5

	1.34    “Codexis Team”
	5

	1.35    “Collaborative Project”
	5

	1.36    “Commercially Reasonable Efforts”
	6

	1.37    “Completion of Wave 1”
	6

	1.38    Completion of Wave 2”
	6

	1.39    Completion of Wave 3”
	6

	1.40    “Confidential Information”
	6

	1.41    “Controlled” or “Controls”
	6

	1.42    “Cover” or “Covers”
	6

	1.43    “Covered Enzyme”
	7

	1.44    “Dollar” or “$”
	7

	1.45    “Embargo Period”
	7

	1.46    “Enzyme”
	7

	1.47    “Enzyme Product”
	7

    - ii -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.48    “FDA”
	7

	1.49    “Field”
	7

	1.50    “Final Round of Enzyme Evolution”
	7

	1.51    “First Commercial Sale”
	7

	1.52    “First Production Run”
	7

	1.53    “FTE”
	8

	1.54    “Fully Burdened Cost”
	8

	1.55    “Generic Version”
	8

	1.56    “Good Clinical Practices” or “GCP”
	8

	1.57    “Good Laboratory Practices” or “GLP”
	8

	1.58    “Good Manufacturing Practices” or “GMP”
	8

	1.59    “GSK Compound”
	9

	1.60    “GSK Exclusive Field”
	9

	1.61    “GSK Existing Pharmaceutical Product”
	9

	1.62    “GSK Initial Enzyme(s)”
	9

	1.63    “GSK Project Library”
	9

	1.64    “GSK Selected Enzyme”
	9

	1.65    “GSK Sole Project”
	9

	1.66    “GSK Team”
	9

	1.67    “IFRS”
	9

	1.68    “Improvements TT Term”
	9

	1.69    “Improvements TT Term Expiration Date”
	9

	1.70    “Initial Enzyme”
	9

	1.71    “Initial Enzyme Optimisation”
	10

    - iii -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.72    “Initial Technology Transfer Inventory”
	10

	1.73    “Initial Training”
	10

	1.74    “In-License Agreements”
	10

	1.75    “In-Licensed IP”
	10

	1.76    “In-Licensed Know-How”
	10

	1.77    “In-Licensed Patents”
	10

	1.78    “Intellectual Property”
	10

	1.79    “Invention”
	10

	1.80    “Invoice”
	10

	1.81    “Know-How”
	10

	1.82    “Licensed Additional Codexis IP”
	10

	1.83    “Licensed Accessory Product”
	11

	1.84    “Licensed Additional Codexis Know-How”
	11

	1.85    “Licensed Additional Codexis Patents”
	11

	1.86    “Licensed Collaborative Project GSK Selected Enzyme”
	11

	1.87    “Licensed Diagnostic Product”
	11

	1.88    “Licensed Enzyme Therapeutic Product”
	11

	1.89    “Licensed GSK Sole Project GSK Selected Enzyme”
	11

	1.90    “Licensed IP”
	11

	1.91    “Licensed Know-How”
	11

	1.92    “Licensed Other Therapeutic Product”
	11

	1.93    “Licensed Patents”
	11

	1.94    “Licensed Product”
	12

	1.95    “Licensed Prophylactic Product”
	12

    - iv -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.96    “Losses”
	12

	1.97    “Major Market Country”
	12

	1.98    “Net Sales”
	12

	1.99    “On-Site Training”
	12

	1.100    “Patent(s)”
	13

	1.101    “Person”
	13

	1.102    “Pharmaceutical Product”
	13

	1.103    “Phase 1b Clinical Trial”
	13

	1.104    “Phase 2a Clinical Trial”
	13

	1.105    “Platform Technology”
	13

	1.106    “Project”
	13

	1.107    “Project Enzyme”
	13

	1.108    “Prosecution”
	13

	1.109    “Regulatory Approval(s)”
	13

	1.110    “Regulatory Authority”
	14

	1.111    “Regulatory Filings”
	14

	1.112    “Restricted Enzyme”
	14

	1.113    “Round(s) of Enzyme Evolution”
	14

	1.114    “Royalty Term”
	14

	1.115    “Scientific Lead”
	14

	1.116    “Technology Transfer”
	14

	1.117    “Technology Transfer Plan”
	14

	1.118    “Territory”
	14

	1.119    “Third Party”
	15

    - v -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	1.120    “TT Term”
	15

	1.121    “TT Term Expiration Date”
	15

	1.122    “Upfront Payment”
	15

	1.123    “United States” or “U.S.”
	15

	1.124    “Valid Claim”
	15

	1.125    “Wave”
	15

	1.126    Additional Definitions
	15

	2.    Technology Transfer and Projects
	17

	2.1    Management of Technology Transfer; Projects; Alliance
	17

	2.2    Technology Transfer
	17

	2.3    Technology Transfer Projects
	20

	2.4    New Projects
	20

	2.5    Transfers of Materials
	21

	2.6    Project Reporting
	21

	2.7    Post- Project Enzyme Supply
	22

	2.8    Regulatory Responsibilities and Costs
	22

	2.9    Commercialization Responsibilities and Costs
	22

	2.10    Availability for Collaborative Projects; Additional Codexis Libraries
	22

	2.11    Party Employees
	23

	3.    Licenses
	23

	3.1    Licenses to Codexis
	23

	3.2    Licenses to GSK
	24

	3.3    Sublicensing
	25

    - vi -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	3.4    Limitations on Licenses
	26

	3.5    Codexis Core Technology Improvements Option
	30

	3.6    Third Party Licences
	31

	3.7    Restricted Enzymes
	31

	3.8    Responsibility for Freedom to Operate Analyses
	31

	3.9    Public Domain Information and Material
	32

	3.10    No Implied Licenses
	32

	4.    Projects
	32

	4.1    Collaborative Projects
	32

	4.2    Project Summaries
	32

	4.3    Project Activities
	33

	4.4    Subcontracting
	33

	4.5    Records
	33

	5.    Governance
	34

	5.1    Joint Steering Committee
	34

	5.2    Patent Committee
	36

	6.    Intellectual Property
	37

	6.1    Background Rights
	37

	6.2    Ownership of Inventions
	37

	6.3    Further Assurances
	38

	6.4    Employees and Agents
	38

	6.5    Prosecution of Patents
	38

	6.6    Enforcement of Patents
	39

	6.7    Defense Against Claims of Infringement of Third Party Patents
	40

    - vii -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	7.    Financial Terms
	41

	7.1    Upfront Payment
	41

	7.2    Annual Option Fee
	41

	7.3    Technology Transfer Milestones
	41

	7.4    Collaborative Project Milestones
	41

	7.5    GSK Sole Project Milestones
	42

	7.6    GSK Existing Pharmaceutical Product Milestones
	43

	7.7    Enzyme Product Milestones
	44

	7.8    Manner of Milestone Payments and Other Payments
	46

	7.9    Royalties
	46

	7.10    Royalty Payment Reports
	46

	7.11    Applicability of Milestones and Royalties
	47

	7.12    Manner of Payment
	47

	7.13    Records Retention
	47

	7.14    Audit Rights
	47

	7.15    Taxes
	49

	7.16    Interest Due
	49

	8.    Representations, Warranties, and Covenants; Disclaimers; Limitation of Liability
	50

	8.1    Mutual Representations and Warranties
	50

	8.2    Additional Representations and Warranties of Codexis
	50

	8.3    Mutual Covenants
	52

	8.4    Additional Covenants of GSK
	53

	8.5    Additional Covenant of Codexis
	53

    - viii -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	8.6    DISCLAIMERS
	54

	8.7    LIMITATION OF LIABILITY
	55

	9.    Confidentiality
	55

	9.1    Nondisclosure
	55

	9.2    Exceptions
	56

	9.3    Authorized Disclosure
	56

	9.4    Terms of this Agreement
	57

	9.5    Securities Filings
	57

	9.6    Publicity
	57

	10.    Indemnity and Insurance
	58

	10.1    GSK Indemnity
	58

	10.2    Codexis Indemnity
	59

	10.3    Indemnification Procedure
	59

	10.4    Insurance
	59

	11.    Term and Termination.
	60

	11.1    Term; Expiration
	60

	11.2    Termination for Material Breach
	60

	11.3    Insolvency or Bankruptcy
	60

	11.4    Termination for Challenge of any Codexis Patent
	61

	11.5    Consequences of Expiration or Termination
	61

	11.6    GSK Continuing Rights
	62

	11.7    GSK Termination at Will
	62

	11.8    Additional Consequence of Certain Terminations
	63

	11.9    Survival
	63

    - ix -

SV\1263057.27

TABLE OF CONTENTS
Page

						
	12.    Dispute Resolution.
	63

	12.1    Resolution by Executive Officers
	63

	12.2    Mediation
	64

	12.3    Arbitration
	64

	12.4    Confidentiality and Patent Disputes
	66

	13.    Miscellaneous.
	66

	13.1    Non-Solicitation
	66

	13.2    Severability
	66

	13.3    Notices
	66

	13.4    Force Majeure
	67

	13.5    Assignment
	67

	13.6    Change of Control of Codexis
	68

	13.7    GSK Divestments
	68

	13.8    Waivers and Modifications
	68

	13.9    Choice of Law
	68

	13.10    Relationship of the Parties
	68

	13.11    Entire Agreement
	69

	13.12    Counterparts
	69

	13.13    Interpretation
	69

	13.14    Anti-Bribery and Corruption
	70

	13.15    Ethical Standards and Human Rights
	70

	13.16    Good Data Management
	70

    - x -

SV\1263057.27

Exhibits
Exhibit 1.18 – Codexis Core Patents
Exhibit 1.19 – Codexis Core Technology
Exhibit 1.24 – Codexis Enzyme Patents
Exhibit 1.30 – Codexis Mayflower Patents
Exhibit 1.74 – In-License Agreements
Exhibit 1.77 – In-Licensed Patents
Exhibit 1.80 – Invoice Requirements
Exhibit 1.112 – Restricted Enzyme
Exhibit 1.117 – Technology Transfer Plan
Exhibit 2.5 – Material Transfer Record Form
Exhibit 3.3.1 – Codexis Strain-Related Protocols
Exhibit 8.5.4 – Third Party In-License Agreements
Exhibit 9.6 – Press Release
Exhibit 13.14 – Prevention of Corruption – Third Party Guidelines

    - i -

SV\1263057.27

PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT
This Platform Technology Transfer, Collaboration and License Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of 10 July 2014 (the “Effective Date”), by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America, (“Codexis”) and GlaxoSmithKline Intellectual Property Development Limited, an English company headquartered at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”).  Codexis and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”   
RECITALS
Whereas, GSK possesses expertise in bioprocess development and scale up, including commercial scale manufacture, as well as certain expertise in biocatalyst development;
Whereas, Codexis possesses expertise in the engineering and optimization of biocatalysts for use in pharmaceutical compound synthesis and manufacture;
Whereas, GSK seeks to collaborate with Codexis on certain biocatalysis projects in order to develop biocatalytic approaches to synthesize compounds of interest to GSK and to practice the Platform Technology under the licenses granted by Codexis and in connection with a technology transfer from Codexis; and 
Whereas, Codexis desires to grant to GSK such license and perform such technology transfer, on the terms and conditions set forth herein.  
AGREEMENT
Now, Therefore, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows:
1.DEFINITIONS.The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth below.
1.1“Affiliate” means any Person that directly or indirectly is controlled by, controls or is under common control with a Party to this Agreement.  For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast more than fifty percent (50%) of the votes in the election of directors, (b) in the case of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power to direct the management and policies of such entity, or (c) any other arrangement 
    - 1 -

SV\1263057.27

whereby a Person controls or has the right to control the board of directors or equivalent governing body or management of a corporation or other entity; provided that, if local Applicable Law restricts foreign ownership, control shall be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Applicable Law, be owned by foreign interests.
1.2“Alliance Manager” has the meaning assigned to such term in Section 2.1.2.
1.3“Applicable Law” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, government or Regulatory Authority.
1.4“Arising Codexis Enzyme Technology” means: (a) the amino acid sequence and structure of any Project Enzyme developed under a Project during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) structure-activity data that describes the structure-activity relationship and other characteristics of any Project Enzyme(s) noted in (a), and in each of (a) and (b), which data and information are Controlled by Codexis during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term). 
1.5“Arising Codexis Enzyme Technology IP” means Intellectual Property which has arisen directly from the Arising Codexis Enzyme Technology.
1.6“Arising Codexis Process Technology” means methods of using Project Enzymes in compound synthesis, developed under a Project during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and which methods are Controlled by Codexis during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term); provided that Arising Codexis Process Technology shall exclude technology that is generally applicable to chemical process development and to the synthesis and scale up of small molecule compounds and that does not specifically require the use or performance of such Project Enzyme.  
1.7“Arising Codexis Process Technology IP” means Intellectual Property which has arisen directly from the Arising Codexis Process Technology.
1.8“Arising GSK Enzyme Technology” means: (a) the amino acid sequence and structure of any Project Enzyme researched under a Project during the TT Term and (b) structure-activity data that describes the structure-activity relationship and other characteristics of any Project Enzyme(s) noted in (a) and, in each of (a) and (b), which data and information are Controlled by GSK during the TT Term.  
1.9
    - 2 -

SV\1263057.27

“Arising GSK Enzyme Technology IP” means Intellectual Property which has arisen directly from the Arising GSK Enzyme Technology. 
1.10“Arising GSK Process Technology” means methods of using Project Enzymes developed under a Project during the TT Term; provided that Arising GSK Process Technology shall exclude technology that is generally applicable to chemical process development and to the synthesis and scale up of small molecule compounds and that does not specifically require the use or performance of such Project Enzyme, which methods are Controlled by GSK during the TT Term. 
1.11“Arising GSK Process Technology IP” means Intellectual Property which has arisen directly from the Arising GSK Process Technology. 
1.12“Background IP” means any and all Intellectual Property which is Controlled by a Party and  (a) exists as of the Effective Date and/or (b) arises independently of the other Party during the Term.
1.13“Business Day” means a day other than Saturday, Sunday or any day on which commercial banks located in New York, New York are authorized or obligated by Applicable Law to close.
1.14“Calendar Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls and, thereafter, each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31.  
1.15“Calendar Year” means the period beginning on the Effective Date and ending on December 31st of the calendar year in which the Effective Date falls, and thereafter, each successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31. 
1.16“Change of Control” means, with respect to a Party, any one of the following events: (a) any entity or two or more entities acting in concert shall have acquired beneficial ownership, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of the Party normally entitled to vote in elections of directors; (b) the Party consolidates with or merges into another entity, or any entity consolidates with or merges into the Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of such total voting power of the Party preceding such consolidation or merger; or (c) the Party conveys, transfers or leases all or substantially all of its assets to a another entity that is not an Affiliate of the Party (such entity or entities in each of (a), (b) and (c), the “Acquiring Entity”).
1.17
    - 3 -

SV\1263057.27

“Clinical Proof of Concept” means the initial demonstration of clinical efficacy of an Enzyme Product in a patient population demonstrated through the conduct of a Phase 1b Clinical Trial or a Phase 2a Clinical Trial. 
1.18“Codexis Core Patents” means the Patents set forth on Exhibit 1.18.
1.19“Codexis Core Technology” means those (i) tools, processes and methods Controlled by Codexis; and (ii) generally applicable tools, processes and methods which Codexis has the ability to transfer to or license to GSK, in each of (i) and (ii) above: (a) used to identify, select, optimise, isolate, modify, engineer, research, develop, make, have made and/or import enzymes, Covered Enzymes and Enzymes, through the recombination and/or rearrangement and/or mutation of genetic material for the creation of genetic diversity, using any methods, including but not limited to Codexis Software, in silico, in vitro, and/or in vivo technologies, (b) screening techniques, methodologies and/or processes of using the resulting genes and/or proteins to identify and assess their potential utility, (c) gene expression methods applicable in high throughput screening, (d) techniques for cultivation of microorganisms, (e) techniques for producing, harvesting, and/or purifying proteins, and (f) Codexis Software, in each of (a) – (f) above, as described in Exhibit 1.19. 
1.20“Codexis Core Technology Improvements” means any improvement or advance to the Codexis Core Technology practiced by Codexis or any Affiliate of Codexis which are licensed to GSK under Section 3.2, that is generated by either Party, or both Parties, or on behalf of either Party or both Parties, or by Codexis with a Third Party, during the TT Term and is Controlled by Codexis, excluding any improvement or advance to the Codexis Core Technology which arises from GSK’s Background IP. 
1.21“Codexis Core Technology Improvements IP” means any and all Intellectual Property which is generated by or on behalf of either Party or any Affiliate of the Parties or jointly between the Parties or any Affiliate of the Parties which Covers the Codexis Core Technology Improvements. 
1.22“Codexis Documentation” means any documentation disclosed by Codexis to GSK pursuant to Article 2 (including with respect to Codexis Core Technology Improvements or the Platform Technology), including all Codexis Methods, the Technology Transfer Plan, and documentation related to the Codexis Software and the documentation described in the Technology Transfer Plan and any and all copies thereof, in whole or in part.   
1.23“Codexis Enzymes” means any Covered Enzyme which is Controlled by Codexis and transferred to GSK pursuant to the Technology Transfer Plan.  For clarity, Codexis Enzymes does not include GSK Initial Enzymes and GSK Selected Enzymes.
1.24“Codexis Enzyme Patents” means the Patents set forth on Exhibit 1.24.
1.25
    - 4 -

SV\1263057.27

“Codexis Exclusive Field” means, the use, research or development (whether in vitro or in vivo), or commercialization of any Enzyme or Enzyme fusion protein (except where the use of any Enzyme or Enzyme fusion protein which is used by GSK solely: (i) as a research reagent or a research tool, or (ii) to synthesize any GSK Compound), that: (a) effects a chemical transformation in humans, (b) facilitates, assists or enables the action, dispersion, absorption or bioavailability of a molecule, biologic agent, drug product, therapeutic agent, or other compound (other than such Enzyme or Enzyme fusion protein) in humans, or (c) transports a molecule, biologic agent, drug product, therapeutic agent, or any other compound (other than such Enzyme or Enzyme fusion protein) in humans, in each of cases (a) through (c) for any purpose, including without limitation the use of Enzymes for medicinal or therapeutic purposes, such as the treatment of lysosomal storage diseases, removal of toxic metabolites and by-products resulting from defects in metabolism, metabolite depletion therapy (e.g., for the treatment of cancer), permeabilization of tissue for improved uptake of a molecule, biologic agent, drug product, therapeutic agent, or any other compound into cells (e.g., hyaluronidase type application, [***], etc.), as well as combinations of the above; provided that the Codexis Exclusive Field [***].
1.26“Codexis Initial Enzyme(s)” means any Codexis Enzyme or any Enzyme derived from a Codexis Enzyme or a Codexis Library which is designated as an Initial Enzyme pursuant to a Project.
1.27“Codexis Initial Enzyme IP” means any and all Intellectual Property which Codexis Controls during the Term and which Covers any Codexis Initial Enzymes. 
1.28“Codexis Library” means any collection, set or sub-set of expression vectors containing genes Controlled by Codexis that encode for Covered Enzymes, Enzymes or enzymes, transferred to GSK under the Technology Transfer Plan, for the propagation of additional enzyme stock. 
1.29“Codexis Materials” means those materials disclosed or transferred to GSK by Codexis for the practice of the Platform Technology, including (a) the Codexis Libraries and Codexis Enzymes, and (b) the Codexis Core Technology Improvements to which GSK is entitled pursuant to Section 2.2.9.
1.30“Codexis Mayflower Patents” means the Patents set forth on Exhibit 1.30.
1.31“Codexis Methods” means (a) as of the Effective Date, the methods and protocols listed in Appendix IV of the Technology Transfer Plan, and (b) after the Effective Date, the methods and protocols disclosed by Codexis and drafted by Codexis, documenting all 
    - 5 -

SV\1263057.27

material methods relating to the Codexis Core Technology in sufficient detail to enable a scientist with reasonable skills and experience in the field of protein engineering or protein biochemistry to practice the Platform Technology.  The Codexis Methods shall include the most current and complete procedures used by Codexis as of the date on which they are disclosed to GSK with respect to the procedures described therein. 
1.32“Codexis Senior Management” means, as of the Effective Date, [***]. 
1.33“Codexis Software” means [***], and all other software disclosed under the Technology Transfer Plan, as amended from time to time, together with all software Controlled by Codexis and disclosed by Codexis under this Agreement, including all versions and improvements practiced by Codexis during the TT Term.  
1.34“Codexis Team” has the meaning assigned to it in Section 2.2.5(b).
1.35“Collaborative Project” means any collaborative enzyme evolution project in the GSK Exclusive Field agreed by the JSC as such prior to the commencement of such collaborative enzyme evolution project, using the Platform Technology where both Codexis and GSK perform the research plan to identify a GSK Selected Enzyme.  
1.36“Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this Agreement, efforts consistent with the efforts and resources normally used by a similarly situated pharmaceutical, biotechnology or technology company in the exercise of its reasonable business discretion relating to the development or commercialization of a product with similar product characteristics that is of similar market potential at a similar stage of development or commercialization, taking into account issues of efficacy, safety, patent and regulatory exclusivity, product profile, anticipated or approved labeling, present and future market potential, competitive market conditions, the proprietary position of the compound or product, the regulatory structure involved, and other technical, legal, scientific, medical or commercial factors, and the profitability of the product, including in light of pricing and reimbursement issues.
1.37“Completion of Wave 1” means achievement of all the “Wave 1 Milestone Success Criteria” as defined under the Technology Transfer Plan. 
1.38Completion of Wave 2” means achievement of all the “Wave 2 Milestone Success Criteria” as defined under the Technology Transfer Plan. 
1.39Completion of Wave 3” means achievement of all the “Wave 3 Milestone Success Criteria” as defined under the Technology Transfer Plan. 
    - 6 -

SV\1263057.27

1.40“Confidential Information” means all trade secrets, processes, formulae, Know-How, improvements, inventions, chemical or biological materials, chemical structures, techniques, marketing plans, strategies, customer lists, suppliers, or other information that has been created, discovered, or developed by a Party, or has otherwise become known to a Party, or to which rights have been assigned or licensed to a Party, as well as any other information and materials that are deemed confidential or proprietary to or by a Party (including all information and materials of a Party’s customers and any other Third Party and their consultants), in each case that are disclosed by such Party to the other Party, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by the disclosing Party in oral, written, graphic or electronic form.  
1.41“Controlled” or “Controls” means, when used in reference to an item or to Intellectual Property rights, the legal authority or right of a Party (or any of its Affiliates) (whether by ownership, assignment or by license, other than pursuant to this Agreement) to grant the right to use such item or a license or sublicense of such Intellectual Property rights to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, without violating any Applicable Law, breaching the terms of any agreement with any Third Party, or misappropriating the proprietary or trade secret information or other Know-How of a Third Party. 
1.42“Cover” or “Covers” means a particular item or method claimed in any Intellectual Property that, but for a license under or ownership right in such Intellectual Property, the use, making, having made, offering for sale, sale, importation, or other exploitation of such item would infringe or misappropriate such Intellectual Property (assuming, in the case of pending Patent applications, that such pending Patent applications were issued Patents). 
1.43“Covered Enzyme” means any immature or mature peptide or protein, including derivatives, with enzymatic or biocatalytic activity Covered by the Licensed IP pursuant to this Agreement.
1.44“Dollar” or “$” means the lawful currency of the United States.
1.45“Embargo Period” means the period beginning on the Effective Date and continuing until and ending on the five (5) year anniversary of the Effective Date.
1.46“Enzyme” means any immature or mature peptide or protein, including derivatives, with enzymatic or biocatalytic activity derived from the use of the Platform Technology pursuant to this Agreement.   
1.47“Enzyme Product” means any of: (a) Licensed Enzyme Therapeutic Product, (b) Licensed Diagnostic Product, (c) Licensed Accessory Product, (d) Licensed Prophylactic Product, or (e) Licensed Other Therapeutic Product.
1.48
    - 7 -

SV\1263057.27

“FDA” means the U.S. Food and Drug Administration, or any successor agency thereto.
1.49“Field” means (a) the manufacture and commercialization of compounds, molecules and products (including, but not limited to, Licensed Products) for the treatment of any human disease or medically treatable human condition; (b) the prophylaxis, diagnosis, or treatment of any human disease or medically treatable human condition; and (c) the research and development of compounds, molecules and products (including, but not limited to, Licensed Products) for the treatment of any human disease or medically treatable human condition.  
1.50“Final Round of Enzyme Evolution” means that final one (1) Round of Enzyme Evolution in the series of successive Rounds of Enzyme Evolution in which the GSK Selected Enzyme was identified.
1.51“First Commercial Sale” means the first sale of a Licensed Product in a given country or other regulatory jurisdiction in the Territory by or on behalf of GSK, its Affiliates or sublicensees to a Third Party, after receipt of Regulatory Approval (including pricing approval, to the extent required for sale of Licensed Products in a given country or regulatory jurisdiction, and the completion of any necessary labeling negotiations that may be required after Regulatory Approval and such pricing approval) for Licensed Products in such country or regulatory jurisdiction.  First Commercial Sale shall specifically exclude sales or transfers for clinical study purposes or compassionate use, named-patient, indigent patient or similar uses, if such uses do not result in monetary compensation to GSK above the cost of goods.  
1.52“First Production Run” means the use of a Licensed Collaborative Project GSK Selected Enzyme or a Licensed GSK Sole Project GSK Selected Enzyme in the synthesis of a GSK Compound (a) for use in clinical trials or (b) for commercial sales. 
1.53“FTE” means the equivalent of the work performed after the Effective Date of one (1) Codexis scientist or one (1) GSK scientist, full time for one (1) year.  In no event will one (1) person count for more than one (1) FTE in any Calendar Year.
1.54“Fully Burdened Cost” means [***].  For the avoidance of doubt, the calculation of “Fully Burdened Cost” shall exclude for all purposes the cost of any and all materials supplied by GSK.  [***]. 
    - 8 -

SV\1263057.27

1.55“Generic Version” means, with respect to a Pharmaceutical Product, a product meeting all of the following criteria: (a) such product contains the same active pharmaceutical ingredient(s) in the same dosage form and the same formulation as is contained in such Pharmaceutical Product, and (b) such product is A/B Rated with respect to such Pharmaceutical Product.  For the purposes of this definition, “A/B Rated” means, inside the United States, “therapeutically equivalent” as evaluated by the FDA, applying the definition of “therapeutically equivalent” set forth in the preface to the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations” and, outside the United States, such equivalent determination by the applicable Regulatory Authorities as is necessary to permit pharmacists or other individuals authorized to dispense pharmaceuticals under Applicable Law to substitute one product for another product in the absence of specific instruction from a physician or other authorized prescriber under Applicable Law.  
1.56“Good Clinical Practices” or “GCP” means the then-current international ethical and scientific quality standards for designing, conducting, recording and reporting trials that involve the participation of human subjects.  In the United States, GCP shall be based on Good Clinical Practices established through FDA guidance (including ICH E6) and, outside the United States, GCP shall be based on ICH E6.  
1.57“Good Laboratory Practices” or “GLP” means the then-current Good Laboratory Practice (or similar standards) for the performance of laboratory activities for pharmaceutical products as are required by applicable Regulatory Authorities or Applicable Law.  In the United States, Good Laboratory Practices are established through FDA regulations (including 21 C.F.R. Part 58), FDA guidance, FDA current review and inspection standards and current industry standards. 
1.58“Good Manufacturing Practices” or “GMP” means the then-current Good Manufacturing Practices for the manufacture of products as are required by applicable Regulatory Authorities or Applicable Law.  In the United States, GMP shall be as defined under the rules and regulations of the FDA, as the same may be amended from time to time.
1.59“GSK Compound” means any compound which is Controlled by GSK or its Affiliates [***], in any form including, but not limited to the final active pharmaceutical ingredient (i.e., an API) form (but excluding, for clarity, any Enzyme). 
1.60“GSK Exclusive Field” means the development and/or use of any Enzyme for the synthesis of any GSK Compound, within the Field.   
1.61“GSK Existing Pharmaceutical Product” means any GSK product containing a GSK Compound which has obtained Regulatory Approval and where the first such GSK product sold in a Major Market Country did not include the use of a GSK Selected Enzyme within the route of synthesis of the GSK Compound included within the product.
1.62
    - 9 -

SV\1263057.27

“GSK Initial Enzyme(s)” means any enzyme (which for clarity is not an “Enzyme”) that is provided by GSK and which is designated as an Initial Enzyme pursuant to a Project excluding, for clarity, Enzymes derived from a Codexis Enzyme or a Codexis Library.
1.63“GSK Project Library” means any collection, set or sub-set of Enzymes and/or expression vectors containing genes that encode for Enzymes derived from a Project.
1.64“GSK Selected Enzyme” means an Enzyme derived from an Initial Enzyme and has been selected by GSK from a Project for use pursuant to this Agreement to synthesize any GSK Compound.  
1.65“GSK Sole Project” means any Enzyme evolution project that was initiated using a GSK Initial Enzyme or a Codexis Initial Enzyme, conducted in the GSK Exclusive Field by GSK or any Affiliate of GSK, whether or not in collaboration with any Third Party permitted under this Agreement, using the Platform Technology which may involve limited Codexis’ participation (which, for clarity, would not constitute such level of participation that the JSC would otherwise deem such participation as constituting a Collaborative Project). 
1.66“GSK Team” shall have the meaning assigned to it in Section 2.2.5(a).  
1.67“IFRS” means the International Financial Reporting Standards.
1.68“Improvements TT Term” means the period beginning on the expiration of the TT Term and continuing until and ending on the earlier of (a) the Improvements TT Term Expiration Date, (b) the date on which GSK fails to timely pay an Annual Option Fee in accordance with Section 7.2 or (c) the early termination of this Agreement by Codexis in accordance with Sections 11.2 or 11.4.
1.69“Improvements TT Term Expiration Date” means, if GSK exercises the Option under Section 3.5.2 and timely pays the First Annual Option Fee and each Annual Option Fee set forth in Section 7.2, the three (3) year anniversary of the TT Term Expiration Date or a later date if the Improvements TT Term is extended in accordance with Section 3.5.4. 
1.70“Initial Enzyme” means any GSK Initial Enzyme or Codexis Initial Enzyme contributed to a Project which is selected to undergo Initial Enzyme Optimisation.
1.71“Initial Enzyme Optimisation” means the process of optimising Initial Enzymes for desired characteristics directly using the Platform Technology in any Project.
1.72“Initial Technology Transfer Inventory” means all of the items set out in Appendix I of the Technology Transfer Plan.
1.73“Initial Training” has the meaning assigned to such term in Section 2.2.6.   
1.74
    - 10 -

SV\1263057.27

“In-License Agreements” means the agreements set forth in Exhibit 1.74 in the versions sent by Codexis to GSK in an e-mail(s) dated July 7, 2014. 
1.75“In-Licensed IP” means the In-Licensed Patents and any In-Licensed Know-How.
1.76“In-Licensed Know-How” means all Know-How of Third Parties Controlled by Codexis as of the Effective Date and licensed to Codexis pursuant to the In-License Agreements, in each case that Covers the Codexis Documentation, the Codexis Materials, the Codexis Software or the practice of the Platform Technology.
1.77“In-Licensed Patents” means all Patents of Third Parties Controlled by Codexis as of the Effective Date and licensed or sub-licensed to Codexis pursuant to the In-License Agreements, in each case, that Cover the Codexis Documentation, the Codexis Materials, the Codexis Software or the practice of the Platform Technology, set forth on Exhibit 1.77.  
1.78“Intellectual Property” means Patents, Know-How, copyrights and software, including all applications for registration for the foregoing and all other similar proprietary rights as may exist anywhere in the world. 
1.79“Invention” means any discovery, invention, contribution, method, finding, or improvement, whether or not patentable, and all related Know-How.
1.80“Invoice” means any invoice submitted to GSK by Codexis under this Agreement, produced in accordance with GSK’s processing requirements, as set forth in Exhibit 1.80. 
1.81“Know-How” means non-public materials and technical information, including techniques, methods, processes, technology, recipes, designs, equipment configurations and uses, biological samples, compounds and cell lines, and biological, chemical, pharmacological, toxicological, clinical, assay and related trade secrets, and manufacturing data, preclinical and clinical data, the specifications of ingredients, the manufacturing processes, formulation, specifications, sourcing information, quality control and testing procedures, and related know-how and trade secrets.  
1.82“Licensed Additional Codexis IP” means Licensed Additional Codexis Know-How and Licensed Additional Codexis Patents.
1.83“Licensed Accessory Product” means [***]. 
    - 11 -

SV\1263057.27

1.84“Licensed Additional Codexis Know-How” means any and all Know-How which (a) Codexis or any Codexis Affiliate comes to Control during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) which Covers (i) the Platform Technology, (ii) Arising Codexis Enzyme Technology, (iii) Arising Codexis Process Technology, (iv) any Codexis Core Technology Improvements, (v) the Codexis Documentation and (vi) Codexis Materials.
1.85“Licensed Additional Codexis Patents” means any and all Patents which (a) Codexis or any Affiliate comes to Control during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) which Covers (i) the Platform Technology, (ii) Arising Codexis Enzyme Technology, (iii) Arising Codexis Process Technology, or (iv) any Codexis Core Technology Improvements.
1.86“Licensed Collaborative Project GSK Selected Enzyme” means any GSK Selected Enzyme arising from a Collaborative Project. 
1.87“Licensed Diagnostic Product” means [***].
1.88“Licensed Enzyme Therapeutic Product” means [***].
1.89“Licensed GSK Sole Project GSK Selected Enzyme” means any GSK Selected Enzyme arising from a GSK Sole Project. 
1.90“Licensed IP” means (a) the Licensed Patents, (b) the In-Licensed Patents, (c) the Licensed Know-How, (d) the In-Licensed Know-How, (e) the Licensed Additional Codexis Know-How, and (f) the Licensed Additional Codexis Patents. 
1.91“Licensed Know-How” means any Know-How Controlled by Codexis as of the Effective Date which is disclosed or provided to GSK hereunder in accordance with Section 2.2.3, including the Codexis Documentation, Codexis Materials and Codexis Software but only to the extent existing as of the Effective Date. 
1.92“Licensed Other Therapeutic Product” means [***].
1.93“Licensed Patents” means (a) the Codexis Core Patents and (b) the Codexis Enzyme Patents.  
    - 12 -

SV\1263057.27

1.94“Licensed Product” means an Enzyme Product and/or a Pharmaceutical Product.
1.95“Licensed Prophylactic Product” means [***].
1.96“Losses” means any claim, threatened claim, suit, proceeding, liability, loss, damage, expense (including reasonable legal expenses, costs of litigation, and attorneys’ fees) or judgment, whether for money or equitable relief, of any kind. 
1.97“Major Market Country” means [***]. 
1.98“Net Sales” means gross invoiced sales of the Licensed Product to Third Parties, in each quarter less the following deductions from such gross amounts which are actually incurred, allowed, paid, accrued or specifically allocated to the extent that such amounts are deducted from gross invoiced sales amounts as reported in financial statements in accordance with the International Financial Reporting Standards (“IFRS”), applied on a consistent basis:  
1.1.1credits or allowances actually granted for damaged Licensed Product, returns or rejections of Licensed Product, price adjustments, and billing errors;
1.1.2governmental and other rebates (or equivalents thereof) to national, state/provincial, local and other governments, their agencies and purchasers, and reimbursers, or to trade customers;
1.1.3normal and customary trade, cash and quantity discounts, allowances, and credits actually allowed or paid; 
1.1.4commissions allowed or paid to Third Party distributors, brokers or agents other than sales personnel, sales representatives and sales agents; 
1.1.5transportation costs, including insurance, for outbound freight related to delivery of Licensed Product to the extent included in the gross amount invoiced; 
1.1.6sales taxes, value added taxes, and other taxes directly linked to the sales of Licensed Product to the extent included in the gross amount invoiced; and 
1.1.7any other items actually deducted from gross invoiced sales amounts as reported in financial statements in accordance with the IFRS, applied on a consistent basis.  
    - 13 -

SV\1263057.27

For purposes of this definition, the Licensed Product shall be considered “sold” and “deductions” allowed when recorded as invoiced in financial statements prepared in accordance with IFRS.
1.99“On-Site Training” has the meaning assigned to such term in Section 2.2.7. 
1.100“Patent(s)” means (a) patents and patent applications anywhere in the world, (b) all divisionals, continuations, continuations in-part thereof or any other patent application claiming priority, or entitled to claim priority, directly or indirectly to (i) any such patents or patent applications, or (ii) any patent or patent application from which such patents or patent applications claim, or is entitled to claim, direct or indirect priority, and (c) all patents issuing on any of the foregoing anywhere in the world, together with all registrations, reissues, re-examinations, patents of addition, renewals, substitutions, validations, and re-validations, supplemental protection certificates or extensions of any of the foregoing anywhere in the world, and (d) all provisional and any other priority patent applications filed worldwide.
1.101“Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, governmental authority, association or other entity.  
1.102“Pharmaceutical Product” means any product containing a GSK Compound that includes a GSK Selected Enzyme within its route of synthesis, and which has been formulated into such product.
1.103“Phase 1b Clinical Trial” means a pilot human clinical trial usually conducted in patients diagnosed with the disease, or condition for which the study drug is intended, who demonstrate some biomarker, surrogate, or possible clinical outcome.
1.104“Phase 2a Clinical Trial” means a human clinical trial, the principal purpose of which is a determination of efficacy and safety, in the target population, at the intended clinical dose or doses, to confirm the optimal manner of use.
1.105“Platform Technology” means (a) the Codexis Core Technology, (b) the Codexis Enzymes and (c) the Codexis Libraries which are provided to GSK by Codexis under this Agreement in such a state and condition and in the detail which are necessary to enable a scientist with reasonable skills and experience in the field of protein engineering or protein biochemistry to use, identify, select, optimise, isolate, modify, engineer, research, develop, make, have made and/or import any Enzyme, in each of (a), (b) and (c), that (i) is described in, and embodies the subject matter of, the Codexis Documentation, and (ii) uses the Codexis Materials and the Codexis Software.
1.106“Project” means any GSK Sole Project or Collaborative Project.
    - 14 -

SV\1263057.27

1.107“Project Enzyme” means any Enzyme derived from an Initial Enzyme arising from a Round of Enzyme Evolution.
1.108“Prosecution” means the preparation, drafting, filing, prosecution (including any interferences, reissue proceedings, reexaminations, inter partes reviews, post-grant reviews, oppositions and Patent office appeals) and maintenance of Patents in the Territory.  When used as a verb, “Prosecute” means to engage in Prosecution.
1.109“Regulatory Approval(s)” means, with respect to any Licensed Product in any jurisdiction, all approvals from any Regulatory Authority necessary for the commercial manufacture, marketing and sale of any product containing such Licensed Product in such jurisdiction in accordance with Applicable Law, including without limitation, receipt of pricing and reimbursement approvals, where required. 
1.110“Regulatory Authority” means any national or supranational governmental authority, including without limitation the FDA, that has responsibility in countries in the Territory over the development and/or commercialization of any Licensed Product, as applicable.  
1.111“Regulatory Filings” means any and all regulatory applications, filings, approvals and associated correspondence required to develop any Licensed Product in each country or jurisdiction in the Territory.
1.112“Restricted Enzyme” means any immature or mature peptide or protein with enzymatic or biocatalytic activity, or any vector that encodes for any such peptide or protein, listed in Exhibit 1.112, which list as of the Effective Date will be provided in accordance with Section 3.7.1.  During the Term, Exhibit 1.112 may be revised in accordance with Section 3.7.1.  
1.113“Round(s) of Enzyme Evolution” means round of Initial Enzyme Optimisation conducted during a Project resulting in Project Enzymes comprising a GSK Project Library. 
1.114“Royalty Term” means, on a country-by-country and Enzyme Product-by-Enzyme Product basis, the period commencing as of the date of First Commercial Sale of such Enzyme Product in such country and ending upon [***]: (a) [***] years after the date of First Commercial Sale of such Enzyme Product in such country, and (b) the date of expiration of the last to expire Valid Claim of the last to expire Patent that claims the composition of matter or method of use of the Enzyme Product that would be infringed by the manufacture, use or sale of such Enzyme Product in such country, but for the licenses granted to GSK under this Agreement.  
1.115“Scientific Lead” shall have the meaning assigned to it in Section 2.1.1.
    - 15 -

SV\1263057.27

1.116“Technology Transfer” means (a) the transfer of the Codexis Documentation, Codexis Software and Codexis Materials and (b) the training with respect to the Platform Technology, in each case to be conducted in accordance with the Technology Transfer Plan and Article 2.  
1.117“Technology Transfer Plan” means that plan for the Technology Transfer as mutually agreed between the Parties and set forth in Exhibit 1.117 as of the Effective Date and as may be amended by the Parties during the TT Term in accordance with Section 2.2.4, itemising each Party’s responsibilities and obligations, the activities to be performed by each Party, and a timeline for performance of such activities, in connection with the Technology Transfer from Codexis to GSK to fully implement the Platform Technology within GSK.  
1.118“Territory” means worldwide. 
1.119“Third Party” means any Person other than GSK and Affiliates of GSK, and Codexis and Affiliates of Codexis.
1.120“TT Term” means the period beginning on the Effective Date and ending on the earlier of (a) the date on which Codexis receives notification from GSK, in accordance with Section 7.3, of Completion of Wave 3, (b) the third (3rd) anniversary of the Effective Date, or (c) the date GSK initiates the first GSK Sole Project that is not a Technology Transfer Project and for which GSK will provide prompt notification to Codexis of such initiation date.
1.121“TT Term Expiration Date” means the earlier of (a) the date on which Codexis receives notification from GSK, in accordance with Section 7.3, of Completion of Wave 3, (b) the third (3rd) anniversary of the Effective Date, or (c) the date GSK initiates the first GSK Sole Project that is not a Technology Transfer Project and for which GSK will provide prompt notification to Codexis of such initiation date.   
1.122“Upfront Payment” shall have the meaning assigned to it in Section 7.1.
1.123“United States” or “U.S.” means the United States of America and all its territories and possessions.
1.124“Valid Claim” means either (a) a claim of an issued and unexpired Patent which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise (i.e., only to the extent the subject matter is disclaimed or is sought to be deleted or amended through reissue), or (b) a claim of a pending Patent application that has not been abandoned, finally rejected or expired without the possibility of appeal or refiling. 
1.125“Wave” means each phase of the Technology Transfer noted as Wave 1, Wave 2 and Wave 3 of the Technology Transfer Plan in force as of the Effective Date, and from time-to-time during the TT Term. 
1.126Additional Definitions.  Each of the following terms has the meaning set forth in the corresponding section of this Agreement indicated below:
    - 16 -

SV\1263057.27

						
	Definition:	Section:
	AAA	12.3

	A/B Rated	1.55

	Acquiring Entity	1.16

	Agreement	Preamble
	Annual Option Fee	7.2

	Bankruptcy Code	11.3

	Breaching Party	11.2

	Challenging Party	11.4

	Codexis	Preamble
	Codexis Indemnitees	10.1

	Codexis Patents	6.5.2

	Covered Patent Claim	3.1.3

	Cure Period	11.2

	Disclosing Party	9.1

	Dispute	12.1

	Effective Date	Preamble
	Exclusive Option	3.5.1

	First Annual Option Fee	7.2

	Force Majeure	13.4

	GSK	Preamble
	GSK Indemnitees	10.2

	GSK Patents	6.5.3

	Indemnification Claim	10.3

	Indemnitee	10.3

	Indemnitor	10.3

	Infringement Action	6.6.1

	Joint Steering Committee or JSC	5.1.1

	Lactosan	3.4.6

	Material	2.5

	Material Transfer Record Form	2.5

	Non-Breaching Party	11.2

	Non-Exclusive Option	3.5.1

	Non-Solicitation Period	13.1

	Option	3.5.1

	Option Period	3.5.2

	Parties	Preamble
	Party	Preamble
	Patent Challenge	11.4

    - 17 -

SV\1263057.27

						
	Patent Claim	3.1.3

	Patent Committee	5.2.1

	Patent Committee Embargo License Period	3.1.4(a)

	Potentially Restricted Enzyme	3.7.1

	Project Team	5.1.3

	Receiving Party	9.1

	Royalties	7.9

	Technology Transfer	1.116

	Technology Transfer Project	2.3

	Technology Transfer Project Activities	2.3

	Technology Transfer Project Plan	2.3

	Term	11.1

	Termination Audit Right	11.5.3

	Terminated Country	11.5.2

	Transferor	2.5

	Transferee	2.5

2.TECHNOLOGY TRANSFER AND PROJECTS
1.127Management of Technology Transfer; Projects; Alliance.
1.1.1Scientific Lead.  Each Party shall designate in writing within fifteen (15) days after the Effective Date, a “Scientific Lead” with all necessary scientific skill and expertise to fulfil such role in accordance with this Article 2, to be the primary contact for such Party responsible for managing day-to-day communications between the Parties with respect to the technical aspects of the Technology Transfer and other scientific and technical activities set forth in this Agreement, including responsibility for scheduling teleconferences and coordinating meetings and technical support as required hereunder.  Each Party may respectively appoint a substitute Scientific Lead to represent it under this Section 2.1.1.  
1.1.2Alliance Manager.  Each Party shall designate in writing within fifteen (15) days after the Effective Date, an “Alliance Manager” with all necessary business skill and expertise as necessary to be the primary contact for such Party as regards all business development and/or contract-related communications between the Parties for all matters in connection with this Agreement, outside of the purview of the technical matters for which the Scientific Leads are responsible.  The Alliance Managers shall be responsible for initially 
    - 18 -

SV\1263057.27

addressing any finance, legal and business issues that may arise.  Each Party may respectively appoint a substitute Alliance Manager to represent it under this Section 2.1.2.
1.1.3Limitations.  The Scientific Leads and the Alliance Managers shall not have the authority to amend, modify or waive compliance with this Agreement, through meeting minutes, e-mails or otherwise.
1.128Technology Transfer.
1.1.1Codexis Methods.  Except for the protocols listed under the heading “Protocols to be Generated in the Context of Training during Technology Transfer” in Appendix IV of the Technology Transfer Plan, Codexis shall provide the Codexis Methods within thirty (30) days after the Effective Date. 
1.1.2Codexis Technology Transfer.  Codexis shall transfer to GSK the Initial Technology Transfer Inventory and: (a) the Codexis Materials, (b) the Codexis Documentation, and (c) the Codexis Software, each in accordance with the Technology Transfer Plan.  The Parties shall perform the Technology Transfer during the TT Term pursuant to the timelines under the Technology Transfer Plan.  
1.1.3Technology Transfer Plan.  Upon the Effective Date the Parties shall commence the Technology Transfer in sequential order of Waves as described in, and in accordance with, the Technology Transfer Plan.  Each Party shall perform the activities assigned to such Party under the Technology Transfer Plan at the sites identified in Section 2.2.6 and 2.2.7 and shall perform all such activities in compliance with Applicable Law.  Notwithstanding anything to the contrary, subject to any updates to the Technology Transfer Plan pursuant to Section 2.2.4, Codexis shall not be obligated to transfer to GSK any information and/or materials not described in the Technology Transfer Plan.
1.1.4Updates to Technology Transfer Plan.  In the event that errors and/or omissions in the Technology Transfer Plan are discovered by GSK and/or Codexis during the TT Term and the Parties mutually agree to update the Technology Transfer Plan pursuant to any reasonable scientific rationale agreed between the Parties to enable GSK to practice the Platform Technology, the Parties shall then update the Technology Transfer Plan accordingly. 
1.1.5Technology Transfer Teams.  In order to effect Section 2.2:
(a)GSK shall identify a Technology Transfer team of personnel and in such numbers as it may so determine (the “GSK Team”) to participate in each Wave of the Technology Transfer.  GSK shall change any member(s) of the GSK Team in its sole discretion at any time.  The GSK Team shall have all reasonable skills and experience in the field of protein engineering to perform the Technology Transfer.
(b)
    - 19 -

SV\1263057.27

Codexis shall identify a Technology Transfer team to lead the GSK Team in each Wave of the Technology Transfer, including the Initial Training and the On-Site Training [***] (the “Codexis Team”) as detailed in the Technical Transfer Plan.  Codexis, in its sole discretion, may change any member(s) of the Codexis Team at any time.  Each member of the Codexis Team shall have all necessary scientific experience and expertise to perform the Technology Transfer. 
1.1.4Initial Training at Codexis’ Facility.  After the Effective Date, the GSK Team will participate in Wave 2 of Technology Transfer at Codexis’ facility in Redwood City, California, which training shall be completed as outlined in the Technology Transfer Plan (the “Initial Training”).  GSK shall bear its own costs and expenses of participating in such Initial Training.
1.1.5On-Site Training at GSK’s Upper Merion West Campus Facility.  On an agreed-upon date, promptly following Completion of Wave 1 the Codexis Team and the GSK Team will participate in Wave 2 Technology Transfer activities at a GSK facility in Upper Merion West Campus facility (or any other GSK facility nominated by GSK in the greater Philadelphia region). Codexis shall bear its own costs and expenses of providing such training (the “On-Site Training”).  The On-Site Training shall be conducted by the Codexis Team in accordance with the Technology Transfer Plan.  The On-Site Training shall include training on all items identified in the Technology Transfer Plan as required at the On-Site Training.
1.1.6Acceptance by GSK of the Initial Technology Transfer Inventory; Completion of Technology Transfer.  The Initial Technology Transfer Inventory to be transferred in accordance with the Technology Transfer Plan shall be deemed to have been accepted by GSK [***] (the “Initial Technology Transfer Inventory Acceptance Criteria”).  In the event that any item in the Initial Technology Transfer Inventory fails to meet the Initial Technology Transfer Inventory Acceptance Criteria, GSK shall notify Codexis in writing [***].  In the event that any item of the Initial Technology Transfer Inventory fails to meet the Initial Technology Transfer Inventory Acceptance Criteria and GSK so notifies Codexis of such, Codexis shall promptly provide replacements for any item of the Initial Technology Transfer Inventory which shall meet the Initial Technology Transfer Inventory Acceptance Criteria.  The Technology Transfer will have been completed when each item of the Initial Technology Transfer Inventory and each step in the Technology Transfer Plan has been successfully completed[***].  
1.1.7Codexis Core Technology Improvements, Arising Codexis Enzyme Technology and Arising Codexis Process Technology During the TT Term.
    - 20 -

SV\1263057.27

(c)Initial Disclosure.  Within [***] days after the end of the Calendar Quarters ending June 30 and December 31:
(i)during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Codexis Core Technology Improvements by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any; and
(ii)during the TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any.  
(d)Subsequent Disclosure.  If the GSK Alliance Manager requests further information regarding Codexis Core Technology Improvements, Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis, and [***] corresponding Licensed Additional IP during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, and corresponding Licensed Additional Codexis IP disclosed to GSK in accordance with Section 2.2.9(a), GSK shall, within [***] days after receipt of the initial disclosure of Codexis Core Technology Improvements by Codexis pursuant to Section 2.2.9(a) request the disclosure of such further information Controlled by Codexis, and with respect to Section 2.2.9(a), in sufficient detail as reasonably necessary for GSK to make a decision as to whether to exercise its rights pursuant to Section 3.5.2 to obtain a license to such Codexis Core Technology Improvements and corresponding Licensed Additional Codexis IP. All information, documents and other materials disclosed by Codexis to GSK pursuant to this Section 2.2.9 shall constitute the Confidential Information of Codexis.
(e)Disclosure of Codexis Core Technology Improvements During the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  During the TT Term and, if GSK exercises the Option, during the Improvements TT Term, GSK shall have [***] days after the disclosure of such further information relating to the Codexis Core Technology Improvements and corresponding Licensed Additional Codexis IP pursuant to Section 2.2.9(b) to request in writing that Codexis disclose such Codexis Core Technology Improvement(s) and [***] corresponding Licensed Additional Codexis IP to GSK.  If GSK makes such request during such period, Codexis shall disclose such Codexis Core Technology and Licensed Additional Codexis IP to GSK as promptly as possible, and in any event no later than within [***] days and such Codexis Core Technology and Licensed Additional Codexis IP shall be deemed licensed to GSK under Section 3.2.1.
  
    - 21 -

SV\1263057.27

(f)Role of Scientific Lead.  For one (1) Calendar Year following the end of the TT Term, and during the Improvements TT Term, if GSK exercises the Option, Codexis shall make its Scientific Lead reasonably available to provide telephonic or web-based advisory technical support and assistance to GSK in GSK’s practice of the Platform Technology pursuant to the licenses granted pursuant to Section 3.5.3.  
1.1.1Arising GSK Enzyme Technology and Arising GSK Process Technology During the TT Term.
(g)Initial Disclosure.  Within [***] days after the end of the Calendar Quarters ending June 30 and December 31, during the TT Term, GSK shall disclose to Codexis’ Alliance Manager [***] Arising GSK Enzyme Technology and Arising GSK Process Technology, if any.  
(h)Subsequent Disclosure.  If the Codexis Alliance Manager requests further information regarding Arising GSK Enzyme Technology and/or Arising GSK Process Technology, Codexis shall, within [***] days after receipt of the initial disclosure of such Arising GSK Enzyme Technology and/or such Arising GSK Process Technology by GSK pursuant to Section 2.2.10(a) request the disclosure of such further information Controlled by GSK.
1.1Technology Transfer Projects.  During the TT Term, the Parties shall conduct at least four (4) Projects as set forth in the Technology Transfer Plan (each, a “Technology Transfer Project”) pursuant to the terms of written project plans (each, a “Technology Transfer Project Plan”) agreed upon and approved by the JSC at appropriate times during the TT Term in light of the schedule set forth in the Technology Transfer Plan.  The Parties acknowledge and agree that Technology Transfer Projects [***] (as described in the Technology Transfer Plan) shall be [***], and Technology Transfer Projects [***] (as described in the Technology Transfer Plan) shall be [***]. Subject to Article 7, each Party shall be solely responsible for all costs and expenses arising from activities performed by such Party pursuant to the Technology Transfer Project Plans (“Technology Transfer Project Activities”).  Each such Technology Transfer Project shall be deemed completed upon satisfaction of the criteria for such project as set forth in the Technology Transfer Plan.   
1.2New Projects.  Upon reasonable request by GSK during the TT Term, the JSC shall meet to discuss in good faith one or more additional Collaborative Projects to be conducted by the Parties under this Agreement.  If the JSC agrees that any such Collaborative Project shall be performed by the Parties, the Parties shall prepare in good faith a written research plan for such Collaborative Project and submit such written research plan to the JSC for approval.  If the JSC approves such Collaborative Project, the written research plan will automatically be made a part of this Agreement. 
    - 22 -

SV\1263057.27

1.3Transfers of Materials.  In the event that the Parties mutually agree that a transfer of any biopharmaceutical, biological, chemical or other material (“Material(s)”) from GSK or Codexis (the “Transferor”) to Codexis or GSK (as applicable) (the “Transferee”)  is necessary or desirable to facilitate the Parties’ collaborative activities pursuant to this Agreement, except where Codexis Materials are transferred by Codexis to GSK pursuant to the Technology Transfer Plan (which in all cases shall be itemised and recorded in writing, such written records to be sent to GSK for confirmation of receipt of all such items), the Parties shall document such transfer using the material transfer record form set out in Exhibit 2.5 (the “Material Transfer Record Form”) and the Transferor shall effect such transfer in accordance with the following provisions: 
1.1.1the Transferor shall complete and submit to the Transferee for counter-signature, the Material Transfer Record Form prior to the transfer of the Material.
1.1.2both Parties warrant that they have the full right and authority to transfer the Materials to the Transferee for use within the contemplated research program.
1.1.3the Material and related information provided by Transferor will remain the property of Transferor or remain under the control of Transferor and will be kept securely by Transferee and will not be provided by Transferee, without the prior written consent of Transferor, to any Third Party.
1.1.4the Transferee shall only use the Material for the purpose of the performing the applicable work as laid out under any applicable Project or in connection with the Platform Technology, in each case in accordance with Applicable Law.
1.1.5the Transferee acknowledges that the Material is experimental in nature and provided “AS IS.” 
1.1.6the Transferee shall use the Material at its own risk and in accordance with Applicable Law and any safety instructions provided by the Transferor. 
1.1.7all right title and interest in Materials transferred in accordance with this Section 2.5 shall remain vested in the Transferor and the Transferee shall gain no right, title or interest of any sort, other than as may be granted to the Transferee pursuant to the rights and licenses in this Agreement, in such Material.  
1.1Project Reporting.  At each JSC meeting or as otherwise agreed between the Parties (but in no event less than once per Calendar Quarter), each Party will provide the JSC with presentations regarding the Technology Transfer Project Activities performed by it, including a summary of results relating to each Technology Transfer Project. 
    - 23 -

SV\1263057.27

1.2Post- Project Enzyme Supply.   
1.1.8Request, Audit and Supply Terms.  Subject to the limitations in Section 2.7.2, GSK, during the Term, may request that Codexis supply to GSK any Enzyme for use in any Project.  Prior to obtaining supply of any Enzyme from Codexis, GSK shall have the right to perform a quality and technical audit of Codexis’ manufacturing facility to determine such facility’s suitability for manufacture of the Enzyme and compliance with Applicable Law, including without limitation, whether such facility (a) holds necessary permits and licenses; and (b) maintains such Good Laboratory Practices and/or Good Manufacturing Practices, in each case as may be applicable to the Enzyme to be obtained from Codexis.  If GSK elects to proceed with obtaining supply from Codexis after satisfactory completion of the audit, the Parties shall negotiate in good faith to agree to mutually acceptable commercial supply and quality terms, defining the roles and responsibilities related to Codexis’ manufacture and delivery of the Enzyme to GSK.  [***]. 
1.1.9Limitations.  GSK may only request the use of [***], and Codexis will have no obligation under Section 2.7.1 to supply Enzyme to GSK [***].
1.4Regulatory Responsibilities and Costs. As between the Parties, GSK shall prepare, file, maintain and own all Regulatory Filings and related submissions with respect to all Licensed Products and shall bear the cost of such preparation, filing, maintenance and ownership.  GSK shall be responsible for all safety reporting obligations globally with respect to all Licensed Products and shall maintain the global safety database for all Licensed Products.  GSK shall be solely responsible for communicating with the FDA and/or any other Regulatory Authority in any country or jurisdiction regarding all Licensed Products.
1.5Commercialization Responsibilities and Costs.  GSK shall be solely responsible for all commercialization activities relating to Licensed Products, at GSK’s sole cost and expense, and shall have sole decision-making authority with respect to the foregoing.  GSK shall conduct all commercialization activities under this Agreement in compliance with all Applicable Law.  For clarity, nothing in this Agreement shall require GSK to develop or commercialize any minimum number of Licensed Products or limit the number of Licensed Products that GSK may develop or commercialize. 
1.6Availability for Collaborative Projects; Additional Codexis Libraries.  During the TT Term, [***]
    - 24 -

SV\1263057.27

[***]; provided that the JSC agrees that the performance of such Project Activities by such members of the Codexis Team will not impact negatively the Technology Transfer or any Technology Transfer Project.  
1.7Party Employees.  Notwithstanding anything to the contrary under this Agreement, under no circumstance would any employee, contractor, contingent worker or consultant of a Party be considered an employee, contractor, contingent worker or consultant of the other Party.  The Party who sends any employee, contractor, contingent worker or consultant to work at the other Party’s premises shall assume all liability for such employees, contractors, contingent workers or consultants working at the other Party’s premises and shall procure  that its employees, contractors, contingent workers or consultants comply with all security, health and safety and other policies applicable to occupiers of the hosting Party’s premises.
3.LICENSES
1.1Licenses to Codexis.
1.1.1GSK Background IP License.  Subject to the terms and conditions of this Agreement, GSK hereby grants to Codexis a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5), fully paid-up, royalty-free right and license, with the right to grant sublicenses solely to Affiliates, under GSK’s Background IP in the GSK Exclusive Field solely as necessary for Codexis to perform its obligations during the Technology Transfer and under each Project as set forth in the written research plan applicable to such Project.  
1.1.2Arising GSK Enzyme Technology IP and Arising GSK Process Technology IP.  Subject to the terms and conditions of this Agreement, GSK hereby grants to Codexis a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5), fully paid-up, royalty-free right and license, with the right to grant sublicenses through multiple tiers, under the Arising GSK Enzyme Technology IP and the Arising GSK Process Technology IP (in each case, if any) for any use outside of the GSK Exclusive Field; provided that the foregoing license [***] which shall include any GSK Selected Enzyme.  
1.1.3Embargo License.  If it is determined pursuant to Section 3.1.4(a) that GSK, during the Embargo Period, used Platform Technology in any way with respect to any Enzyme or Enzyme fusion protein within the Codexis Exclusive Field that is claimed in any Patent (whether or not filed during the Embargo Period) that is Controlled by GSK, licensed to GSK by a Third Party or licensed by GSK to a Third Party  and that such Patent claims the composition, manufacture or use of any product or product candidate in the Codexis Exclusive Field that is Controlled by Codexis or, if applicable, an exclusive licensee or 
    - 25 -

SV\1263057.27

assignee of Codexis with respect to such product or product candidate ( “Patent Claim”), then GSK hereby grants to Codexis or, if applicable, each such exclusive licensee or assignee a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5, fully paid-up, royalty-free right and license, with the right to grant sublicenses only to Affiliates, and collaborators, partners, suppliers or vendors, under each Patent Controlled by GSK that includes a Patent Claim, to develop, make, use, sell, offer for sale, market, import and export such product or product candidate in the Codexis Exclusive Field.
1.1.4Patent Claims.
(a)The determination of the existence of a Patent Claim, as described in Section 3.1.3, shall be made by the Patent Committee pursuant to Section 5.2.1, provided, however, that if the Patent Committee is unable to resolve such matter within thirty (30) days (the “Patent Committee Embargo License Period”), then notwithstanding Section 5.2.3 and Article 12, the determination will be made pursuant to Section 3.1.4(b).
(b)Independent Patent Counsel.  If the Patent Committee cannot make a determination under Section 3.1.4(b), the determination of the existence of a Patent Claim, notwithstanding Article 12, will be made by independent patent counsel in accordance with the following procedure: 
(i)Selection of Independent Patent Counsel.  The Parties’ representatives on the Patent Committee, within fifteen (15) days after the end of the Patent Committee Embargo License Period, shall mutually agree on, and the Patent Committee shall select, one person to serve as an independent patent counsel.
(ii)Process.  The Parties may submit evidence and written arguments as deemed necessary by the independent patent counsel; provided, however, that any evidence and arguments shall be submitted within fifteen (15) days or any longer period of time mutually agreed between the Parties after the selection of the independent patent counsel. 
(iii)Costs and Expenses.  Each Party will share equally the cost and expenses of the independent patent counsel selected in 3.1.4(b)(i).  Each Party shall bear its own costs and expenses and attorneys’ fees in connection with any such determination; provided, however, that the prevailing Party in any such determination shall be entitled to recover from the other Party the reasonable attorneys’ fees, costs and expenses incurred by such prevailing Party in connection with such determination.
(iv)Binding Decision.  The decision of the independent patent counsel shall be the sole, exclusive and binding decision regarding the determination of the existence of a Patent Claim.  The independent patent counsel shall prepare and deliver to the Parties a written, reasoned opinion conferring its decision.
(a)
    - 26 -

SV\1263057.27

After the grant of a second license under Section 3.1.3, GSK will be deemed in material breach of this Agreement, and Codexis shall have a right to terminate this Agreement pursuant to Section 11.2, such termination to be effective immediately upon notice to GSK, notwithstanding the sixty (60) day cure period set forth in such Section 11.2. 
1.1Licenses to GSK.  
1.1.1Platform Technology Licenses.  Subject to the terms and conditions of this Agreement (including the restrictions under Section 3.4), Codexis hereby on behalf of itself and its Affiliates, grants to GSK, during the Term, a nontransferable (except as provided in Section 13.5), right and license, with the right to grant sublicenses to Affiliates and Third Parties, in accordance with, and to the extent permitted under, Section 3.3, under the Licensed IP in the Territory, with respect to enzymes, including any enzyme owned or otherwise controlled by GSK under this Agreement or otherwise, to use the Platform Technology (or any aspect of the Platform Technology), which right and license shall be:
(a)exclusive in the GSK Exclusive Field; and
(b)non-exclusive otherwise in the Field; 
in each of Sections 3.2.1(a) and 3.2.1(b), solely to research, develop, use, optimize, modify, isolate, engineer, identify, select, make, have made, import and/or export Enzymes, other than any Restricted Enzyme.  
1.1.1Manufacturing Licenses.  Subject to the terms and conditions of this Agreement (including the restrictions under Section 3.4), Codexis hereby on behalf of itself and its Affiliates grants to GSK, during the Term, a non-transferable (except as provided in Section 13.5) right and license, with the right to grant sublicenses solely to Affiliates, contract manufacturing organizations (CMOs),  contract research organizations (CROs), or other contract service organizations in accordance with and to the extent permitted under Section 3.3 under the Licensed IP in the Territory, solely to make or have made, for the purpose of sale or to have sold:
(c)Pharmaceutical Products, which shall be exclusive in the GSK Exclusive Field and otherwise non-exclusive in the Field; and
(d)Enzyme Products, which shall be a non-exclusive license in the Field.  
1.1.2Loss of Pharmaceutical Product Exclusivity.  The exclusive licenses granted by Codexis to GSK in the GSK Exclusive Field pursuant to Sections 3.2.1, 3.2.2 and 3.5.3 shall become non-exclusive, on a Pharmaceutical Product-by-Pharmaceutical 
    - 27 -

SV\1263057.27

Product and country-by-country basis, on the first date that both a first and a second Generic Version of such Pharmaceutical Product is commercially available in such country. 
1.2Sublicensing.  To the extent that either Party is permitted to grant sublicenses under the licenses granted to it under this Agreement, either Party shall have the right to grant such sublicenses through multiple tiers of sublicensees; provided that:
1.1.1no sublicense may be granted to any Third Party under Section 3.2.1 [***].  For clarity, nothing in this Section 3.3 shall permit the grant by GSK of any sublicense to any Codexis Enzyme or any Codexis Core Technology (except the specific Codexis Methods listed on Exhibit 3.3.1); 
1.1.2in relation to the rights under Section 3.3.1, any sublicense agreement between GSK and a Third Party sublicensee relating to the performance of GSK’s obligations or exercise of GSK’s rights under this Agreement shall include material transfer terms, and non-use and non-disclosure confidentiality terms, that are no less stringent than terms consistent with GSK’s ordinary practice involving GSK proprietary materials and information of a similar nature;
1.1.3any such sublicense is consistent with and subject to the terms of this Agreement and shall terminate automatically upon termination of the corresponding license hereunder; 
1.1.4each Party, within thirty (30) days after the effective date of any sublicense, shall provide written notice to the other Party of the grant, the date, and the identity of the Third Party of any sublicense to a Third Party; 
1.1.5each Party shall not be relieved of its obligations pursuant to this Agreement as a result of such sublicense; and
1.1.6any sublicense granted by GSK shall (a) prohibit the sublicensee from using the Platform Technology for any purpose other than as specified in Section 3.2.1 and Section 3.2.2 and (b) require the sublicensee to destroy all Platform Technology, and all Confidential Information of Codexis, in possession of such sublicensee after completion of the sublicensee’s obligations under such sublicense. 
1.3Limitations on Licenses.
1.1.3In-Licensed Patents.  With respect to any aspect of the In-Licensed Patents for which Codexis has less than fully exclusive, worldwide rights (e.g., co-exclusive, non-exclusive, limited territorial or otherwise restricted rights), the licenses provided 
    - 28 -

SV\1263057.27

in Sections 3.2.1, 3.2.2 and 3.5.3 shall be limited to the scope of those rights that Codexis Controls.
1.1.4Codexis Mayflower Patents.  Notwithstanding anything set forth in this Article 3, GSK shall have no right under the Codexis Mayflower Patents with respect to:
(a)the making, having made, using and selling of reagents, instruments and services for the diagnostics and research supply markets, only as follows: (a) clinical and diagnostic tests, including those conducted to identify genetic disease predisposition, genetic or other disease conditions, and infectious or pathogenic agents, as well as those conducted for other medical, agricultural or veterinary purposes; (b) tests for analytical/bioanalytical purposes, including those conducted for biomedical, chemical, or medical research or treatment purposes, for environmental purposes, and for forensic purposes, including paternity, maternity or identity tests; and (c) sequencing and sequence analysis of nucleic acids or other biological polymers for any purposes; but excluding (i) the use of a reagent, other than a nucleic acid array, that specifically binds to selected cells, organs or tissue, and that is sold for medical use in procedures to image selected cells, organs or tissue, which procedure is carried out inside the body of an animal or human, and that requires FDA approval, and (ii) the sale of products and performance of services requiring a license under the In-Licensed Patents, to identify compounds that bind to receptors for use as pharmaceuticals;
(b)any (i) amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a human or humanized protein, or any variant, homology, derivative, mutant or fragment thereof, and (ii) any molecule described in subsection (i) that is conjugated or otherwise coupled to any other molecule, in each of cases (i) and (ii) expressly including (iii)(A) any amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a cytotoxic T lymphocyte associated antigen 4 or any variant, homolog, derivative, mutant or fragment thereof, and (B) any molecule described in subsection (iii)(A) that is conjugated or otherwise coupled to any other molecule, and (iv)(A) any amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a human or animal protein or any variant, homolog, derivative, mutant or fragment of the foregoing, and (B) any molecule described in subsection (iv)(A) that is conjugated or otherwise coupled to any other molecule, and any pharmaceutical products that contain any of the foregoing as an ingredient; 
(c)any formulation containing one or more antigens (or a nucleic acid sequence encoding an Antigen) in the form of (a) an infectious agent (e.g., bacteria, viruses, parasite, protozoa) whether live, attenuated or dead, (b) protein(s), (c) nucleic acid(s), (d) cells, spores and vectors (i.e., viruses or virus-like particles, liposomes, beads or other substrates for Antigen presentation), (e) fragments of any of the foregoing, or (f) a combination of any of the preceding, which formulation is administered or is intended to be administered to induce an Antigen-Specific Response in the human or animal recipient to at least one such 
    - 29 -

SV\1263057.27

antigen for the prevention of the onset of, or treatment of, a disease state, symptom or condition in humans or animals caused by an infectious agent; where “Antigen” means a molecule (e.g., protein, nucleic acid, polypeptide, peptide, carbohydrate, glycoprotein, glycolipid or any combination of the foregoing) that is produced naturally by, or is derived in whole or in part from, an infectious agent (e.g., bacteria, viruses, parasite, protozoa) that produces an Antigen-Specific Response to such molecule in a human or animal recipient (but excluding any molecule that is derived from, in whole or in part, any human gene or protein); and “Antigen-Specific Response” means an immune state resulting from the modulation of activity (i.e., an increase, decrease or qualitatively different activity) or one or more lymphoid cells (e.g., B cells, NK cells, T cells or professional antigen-presenting cells, such as monocytes, macrophages, Langerhans cells, dendritic cells) following the administration of a stimulus, where such immune state is induced in a human or animal recipient to an Antigen that is specifically directed to the subject Antigen; 
(d)the development, production and/or sale of any and all polypeptides more than twelve (12) amino acids in length, and the development of organisms and vectors (including without limitation plant vectors and plant hosts) for the expression of such polypeptides, in the areas of (a) processes for textile or garment production, (b) processes for the production of leather, (c) cleaning processes or cleaning products, (d) starch processing, (e) food production processes, (f) animal feed processing, (g) personal care processes, excluding pharmaceutical products and oral, topical and intravaginal medications, (g) the processing of wood, paper, pulp and derived lignin and cellulose, (i) oil drilling, (j) dyestuffs and dyeing processes, (k) electronics industry waste water treatment, (l) detoxification of pesticides, chemical weapons and biological weapons, (m) utilization of industrial waste or co-products to generate energy, compost or industrial raw materials including fermentable substrates for e.g. citric acid production from agricultural waste, (n) polymer production, modification or processing of polymers (tetramers of higher) from monomers (including polymers made by addition of dimers or trimers for reactions proceeding to completion in the same reactor), and the enzymatic modification of chemically synthesized polymers, (o) waste water treatment, sewage sludge treatment or cleanup of contaminated soil, (p) synthesis of fuels including bio-diesel and hydrogen, and (q) bioremediation of water, soil and municipal waste, including without limitation biological waste, sewage and sludge (including without limitation biological waste treatment and cleaning of sewer and drain pipes). 
(e)any and all human or humanized granulocyte-colony stimulating factor (G-CSF) protein, or any and all variants, derivatives, mutants or fragments thereof, and any and all pharmaceutical products that contain any of the foregoing.
1.1.1Government Rights.  GSK acknowledges that certain of the inventions claimed in the Codexis Core Technology and/or the Codexis Enzymes and the Intellectual Property rights therein have been made with funds provided by the U.S. government, and that with respect thereto the U.S. government retains a non-exclusive license as set forth in 35 U.S.C. § 202.  In addition, GSK acknowledges that this Agreement is subject 
    - 30 -

SV\1263057.27

to all of the terms and conditions of 35 U.S.C. § 200 et seq., which sets forth additional obligations with regard to inventions made with U.S. government funds and products based thereon, including a preference for manufacture in the U.S. pursuant to 35 U.S.C. § 204.
1.1.2Prohibited GSK Activities.  During the Embargo Period, GSK shall not, and shall cause its Affiliates and permitted sublicensees not to, alone or with a Third Party, on behalf of GSK, its Affiliates or any Third Party, conduct any activities (including, without limitation, any research, drug discovery, development or commercialization activities) in the Codexis Exclusive Field using any Platform Technology; provided that the foregoing restriction shall not apply to the use by GSK of any Platform Technology in connection with the use of an Enzyme or Enzyme fusion protein that is contained within a Licensed Accessory Product in combination with a GSK Compound; and it shall not constitute a breach of this Section 3.4 if GSK generates and/or uses Enzymes solely as research reagents or research tools within the Field.  
1.1.3No Use for Third Parties.  GSK shall not use, and shall cause its Affiliates and permitted sublicensees not to use, the Platform Technology to engineer, synthesize, manufacture or otherwise develop or produce any Enzymes, molecules, biologic agents, drug products, therapeutic agents or any other compounds for or on behalf of any Third Party and to that Third Party’s order or direction.  [***].  If GSK or any Affiliate exclusively licenses, assigns, divests or otherwise transfers to a Third Party all of GSK’s or such Affiliate’s rights relating specifically to a GSK Compound(s) and/or a Licensed Product(s), and GSK or such Affiliate, at the time of such transfer, uses an Enzyme developed using the Platform Technology to manufacture such GSK Compound(s) and/or a Licensed Product(s), then (A) GSK or its Affiliates may synthesize, manufacture and supply such Enzyme (and no other Enzyme) for and to such Third Party solely to manufacture such GSK Compound(s) and/or a Licensed Product(s), and (B) GSK may grant to such Third Party a limited sublicense under the Platform Technology solely to the extent necessary for such Third Party to make and use such Enzyme (and no other Enzyme) solely in connection with the development, making, use, sale, offer for sale, import and export of such GSK Compound(s) and/or a Licensed Product(s) and products incorporating such GSK Compound(s) and/or a Licensed Product(s), but not to make or use such Enzyme (and no other Enzyme) in connection with any other compounds or products.  Notwithstanding anything to the contrary herein, GSK shall remain responsible for any payments due to Codexis under Article 7 on account of such Enzyme or such GSK Compounds and/or Licensed Products.  For clarity, no payments, other than payments due under Article 7, shall be due to Codexis. 
    - 31 -

SV\1263057.27

1.1.4Enzyme Supplier.  [***] would supply to GSK or its Affiliates any Enzymes developed using rights licensed by Codexis to GSK under the terms of this Agreement, [***]. 
1.1.5Certain Kits and Panels.  In the event that GSK or an Affiliate of GSK desires to have a kit or panel containing any Codexis Materials developed for use by GSK or an Affiliate of GSK which was transferred to GSK pursuant to the Technology Transfer, and such kit or panel is not otherwise available, either through development by GSK or an Affiliate of GSK or commercially through Codexis or a Third Party, GSK, subject to the conditions set forth in Section 3.3, [***] request that Codexis develop such kit or panel, [***] exclusively for use by GSK and Affiliates of GSK.  Codexis shall have no obligation to develop such GSK requested kit or panel but, if Codexis agrees to develop such a kit or panel, [***] subject to other reasonable terms and conditions agreed upon by the Parties for such work by Codexis.  [***]. 
1.4Codexis Core Technology Improvements Option.
1.1.5Option Grant.  Subject to the terms and conditions of this Agreement, Codexis hereby grants to GSK an option, exercisable at GSK’s sole discretion in accordance with Section 3.5.2, to acquire the rights described in Section 3.5.3, which option shall be exclusive as to the GSK Exclusive Field (the “Exclusive Option”) and non-exclusive otherwise in the Field (the “Non-Exclusive Option”, together with the Exclusive Option, the “Option”).  
1.1.6Option Exercise.  At any time during the period beginning on the earlier of the second (2nd) anniversary of the Effective Date and the TT Term Expiration Date, and ending on the date that is three (3) months after the TT Term Expiration Date (an 
    - 32 -

SV\1263057.27

“Option Period”), GSK may exercise the Option by (a) providing written notice thereof to Codexis and (b) paying the First Annual Option Fee.  If GSK does not exercise the Option prior to the expiration of the Option Period, the Option shall automatically expire and be of no further force or effect. 
1.1.7Grant of Rights.  Subject to the terms and conditions of this Agreement, effective upon GSK’s exercise of the Option in accordance with Section 3.5.2, Codexis hereby on behalf of itself and its Affiliates grants to GSK a worldwide, non-transferrable (except as permitted under Section 13.5), non-sublicensable (except in accordance with Section 3.2.1 and Section 3.2.2) license, which license shall be exclusive in the GSK Exclusive Field and non-exclusive otherwise in the Field, under all of Codexis’ rights to Codexis Core Technology Improvements practiced by Codexis during the Improvements TT Term.  Codexis shall provide any technology transfer or scientific or technical resources reasonably requested by GSK, and reasonably necessary for GSK, to practice such Codexis Core Technology Improvements, at GSK’s reasonable expense.  During the Improvements TT Term, Codexis’ Alliance Manager will periodically disclose to GSK’s Alliance Manager information regarding new, updated or improved Enzyme kits or panels (as defined in this Section 3.5.3 below) [***].  For purposes of this Section 3.5.3, the term “new, updated or improved Enzyme kits or panels” means a collection of multiple, genetically-diverse Enzymes, Controlled by Codexis, that are first made commercially available to the general public by Codexis through Codexis’ catalog or website.  All information, documents and other materials provided by Codexis to GSK pursuant to this Section 3.5.3 shall constitute Confidential Information of Codexis. 
1.1.8Extension of the Improvements TT Term.  Upon mutual written agreement of the Parties, and payment by GSK to Codexis of an amount to be mutually agreed in good faith by the Parties, within the sixty (60) day period prior to the then-current Improvements TT Term Expiration Date, the Improvements TT Term Expiration Date may be extended by one (1) year.  The Parties may extend the Improvements TT Term Expiration Date any number of times in accordance with this Section 3.5.4.  
1.5Third Party Licences.  [***].  
    - 33 -

SV\1263057.27

1.6Restricted Enzymes.  
1.1.7During the Term, in its ordinary course of business, Codexis will conduct research and development activities for Third Parties under the Licensed IP using the Platform Technology and, in connection with such research and development activities, will generate Potentially Restricted Enzymes that, in certain cases, on a Potentially Restricted Enzyme-by- Potentially Restricted Enzyme basis,(a) will be owned by such Third Parties or exclusively licensed by Codexis to such Third Parties and (b) will not be Controlled by Codexis.  For purposes of this Section 3.7.1, the term “Potentially Restricted Enzyme” means any peptide or protein, including derivatives, with enzymatic or biocatalytic activity, or any vector that encodes for any such peptide or protein, derived from the use of the Platform Technology by Codexis after the Effective Date that, in either case, may not be Controlled by Codexis.  In the event that any Potentially Restricted Enzyme generated by Codexis is owned by a Third Party or exclusively licensed by Codexis to a Third Party, Codexis, subject to confidentiality obligations owed by Codexis to such Third Party, will inform the Patent Committee of such Potentially Restricted Enzyme at its next regularly scheduled meeting and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme.  The Patent Committee will review information provided by Codexis with respect to any such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzymes and, in accordance with Section 5.2.3, determine whether the list of Restricted Enzymes set forth on Exhibit 1.112 shall be revised to include such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme.  Codexis will provide GSK with the initial list of Restricted Enzymes on Exhibit 1.112 within [***] days after the Effective Date.
1.1.8In the event that GSK wishes to exercise its rights under Section 3.2 to any Restricted Enzyme for any specific field(s) and/or use(s), it shall notify Codexis in writing of such request.  Codexis shall then have [***] days in which to confirm to GSK in writing whether Codexis Controls such Restricted Enzyme for such specific field(s) and/or use(s) requested by GSK.  In the event that Codexis does Control such Restricted Enzyme for such specific field(s) and/or use(s) then effective upon the date of such written confirmation from Codexis, such Restricted Enzyme shall be an Enzyme for such specific field(s) or use(s) for the purpose of Section 3.2. 
1.7Responsibility for Freedom to Operate Analyses.  GSK acknowledges and agrees that it is within GSK’s discretion to conduct freedom to operate analyses with respect to the use of any enzyme, other than a Codexis Enzyme, to generate an Enzyme and, in addition, any Enzyme generated in accordance with the terms of the license granted by Codexis to GSK and, whether or not GSK elects to conduct a freedom to operate analysis, GSK will be solely responsible for any such enzyme (other than a Codexis Enzyme) and any such Enzyme. 
    - 34 -

SV\1263057.27

1.8Public Domain Information and Material.  Codexis acknowledges and agrees that GSK shall be free to utilize, without restriction, any information or material that is (a) within the Platform Technology and (b) wholly within the public domain.  
1.9No Implied Licenses.  No license or other right is or shall be created or granted hereunder by implication, estoppel or otherwise.  All licenses and rights are or shall be granted only as expressly provided in this Agreement.  All rights not expressly granted by a Party under this Agreement are reserved by such Party and may be used by such Party for any purpose.  For clarity, there shall be no implied license or implied other right in favor of Codexis to any Enzyme, and there shall be no implied license or implied other right in favor of GSK to any Patent(s) of Codexis or any Know-How of Codexis.  
4.PROJECTS
1.10Collaborative Projects.  Beginning on the Effective Date and continuing during the TT Term and if mutually agreed for such period following the TT Term, GSK and Codexis (or Affiliates of GSK and Codexis) shall work on Collaborative Projects pursuant to the terms of written project plans to be mutually agreed by the Parties.  Upon mutual agreement by the Parties, or agreement of the JSC as applicable, if the JSC is then in existence, upon agreement by the Parties of the written research plan for any Collaborative Project, such research plan shall be attached to and made part of this Agreement.  Each such written research plan shall describe each Party’s responsibilities and obligations, and the activities to be performed by each Party, in connection with the applicable Collaborative Project and the frequency and content of any reports to be provided by one Party to the other Party.  Any amendment to a written research plan in respect of a Collaborative Project must be in writing and signed by both GSK and Codexis or approved by the JSC if the JSC is then in existence.  In the event that GSK subsequently decide to resume a terminated Collaborative Project, whether resumed and progressed independently or in further collaboration with Codexis, such project shall continue to be deemed a Collaborative Project for the purposes of Codexis’ eligibility to earn such associated milestone payments in Section 7.4.
1.11Project Summaries.  During the Term, within thirty (30) days after the end of the Calendar Year ending December 31 or such other date within such Calendar Year as mutually agreed between the Parties, GSK shall disclose to Codexis a summary of [***].  Such summary shall be provided to Codexis in sufficient detail to provide to Codexis reasonable information into GSK activities with respect to GSK’s use of the Platform Technology for the purpose of enabling Codexis to anticipate GSK’s progression toward achievement of milestone events as set forth in Article 7 and to monitor GSK’s compliance with this Agreement.  Each such summary shall include [***] 
    - 35 -

SV\1263057.27

[***]; provided that, in the event [***], the information provided by GSK in any such summary report from such time onwards [***].  
1.12Project Activities.  Each Party shall perform the research activities assigned to such Party under each written research plan in respect of a Collaborative Project and shall perform all such research activities in compliance with all Applicable Law.  Subject to Article 7, each Party shall be solely responsible for all costs and expenses of research activities performed by such Party, unless otherwise specified in the applicable written research plan; provided that, if the Parties agree to perform a Collaborative Project after the expiration of the TT Term, the Parties shall negotiate in good faith and mutually agree upon reasonable compensation from GSK to Codexis for the research activities performed by Codexis in connection with such Collaborative Project. 
1.13Subcontracting.  
1.1.2Generally.  Subject to the limitations set forth in Section 4.4.2, GSK may perform any of its obligations or exercise any of its rights under this Agreement through one or more Third Party contractors, contract manufacturing organizations (CMOs), contract research organizations (CROs) or other contract service organizations [***].  Codexis may perform any of its obligations under [***] (as described in the Technology Transfer Plan) and [***] (as described in the Technology Transfer Plan) through one or more Third Party contractors, contract service organizations and academic or government collaborators; provided that the activities corresponding to such obligations were performed through subcontractors in the ordinary course of Codexis’ business as of the Effective Date including, for illustrative purposes, protein analysis, gene and oligonucleotide synthesis and analysis, polynucleotide and polypeptide sequencing, microbiological testing, protein immobilization, and crystallization.  
1.1.3Limitations.
(a)GSK may not subcontract any activities to a Third Party that would permit such a Third Party to receive and/or use the Platform Technology;
(b)Any agreement between GSK and a Third Party contractor relating to the performance of GSK’s obligations or exercise of GSK’s rights under this Agreement shall include material transfer terms, and non-use and non-disclosure confidentiality 
    - 36 -

SV\1263057.27

terms, that are no less stringent than terms consistent with GSK’s ordinary practice involving GSK proprietary materials and information of a similar nature; and 
(c)GSK may not subcontract activities to any contract service organization unless Codexis consents to the choice of the contract service organization, such consent not to be unreasonably withheld, conditioned, or delayed. 
1.1Records.  Each Party shall, and shall require its Affiliates and subcontractors to, maintain complete and accurate records of all research activities under a Project conducted pursuant to a written research plan and Technology Transfer Project Activities and all results, information and data generated in performing such research activities and Technology Transfer Project Activities.  Such records shall be complete and accurate and shall fully and properly reflect all work done and results achieved in sufficient detail and in a manner appropriate for accounting, Patent and regulatory purposes.  
5.GOVERNANCE
1.3Joint Steering Committee.
1.1.1Establishment.  Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or “JSC”) to have overall responsibility for managing and directing the Projects and to oversee and make certain decisions regarding the Projects, as set forth in this Section 5.1.  The JSC shall also provide a forum for sharing advice, progress and results relating to the activities conducted by the Parties under the Projects and shall attempt to facilitate the resolution of any disputes between the Parties, as described in Section 5.1.4.  At each meeting of the JSC, each Party shall brief the JSC regarding the content, execution and results achieved by such Party under each Project, as described in Section 2.6.  Each Party, through its representatives on the JSC, shall be permitted to provide advice and commentary with respect to the Projects.  The JSC shall have the following specific responsibilities:
(a)oversee, review and provide advice regarding the overall progress of the Projects;
(b)coordinate by way of each Party’s Scientific Leads, the research activities under a written research plan relating to a Project agreed by the Parties and coordinate sharing of results and data arising therefrom;
(c)appoint and oversee subcommittees as it deems appropriate for carrying out activities under this Agreement, including for oversight of any specific aspects of any Projects or other matters;
(d)review each written research plan and, if appropriate, propose modifications thereto to the Parties; 
(e)
    - 37 -

SV\1263057.27

review the Technology Transfer Plan and, if appropriate, propose modifications thereto to the Parties; 
(f)perform any other activities or functions as the Parties may mutually agree in writing; and
(g)determine the initiation and termination of Collaborative Projects. 
1.1.2Membership; Meetings.  The JSC shall be composed of two (2) employees from each of GSK and Codexis and shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or more or less often as the Parties shall determine; provided that nothing under this Agreement shall prevent the Parties from meeting in person, by teleconference, or by video-teleconference more frequently as may be mutually agreed by the JSC representatives, in connection with the Technology Transfer. In-person meetings shall alternate between Codexis and GSK locations within the United States whenever possible unless otherwise agreed by the Parties.  The first such meeting shall be within forty-five (45) days after the Effective Date.  Any member of the JSC may designate a substitute, who shall be an employee of the applicable Party, to attend with prior written notice to the other Party.  Ad hoc guests who are subject to written confidentiality obligations at least as stringent as the provisions in Article 9 may be invited to JSC meetings.  Each Party may replace its JSC members with other of its employees, at any time, upon written notice to the other Party.
1.1.3Project Teams.  The JSC may establish one (1) or more sub-committees (each, a “Project Team”) that includes each Party’s Scientific Leads.  Such Project Team shall have day-to-day oversight of individual Collaborative Projects and/or the Technology Transfer, shall provide primary scientific and technical expertise with respect to such activities and shall regularly and proactively provide updates to the JSC and escalate issues for discussion and resolution, as appropriate.  Any dispute of technical feasibility of any Project that cannot be resolved through good faith negotiation between the members of such Project Team shall be referred for resolution to the JSC.  
1.1.4Decision-Making; Limitations on JSC.  Except as provided under Section 5.1.6, decisions of the JSC shall be made by consensus, including issues concerning technical feasibility and the deployment of Codexis resources, with each Party having collectively one (1) vote in all decisions.  The JSC shall have only such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions set forth herein.  Without limiting the generality of the foregoing, the JSC shall have no power to amend this Agreement or the Technology Transfer Plan.  The Parties shall be alternately responsible for preparing and circulating minutes, for approval by the non-preparing Party, within fourteen (14) days after each meeting including but not limited to a list of topics of discussion at the meeting and a list of any actions, decisions or determinations approved and a list of any issues and actions to be resolved.  If the JSC is unable to reach a consensus decision 
    - 38 -

SV\1263057.27

on a matter that is within its decision-making authority within thirty (30) days after it has met and attempted to reach such decision, then either Party may refer such matter for resolution by the executive officers designated by the Parties for attempted resolution pursuant to Section 12.1.  In the event that the executive officers are unable to resolve such matter within the time period specified in Section 12.1, then in the case of any decision relating to the conduct of a Collaborative Project, such Collaborative Project shall immediately terminate.  Any matter not expressly provided for hereunder and any matter relating to any GSK Background IP, GSK Compound, Licensed Product, Platform Technology, Licensed IP, or Codexis Background IP shall remain outside of the scope of the JSC.  
1.1.5Duration of JSC.  The JSC shall be automatically disbanded upon the expiration of the TT Term or the earlier expiration or termination of this Agreement; provided that the Parties may, by mutual written agreement, extend the term of the JSC for additional one (1) year periods after the expiration of the TT Term, with a separate mutual written agreement required for each such one (1) year extension.
1.1.6Matters Reserved for GSK.  Notwithstanding anything contained in this Section 5.1, GSK shall determine in its sole discretion, decisions in connection with the following matters:
(a)Collaborative Project selection and termination;
(b)GSK Sole Projects;
(c)Selection and use of any GSK Selected Enzyme; and
(d)[***].
1.1Patent Committee.  
1.1.1Establishment.  Within sixty (60) days after the Effective Date, the Parties shall establish a Patent committee (the “Patent Committee”) to discuss, oversee and coordinate the Prosecution (or abandonment) of Patents, enforcement of Patents, and defense against claims of infringement of Third Party patents relating to Intellectual Property licensed under Article 3, Sections 2.2.9 and 2.2.10, including for example Codexis Core Technology Improvements IP, Arising Codexis Enzyme Technology IP, Arising Codexis Process Technology IP, Arising GSK Enzyme Technology IP and Arising GSK Process Technology IP, and any related Intellectual Property matters regarding any Inventions made during the Term, including for example, the Licensed Additional Codexis IP; and to provide recommendations to the Parties regarding the Prosecution of such Patents and related Intellectual Property matters. Within thirty (30) days after the end of each half year, each Party shall provide the Patent Committee with a report listing all Patents relating to such Parties’ utilization of the Platform Technology filed by that Party during that half year. 
1.1.2Membership; Meetings.  The Patent Committee shall be composed of one (1) employee from each of GSK and Codexis knowledgeable in U.S. patent law and the technology areas that are the subject of this Agreement. The Patent Committee shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or more or less often as the Parties shall determine.  In-person meetings shall alternate between Codexis and GSK locations within the United States whenever possible unless 
    - 39 -

SV\1263057.27

otherwise agreed by the Parties.  The first such meeting shall be within ninety (90) days after the Effective Date.  Any member of the Patent Committee may designate a substitute, who shall be an employee of the applicable Party, to attend with prior written notice to the other Party.  Ad hoc guests who are subject to written confidentiality obligations at least as stringent as the provisions in Article 9 may be invited to Patent Committee meetings.  Each Party may replace its Patent Committee members with other of its employees with the qualifications set forth in this Section 5.2.2, at any time, upon written notice to the other Party.  
1.1.3Decision-Making; Limitations on Patent Committee.  Decisions of the Patent Committee shall be made by consensus, with each Party having collectively one (1) vote in all decisions.  The Patent Committee shall have only such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions set forth herein.  Without limiting the generality of the foregoing, the Patent Committee shall have no power to amend this Agreement, the Technology Transfer Plan or any written research plan.  If the Patent Committee is unable to reach a consensus decision on a matter that is within its decision-making authority within thirty (30) days after it has met and attempted to reach such decision, then either Party may refer such matter for resolution by the executive officers designated by the Parties for attempted resolution pursuant to Section 12.1.  In the event that the executive officers of each Party are unable to resolve such matter within the time period specified in Section 12.1, then Codexis shall have final decision-making authority with respect to any dispute relating specifically to Restricted Enzymes and Codexis Patents and GSK shall have final decision-making authority with respect to any dispute relating specifically to GSK Patents.  The Patent Committee shall provide status updates to the JSC once per Calendar Quarter as long as the JSC is in existence and, thereafter, to the Parties. 
1.1.4Duration of Patent Committee.  The Patent Committee shall endure beyond the expiration of the TT Term and shall automatically renew on a year-to-year basis.  Notwithstanding the aforementioned, the Patent Committee may be disbanded at any time upon mutual written agreement of the Parties.  
6.INTELLECTUAL PROPERTY
1.4Background Rights.  Each Party shall retain all right, title and interest to its Background IP, and, except as expressly set forth in this Agreement, no right or license to such Patents, Know-How and other Intellectual Property rights is granted by either Party to the other Party.  
1.5Ownership of Inventions.  
1.1.1Generally.  Inventorship of Inventions shall be determined by application of U.S. patent laws.  Subject to Sections 6.2.2, 6.2.3 and 6.2.4, all patentable Inventions invented solely by or on behalf of either Party or jointly by or on behalf of both Parties under this Agreement, including without limitation in the performance of any responsibilities under a written research plan relating to a Project, and all Intellectual Property rights therein, shall be owned in accordance with inventorship.  
1.1.2Codexis Core Technology Improvements IP.  Codexis shall own any and all Codexis Core Technology Improvements and Codexis Core Technology Improvements IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  GSK hereby assigns to Codexis all of GSK’s right, title and interest in and to the Codexis Core Technology Improvements IP.
    - 40 -

SV\1263057.27

1.1.3Arising Enzyme Technology IP.  GSK shall own any and all Arising GSK Enzyme Technology, Arising GSK Enzyme Technology IP, Arising Codexis Enzyme Technology and Arising Codexis Enzyme Technology IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  Codexis hereby assigns to GSK all of Codexis’ right, title and interest in and to the Arising Codexis Enzyme Technology Improvements IP. 
1.1.4Arising Process Technology IP.  GSK shall own any and all Arising GSK Process Technology, Arising GSK Process Technology IP, Arising Codexis Process Technology and Arising Codexis Process Technology IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  Codexis hereby assigns to GSK all of Codexis’ right, title and interest in and to the Arising Codexis Process Technology IP.
1.1.5Ownership of Enzymes.  GSK shall exclusively own all Enzymes derived from GSK’s use of the Platform Technology pursuant to this Agreement.
1.2Further Assurances.  Each Party and its Affiliates shall sign and deliver to the other Party all writings and do all such things as may be necessary or appropriate to vest in such other Party all right, title and interest in and to all Codexis Core Technology Improvements IP, Arising Enzyme Technology IP and Arising Process Technology IP in accordance with Section 6.2.  
1.3Employees and Agents.  Each Party shall ensure that all employees, agents, consultants, contractors and subcontractors (as permitted under Section 4.4) performing activities under or contemplated by this Agreement, have assigned or are obligated to assign their interest in any Invention invented in the course of such activities to the Party for which such employee, agent, consultant, contractor or subcontractor is providing its services.  
1.4Prosecution of Patents.  
1.1.6
    - 41 -

SV\1263057.27

In General.  The Patent Committee shall have oversight regarding the Prosecution of Patents disclosing and/or claiming Inventions directly related to Codexis Core Technology Improvements, Arising GSK Enzyme Technology, Arising GSK Process Technology, Arising Codexis Enzyme Technology and Arising Codexis Process Technology and shall provide recommendations to the Parties to maximize the value of such Patents.  To the extent necessary, the Parties agree to cooperate in good faith to coordinate the Prosecution of such Patents, including submissions of Patent applications worldwide (e.g., to coordinate the filing of Patent applications to ensure that the Parties file related applications on the same day).  The Parties shall agree in good faith on a strategy with respect to Prosecution of any Patents disclosing and/or claiming any jointly-owned Inventions.
1.1.7Codexis Prosecution.  As between the Parties, Codexis shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Codexis Core Technology, Codexis Core Technology Improvements, Codexis Enzymes and Codexis Libraries (the “Codexis Patents”), in Codexis’ sole discretion and at Codexis’ sole cost and expense. 
1.1.8GSK Prosecution.  As between the Parties, GSK shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Arising GSK Enzyme Technology, Arising GSK Process Technology, Arising Codexis Enzyme Technology, and Arising Codexis Process Technology (collectively, the “GSK Patents”), in GSK’s sole discretion and at GSK’s sole cost and expense. 
1.1.9Back-Up Rights.  If GSK decides not to Prosecute, or not to continue Prosecuting, any GSK Patent, GSK shall provide Codexis with written notice of such decision at least forty-five (45) days prior to the date upon which the subject matter of such GSK Patent shall lapse or become abandoned.  The basis for such decision shall be discussed by the Patent Committee pursuant to Section 5.2 and Codexis shall thereupon have the right (but not the obligation) to assume responsibility for Prosecution of such GSK Patent at Codexis’ expense, and with counsel of Codexis’ choosing, except (a) any GSK Patent covering any Licensed Product; and (b) any GSK Patent relating to any GSK Compound, any GSK Existing Pharmaceutical Product, any GSK Initial Enzyme, and/or any GSK Selected Enzyme.  Effective upon the date Codexis assumes responsibility for Prosecution of such GSK Patent, and the costs and expenses relating thereto, GSK hereby assigns any and all interest held by GSK in, to and under such GSK Patent to Codexis.  
1.1.10CREATE Act.  Each Party acknowledges and agrees that this Agreement is a “joint research agreement” as contemplated by 35 U.S.C. § 102(c), and that all inventions arising under any Collaborative Projects hereunder are intended to have the benefit of the rights and protections conferred by the Cooperative Research and Enhancement Act of 2004 (CREATE Act). Each Party agrees to disclose the names of both Parties in each Patent application for all inventions arising under all Collaborative Projects in accordance with the requirements of 35 U.S.C. § 102(c)(3).
1.1
    - 42 -

SV\1263057.27

Enforcement of Patents.  
1.1.11Notice.  If either Party becomes aware of any suspected infringement of any GSK Patent or Codexis Patent, or any GSK Patent or Codexis Patent is challenged in any action or proceeding (any of the foregoing, an “Infringement Action”), such Party shall notify the other Party’s representative on the Patent Committee, and following such notification, the Parties shall confer.  
1.1.12Enforcement.  As between the Parties, GSK will have the first right, but not the obligation, to bring any Infringement Action with respect to any GSK Patent at its sole cost and expense, and Codexis shall have the sole right, but not the obligation, to bring any Infringement Action with respect to any Codexis Patent at its sole cost and expense.  
1.1.13Procedure for Enforcement.
(a)The non-enforcing Party pursuant to Section 6.6.2 shall reasonably assist the enforcing Party (at the enforcing Party’s expense) in any Infringement Action if so requested, such assistance to be coordinated through the Parties' Patent Committee members, and the non-enforcing Party shall lend its name and be joined as a party plaintiff to such action if reasonably requested by such enforcing Party or required by Applicable Law.  The non-enforcing Party shall have the right to participate and be represented in any such action by its own counsel at its own expense.  The non-enforcing Party shall cooperate, at the enforcing Party’s cost and expense, with the enforcing Party in investigating or terminating any suspected infringement, whether through legal action, negotiation or otherwise, including by producing all reasonably pertinent records, papers, information, samples, specimens and similar items, and directing its employees to testify and grant interviews, upon the request of the enforcing Party.  The enforcing Party will keep the non-enforcing Party reasonably informed of the status of the action through the enforcing Party’s Patent Committee members.  
(b)A settlement, consent judgment or other voluntary final disposition of a suit under this Section 6.6.3 may be entered into by the enforcing Party without the consent of the non-enforcing Party; provided that any such settlement, consent judgment or other disposition of any action or proceeding by an enforcing Party under this Article 6 shall not, without the consent of the non-enforcing Party (not to be unreasonably withheld), (a) impose any liability or obligation on the non-enforcing Party, (b) include the grant of any license, covenant or other rights to any Third Party that would conflict with or reduce the scope of the subject matter included under the licenses granted to the non-enforcing Party under this Agreement, (c) conflict with or reduce the scope of the subject matter claimed in any Patent owned by the non-enforcing Party, or (d) adversely affect the interest of the non-enforcing Party in any material respect.  
1.1.14Damages.  In the event that a Party exercises the rights conferred in this Section 6.6, and such Party recovers any damages or other sums in such action or in 
    - 43 -

SV\1263057.27

settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys’ fees.  If such recovery is insufficient to cover all such costs and expenses of both Parties, it shall be shared in proportion to the total of such costs and expenses incurred by each Party.  If, after such reimbursement of the Parties’ cost and expenses, any funds shall remain from such damages or other sums recovered, such remaining funds shall be retained by the prosecuting Party. 
1.6Defense Against Claims of Infringement of Third Party Patents.
1.1.15Claims of Infringement Relating to Enzyme Products.  If a Third Party asserts, or either Party becomes aware of a Third Party’s intention to assert, that a Patent owned or otherwise controlled by the Third Party is infringed by the manufacture, use, sale, offer for sale, import or export of an Enzyme Product in the Territory, the Party first obtaining knowledge of such a claim shall immediately provide the other Party written notice of such claim along with the related facts in reasonable detail.  In such event, unless the Parties otherwise agree, as between the Parties GSK shall have the first right, but not the obligation, at its expense, to control the defense of such claim with respect to such Enzyme Product.  Each Party shall cooperate with the defending Party, at the defending Party’s reasonable request and expense, such cooperation to be coordinated through the Parties' Patent Committee members, and the defending Party shall have the right to be represented separately by counsel of its own choice, but at its own expense.  The defending Party shall also control settlement of such claim; provided, however, that no settlement shall be entered into without the prior consent of the other Party if such settlement would adversely affect the rights and benefits of, or impose or adversely affect any obligations on, the other Party, such consent not to be unreasonably withheld.
1.1.16Claims of Infringement Relating to Licensed Rights.  If a Third Party asserts, or either Party becomes aware of a Third Party’s intention to assert, that a Patent owned or otherwise controlled by the Third Party is infringed by the exercise by GSK or its Affiliates of any rights licensed to GSK hereunder (other than by the manufacture, use, sale, offer for sale, import or export of an Enzyme Product in the Territory), the Party first obtaining knowledge of such a claim shall immediately provide the other Party notice of such claim along with the related facts in reasonable detail.  In such event, as between the Parties Codexis shall have the sole right, but not the obligation, at its expense, to control the defense of such claim.  GSK shall cooperate with Codexis, at Codexis’ reasonable request and expense, such cooperation to be coordinated through GSK’s Patent Committee members, and GSK shall have the right to be represented separately by counsel of its own choice, but at its own expense.  Codexis shall also control settlement of such claim; provided, however, that no settlement shall be entered into without the prior consent of GSK if such settlement would adversely affect the rights and benefits of, or impose or adversely affect any obligations on, GSK, such consent not to be unreasonably withheld. 
7.FINANCIAL TERMS
1.1
    - 44 -

SV\1263057.27

Upfront Payment.  In consideration, along with Section 7.3, of the Technology Transfer under this Agreement within [***] Business Days after receiving an Invoice from Codexis, after the Effective Date, GSK shall pay to Codexis a non-creditable, non-refundable upfront payment of six million Dollars ($6,000,000) (the “Upfront Payment”).
1.2Annual Option Fee.  In consideration of the licenses granted by Codexis to GSK under Section 3.5.3, upon GSK’s exercise of the Option, as set forth in Section 3.5.2, GSK shall pay, after GSK receipt of an Invoice from Codexis, to Codexis a non-creditable, non-refundable payment of one million Dollars ($1,000,000) (the “First Annual Option Fee”).  On each of the first (1st) and second (2nd) anniversaries of the TT Term Expiration Date, GSK shall pay to Codexis,  after GSK receipt of an Invoice from Codexis, an additional non-creditable, non-refundable payment of one million Dollars ($1,000,000) (each such payment and the First Annual Option Fee, an “Annual Option Fee”); provided that GSK’s failure to timely pay any Annual Option Fee during the Improvements TT Term shall not constitute a breach of this Agreement, but instead shall cause the Improvements TT Term to immediately terminate without opportunity to cure. 
1.3Technology Transfer Milestones.  In consideration for the Technology Transfer, GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.3 upon achievement of the applicable milestone event.  Such milestone payments shall be non-creditable and non-refundable. 

						
	Technology Transfer Milestone Event	Milestone Payment
	Completion of Wave 1 including delivery of all deliverables therefor specified in the Technology Transfer Plan.	$5,000,000
	Completion of Wave 2, including delivery of all deliverables therefor specified in the Technology Transfer Plan.	$6,500,000
	The earlier to occur of the event described in (a) Section 1.120(a) or (b) Section 1.120(c).
	$7,500,000

1.4Collaborative Project Milestones.  GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis,  each of the milestone payments set forth in this Section 7.4 upon achievement of the applicable milestone event with respect to a Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. Each milestone payment will be made for each Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical 
    - 45 -

SV\1263057.27

Product as applicable) that achieves the applicable milestone event, regardless of the number of Collaborative Projects that achieve each such milestone event. For clarity, each milestone payment will be made only once with respect to each Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Such milestone payments shall be non-creditable and non-refundable.  Notwithstanding the foregoing, no milestone payments shall be owed by GSK to Codexis under this Section 7.4 with respect to any GSK Sole Project or any Enzyme Product.

						
	Collaborative Project Milestone Event	Milestone Payment
	Initiation of [***] of the Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of a GSK Compound for [***].	$[***]
	Initiation of [***] of the Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of a GSK Compound for [***] of a Pharmaceutical Product.	$[***]
	[***] of a Pharmaceutical Product in [***].	$[***]
	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]
	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]
	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]

1.5GSK Sole Project Milestones.  GSK shall pay to Codexis after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.5 upon achievement of the applicable milestone event with respect to a Licensed GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. Each milestone payment will be made for each GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as 
    - 46 -

SV\1263057.27

applicable), that achieves the applicable milestone event; provided that each milestone payment shall be made no more than two (2) times, on the first two (2) achievements of the applicable milestone event, regardless of the number of GSK Sole Projects that achieve such milestone event.  For clarity, each milestone payment will be made only once with respect to each GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Such milestone payments shall be non-creditable and non-refundable.  Notwithstanding anything to the contrary, no milestone payments shall be owed by GSK to Codexis under this Section 7.5 with respect to any GSK Collaborative Project or Enzyme Product.

						
	GSK Sole Project Milestone Event	Milestone Payment
	Initiation of [***] of the Licensed GSK Sole Project GSK Selected Enzyme for use in synthesis of a GSK Compound for [***] of a Pharmaceutical Product.	$[***]
	[***] of a Pharmaceutical Product in [***].	$[***]
	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]
	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]
	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])	$[***]

1.6GSK Existing Pharmaceutical Product Milestones.  GSK shall pay to Codexis after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.6 upon achievement of the applicable milestone event with respect to a GSK Existing Pharmaceutical Product (or the Licensed (GSK Sole or Collaborative, as the case may be) Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable). Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. For a GSK Existing Pharmaceutical Product that is the subject of a GSK Sole Project, each milestone payment will be made for each GSK Existing Pharmaceutical Product (or Licensed GSK Sole Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical 
    - 47 -

SV\1263057.27

Product, as applicable) that achieves the applicable milestone event; provided that with respect to all GSK Sole Projects described in BOTH Sections 7.5 and 7.6, each milestone payment shall be made no more than three (3) times, on the first three (3) achievements of the applicable milestone event, regardless of the number of GSK Sole Projects. By way of example, if milestones were paid twice for any milestone event per Section 7.5, there would remain one additional opportunity for the equivalent milestone event to be earned by Codexis in Section 7.6. For a GSK Existing Pharmaceutical Product that is the subject of a Collaborative Project, each milestone payment will be made for each GSK Existing Pharmaceutical Product (or Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable) with respect to Collaborative Projects that achieves the applicable milestone event, regardless of the number of GSK Existing Pharmaceutical Products (or Licensed GSK Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable) with respect to Collaborative Projects that achieve each such milestone event.  For clarity, each milestone payment will be made only once with respect to each GSK Existing Pharmaceutical Product (or Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable). Such milestone payments shall be non-creditable and non-refundable.  

									
	GSK Existing Pharmaceutical Product Milestone Event	Milestone Payment for Collaborative Project	Milestone Payment for GSK Sole Project
	Initiation of a Project following selection of an Initial Enzyme for Initial Enzyme Optimization.	$[***]	$[***]
	Initiation of [***] of the GSK Selected Enzyme used in the synthesis of a GSK Existing Pharmaceutical Product for [***] of a Pharmaceutical Product.	$[***]	$[***]
	[***] of a GSK Existing Pharmaceutical Product synthesized using a GSK Selected Enzyme in [***].	$[***]	$[***]
	First time annual Net Sales of a GSK Existing Pharmaceutical Product synthesized using a GSK Selected Enzyme in the Territory achieve [***] Dollars ($[***])	$[***]	$[***]

    - 48 -

SV\1263057.27

1.7Enzyme Product Milestones. GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.7 upon achievement of the applicable milestone event with respect to an Enzyme Product.  Each milestone payment will be made on an Enzyme Product-by-Enzyme Product basis; provided that with respect to each of Enzyme Products listed in Column 2 and Column 3s, each milestone payment shall be made no more than two (2) times with respect Enzyme Products listed in Column 2 and no more than two (2) times with respect to Enzyme Products listed in Column 3, on the first two (2) achievements of the applicable milestone event with respect to Enzyme Products listed in Column 2 and the first two (2) achievements of the applicable milestone event with respect to Enzyme Products listed in Column 3, regardless of the number of Enzyme Products listed in Column 2 and Column 3 that achieve such milestone event.  Each milestone payment will be made for each Licensed Enzyme Therapeutic Product listed in Column 1 that achieves the applicable milestone event, regardless of the number of Licensed Enzyme Therapeutic Products that achieve each such milestone event.  For clarity, each milestone payment will be made only once with respect to each Enzyme Product.  Such milestone payments shall be non-creditable and non-refundable.  
												
	Enzyme Product Milestone Event	Column 1
Milestone Payment for Licensed Enzyme Therapeutic Products
	Column 2
Milestone Payment for Licensed Prophylactic Products, Licensed Other Therapeutic Products and Licensed Accessory Products
	Column 3
Milestone Payment for Licensed Diagnostic Products

	Demonstration of [***] for an Enzyme Product.	$[***]	$[***]	$[***]
	[***] of an Enzyme Product in [***].	$[***]	$[***]	$[***]

    - 49 -

SV\1263057.27

												
	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])	$[***]	$[***]	$[***]
	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])	$[***]	$[***]	$[***]
	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])	$[***]	$[***]	$[***]
	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])	$[***]	$[***]	$[***]

1.8Manner of Milestone Payments and Other Payments.  GSK shall notify Codexis in writing of the achievement of any milestone event under Sections 7.3 - 7.7  as applicable, within [***] days after its achievement.  Each such milestone event together with the First Annual Option Fee and any Annual Option Fee and all other payments agreed under this Agreement shall be made within [***] days after receipt of an Invoice from Codexis. 
1.9Royalties. GSK, on an Enzyme Product-by-Enzyme Product and country-by-country basis, shall pay to Codexis royalties based upon the total quarterly Net Sales in the Territory, during a Calendar Quarter in which such Enzyme Product is sold, during the Royalty Term, at a rate equal to [***] percent ([***]%) of Net Sales of Licensed Enzyme Therapeutic Products in Column 1, [***] percent ([***]%) of Net Sales of Enzyme Products listed in Column 2 of the table in Section 7.7  and [***] percent ([***]%) of Net Sales of Enzyme Products listed in Column 3 (collectively, “Royalties”).  With respect to Enzyme Products listed in Column 2 and Column 3 of the table in Section 7.7, Royalties will be due only with respect to the first two (2) Enzyme Products listed in Column 2 and the first two (2) Enzyme Products listed in Column 3 of the table in Section 7.7 to achieve First Commercial Sale, regardless of the number of Enzyme Products listed in Column 2 and Column 3 of the table in Section 7.7 that are commercialized by or on behalf of GSK.  Royalties will be due with respect to all Licensed Enzyme Therapeutic Products in Column 1 of the table in Section 7.7 that achieve First Commercial Sale, regardless 
    - 50 -

SV\1263057.27

of the number of Licensed Enzyme Therapeutic Products that are commercialized by or on behalf of GSK. 
1.10Royalty Payment Reports.  After the First Commercial Sale of an Enzyme Product that is subject to the payment of Royalties in accordance with Section 7.9, and for the Royalty Term for such Product, GSK shall furnish to Codexis a written report, within [***] days after the end of each Calendar Quarter (or portion thereof if this Agreement terminates during a Calendar Quarter), showing the amount of Royalties due for such Calendar Quarter (or portion thereof) pursuant to Section 7.9.  Royalty payments for each Calendar Quarter shall be due at the same time as such written report for the Calendar Quarter.  With each quarterly payment, GSK shall deliver to Codexis a full and accurate accounting to include at least the following information:  
(e)the Net Sales on an Enzyme Product-by-Enzyme Product and country-by-country basis in the reporting currency in which sales were made and in Dollars after the application of the exchange rate during the reporting period as reported in Section 7.10(c);
(f)the Royalties payable in Dollars which shall have accrued hereunder in respect of such Net Sales and the basis for calculating such Royalties;
(g)the exchange rates used in converting into Dollars, from the currencies in which sales were made; 
(h)dispositions of Enzyme Products other than pursuant to sale for cash for which a royalty is due; and 
(i)withholding taxes, if any, required by Applicable Law to be deducted in respect of such Royalties. 
1.11Applicability of Milestones and Royalties.  All milestone payments and Royalties set forth in Sections 7.3 through 7.9, inclusive, shall be made during the Term and, after expiration or termination of this Agreement, with respect to all applicable Pharmaceutical Products or Enzyme Products, regardless of whether the applicable Project was initiated during or after the TT Term, or before or after the effective date of expiration or termination of this Agreement; provided that the applicable Project is initiated or, in the case of an Enzyme Product, any Enzyme is generated using the Platform Technology, in either case, prior to the [***] of (a) the date of expiration of the last-to-expire Patent within the Codexis Core Technology licensed to GSK under this Agreement and (b) the date that is [***] years after the Effective Date.
1.12Manner of Payment.  All payments to be made by GSK to Codexis hereunder shall be made in Dollars by wire transfer of immediately available funds to such U.S. bank account as shall be designated by Codexis; provided, however, that any notice by Codexis 
    - 51 -

SV\1263057.27

of a change in such account shall not be effective until [***] days after receipt thereof by GSK.  Late payments shall bear interest at the rate provided in Section 7.16.
1.13Records Retention.  Commencing with the First Commercial Sale of a Product, GSK shall keep, and shall cause each of its Affiliates and permitted sublicensees to keep, full and accurate books of accounting in accordance with IFRS, containing all particulars that may be necessary for the purpose of calculating all Royalties payable to Codexis under this Article 7, for a period of [***] years after the Calendar Year in which such sales occurred, in sufficient detail to permit Codexis to confirm the accuracy of Royalties paid hereunder.  Such books of accounting, including those of GSK’s Affiliates and Sublicensees, shall be kept at the GSK site where such records are stored in the normal course of GSK’s business.
1.14Audit Rights.
1.1.1Technical Audit Right.  If Codexis has a reasonable basis for believing that a product sold by or on behalf of GSK for which GSK has not paid any milestone payments or Royalties under Sections 7.4 through 7.9, inclusive, constitutes a Licensed Product for which such milestone payments and/or Royalties may be payable, Codexis may notify GSK of its belief in writing.  GSK shall allow a designee chosen by Codexis and reasonably acceptable to GSK to review such reasonable documentation and other reasonable materials of GSK as is necessary for such designee to determine whether such product constitutes a Licensed Product.  Results of such investigation shall be made available to both GSK and Codexis; provided that such designee shall disclose to Codexis only its determination of whether the product constitutes a Licensed Product and shall disclose no other information revealed in such investigation to Codexis.  Any materials examined by such designee shall be deemed GSK’s Confidential Information, which may not be disclosed by such designee to any Third Party.  GSK may require such designee to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article 9.  If, as a result of any such investigation, such designee determines that such product constitutes a Licensed Product, then GSK shall (a) make all payments required to be made to Codexis under Sections 7.4 through 7.9, inclusive, with respect to such Licensed Product for achievement of milestones and/or Net Sales that occurred prior to the date the Parties receive such results, within [***] days after such date, and shall be responsible for any such payments with respect to such Licensed Product thereafter, (b) pay interest on all late payments in accordance with Section 7.16 and (c) pay Codexis’ reasonable out-of-pocket costs of the investigation.  
1.1.2Financial Audit Right.  During the Term and for a period of [***] years thereafter, GSK shall permit an independent, certified public accountant appointed by Codexis, and reasonably acceptable to GSK, during normal business hours and upon [***] days prior written notice, but in no case more than [***] per Calendar Year, to examine (but not copy) such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and milestone payments and the correctness of any 
    - 52 -

SV\1263057.27

payment made under this Agreement for any period within the preceding [***] years.  The report of the independent public accountant shall be shared with GSK prior to distribution to Codexis such that GSK can provide the independent, certified public accountant with justifying remarks for inclusion in the report prior to sharing the conclusions of such report with Codexis.  Results of any such examination shall be made available to both GSK and Codexis.  The independent, certified public accountant shall disclose to Codexis only the amounts that the independent auditor believes to be due and payable hereunder to Codexis and details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit.  Any and all records examined by such independent accountant shall be deemed GSK’s Confidential Information, which may not be disclosed by said independent, certified public accountant to any Third Party.  GSK may require such independent accountant to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article 9.  If, as a result of any inspection of the books and records of GSK, it is shown that payments under this Agreement were less than the amount that should have been paid, then GSK shall make all payments required to be made to Codexis to eliminate any discrepancy revealed by such inspection within [***] days.  Codexis shall pay for such audits, except that in the event that the audited amounts were underpaid by GSK by more than [***] of the undisputed amounts that should have been paid during the period in question as per the audit, GSK shall pay Codexis’ out-of-pocket costs of the audit and pay interest on all late payments in accordance with Section 7.16.  In the event that the audited amounts were overpaid by GSK, GSK shall withhold such overpayment from future Royalties or milestone payments.
1.1.3In the event that GSK is determined, as a consequence of an audit conducted by Codexis pursuant to either Section 7.14.1 or Section 7.14.2, as applicable, to have:
(a)not paid to Codexis any milestone payments or Royalties with respect to a Licensed Product for which milestone payments and/or Royalties are payable; or
(b)underpaid any amounts by more than [***] of the undisputed amounts that should have been paid to Codexis; and
(c)whether in the case of (a) or (b), for each occurrence after the first occurrence that GSK is determined, as a consequence of a separate, independent audit conducted by Codexis pursuant to either Section 7.14.1 or Section 7.14.2, as applicable, to have:
(i)not paid any milestone payments or Royalties with respect to a Licensed Product for which milestone payments and/or Royalties are payable; or 
    - 53 -

SV\1263057.27

(ii)underpaid any amounts by more than [***] of the undisputed amounts that should have been paid to Codexis;
GSK shall pay to Codexis, in accordance with Section 7.8: (A) the outstanding amount due to Codexis as determined under this Section 7.14.3; (B) the amount calculated to be [***] percent ([***]%) of the amount noted in (A) above; and (C) the interest of due in respect of the amount noted in (A) above pursuant to Section 7.16.
1.15Taxes.
1.1.4No Deductions or Withholding.  GSK will make all payments to Codexis under this Agreement without deduction or withholding for taxes, except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment.
1.1.5Withholding Required by Applicable Law.  Any tax required to be withheld on amounts payable under this Agreement shall be paid promptly by GSK on behalf of Codexis to the appropriate governmental authority, and GSK will furnish Codexis with proof of payment of such tax.  Any such tax required to be withheld will be borne by Codexis. 
1.1.6Cooperation.  GSK and Codexis will cooperate with respect to all documentation required by any taxing authority or reasonably requested by GSK to secure a reduction in the rate of applicable withholding taxes.  Within thirty (30) days after the execution of this Agreement, Codexis will deliver to GSK an accurate and complete Internal Revenue Service Form W-9. 
1.1.7Reimbursement.  If GSK had a duty to withhold taxes in connection with any payment it made to Codexis under this Agreement but GSK failed to withhold, and such taxes were assessed against and paid by GSK, then Codexis will reimburse GSK for such taxes actually paid by GSK.  If GSK makes a claim under this Section 7.15.4, it will comply with the obligations imposed by Section 7.15.2 as if GSK had withheld taxes from a payment to Codexis.  
1.16Interest Due.  Without limiting any other rights or remedies available to either Party, GSK shall pay to Codexis interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate equal to the lesser of (a) [***] as reported by Citibank, New York, New York, on the date such payment was due to be paid or (b) the maximum applicable legal rate on such date, in either (a) or (b), calculated on the total number of days payment was delinquent. 
8.REPRESENTATIONS, WARRANTIES, AND COVENANTS; DISCLAIMERS; LIMITATION OF LIABILITY
1.17Mutual Representations and Warranties.  Each Party represents and warrants to the other Party as of the Effective Date, that:
1.1.8such Party is duly organized, validly existing, and in good standing under the Applicable Law of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
    - 54 -

SV\1263057.27

1.1.9execution of this Agreement and the performance by such Party of its obligations hereunder have been duly authorized;
1.1.10this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation of such Party, enforceable against it in accordance with the terms hereof;
1.1.11the performance of this Agreement by such Party does not create a breach or default under any other agreement to which it is a party, which breach or default would adversely affect the other Party;
1.1.12the execution, delivery, and performance of this Agreement by such Party does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law of any court, governmental body or administrative or other agency having jurisdiction over such Party;
1.1.13no government authorization, consent, approval, license, exemption, filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by such Party of its obligations under this Agreement and such other agreements, except as may be required to obtain applicable Regulatory Approvals or Regulatory Filings related to the development of any Licensed Product; and
1.1.14such Party has not employed and, to its knowledge, has not used a contractor or consultant that has employed, any individual or entity (a) debarred by the FDA (or subject to a similar sanction of any other applicable Regulatory Authority), (b) who is the subject of an FDA debarment investigation or proceeding (or similar proceeding of any other applicable Regulatory Authority), or (c) has been charged with or convicted under Applicable Law of the United States for conduct relating to the development or approval, or otherwise relating to the regulation of any product under the Generic Drug Enforcement Act of 1992, in each case, in the conduct of its activities prior to the Effective Date.
1.18Additional Representations and Warranties of Codexis.  Codexis, on behalf of itself and its Affiliates, hereby represents and warrants to GSK that, except as 
    - 55 -

SV\1263057.27

otherwise disclosed in writing by Codexis to GSK and accepted in writing by GSK, as of the Effective Date:  
1.1.1[***];
1.1.2Codexis is the sole and exclusive owner of the Licensed Patents (other than In-Licensed Patents) and the Licensed Know-How (other than In-Licensed Know-How) and has the full authority to grant the full and unencumbered scope of rights and licenses (other than as set forth in Section 3.4.2) granted to GSK under this Agreement; 
1.1.3to the knowledge of the Codexis Senior Management, no licenses under any Third Party Intellectual Property rights are necessary for Codexis to grant to GSK the licenses hereunder (other than licenses to commercially available software such as, by way of example only, [***] or [***]); 
1.1.4the Licensed Patents are all of the Patents Controlled by Codexis that are (i) necessary to practice the Platform Technology; and (ii) which Cover the practice of the Platform Technology;  
1.1.5the Licensed Know-How accounts for all of the Codexis Know-How that is (i) necessary to practice the Platform Technology; and (ii) which Cover the practice of the Platform Technology;  
1.1.6neither Codexis nor any of its Affiliates has granted any right, license or interest to any Third Party relating to or under the Licensed IP or to the Platform Technology that would conflict or would otherwise be inconsistent with any of the rights, licenses or interests granted to GSK under this Agreement; 
1.1.7the Licensed Know-How (other than In-Licensed Know How) were generated either by employees or contractors of Codexis, and in each case the terms of employment or engagement of such employees or contractors vested in Codexis all right, title and interest in and to any Know-How generated by them or has obtained or has the legal right to obtain assignments of all such Licensed Know-How; 
1.1.8to the knowledge of Codexis Senior Management, no Third Party has rights in the Licensed Patents, the Licensed Know-How or the Platform Technology that would adversely affect GSK’s rights under this Agreement;  
    - 56 -

SV\1263057.27

1.1.9[***]; 
1.1.10[***]; 
1.1.11[***]; 
1.1.12to the knowledge of Codexis Senior Management, neither Codexis nor any of its Affiliates:
(a)is a party to any legal action relating to the Licensed IP; and
(b)[***];  
1.1.15in respect of each of the In-License Agreements, to the knowledge of Codexis Senior Management: 
(c)each of the In-License Agreements is in full force and effect and neither Codexis nor its Affiliates have materially breached or received any written or oral notice of any breach or any written or oral notice of the intent to terminate under any of the In-License Agreements; 
(d)each sublicense granted to GSK has been granted to GSK pursuant to the terms of each respective In-License Agreement; and
(e)each of the In-License Agreements disclosed to GSK is true, accurate and not misleading as to the terms thereof that have not been redacted; 
1.1.6the license limitations in Section 3.4.2 with respect to the Codexis Mayflower Patents are exhaustive, complete, accurate and not misleading; and 
1.1.7[***].  
1.19Mutual Covenants.  Each Party hereby covenants to the other Party that:
1.1.16
    - 57 -

SV\1263057.27

all employees of such Party or its Affiliates, and all agents, consultants, contractors and subcontractors (as provided in Section 4.4) of such Party or its Affiliates performing any research activities under a research plan under a Project shall be under the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, if any, to such Party as the sole owner thereof;  
1.1.17such Party shall perform its obligations and activities in compliance with Applicable Law and industry standards, including, without limitation, GLP, GCP and GMP, in each case as applicable under Applicable Law of the country and the state and local government wherein such activities are conducted, and with respect to the care, handling and use in research and development activities hereunder of any non-human animals by or on behalf of such Party, shall at all times comply (and shall ensure compliance by any of its subcontractors) with Applicable Law, and also with the standards in the pharmaceutical industry for the development and manufacture of pharmaceutical products, and (b) with individuals who are appropriately trained and qualified; 
1.1.18neither Party shall employ (or, to its knowledge, use any contractor or consultant that employs) any individual or entity (a) debarred by the FDA (or subject to a similar sanction of any other applicable Regulatory Authority), (b) who is the subject of an FDA debarment investigation or proceeding (or similar proceeding of any other applicable Regulatory Authority), or (c) has been charged with or convicted under any Applicable Law of the United States for conduct relating to the development, approval or otherwise relating to the regulation of any product under the Generic Drug Enforcement Act of 1992, in each case, in the conduct of its activities under this Agreement; and
1.1.19neither Party shall, during the Term, grant any right or license to any Third Party relating to any of the Intellectual Property rights it Controls that would conflict or interfere with any of the rights or licenses granted to the other Party hereunder.
1.20Additional Covenants of GSK.  GSK hereby covenants to Codexis that:
1.1.13GSK acknowledges and agrees that the use of any enzyme, other than a Codexis Enzyme, to generate an Enzyme and, in addition, any Enzyme generated in accordance with the terms of the license granted by Codexis to GSK may be Covered by a Patent(s) owned or otherwise controlled by a Third Party;  
1.1.14all GSK employees and contractors that will have access to Codexis Confidential Information and/or Platform Technology shall be subject to a confidentiality obligations with GSK subjecting the employee or contractor to GSK’s maintenance, non-disclosure, and non-use obligations under Article 9; 
1.1.15the financial information contained in any GSK report delivered pursuant to Article 7 will be generated using the same financial reporting system, using the same 
    - 58 -

SV\1263057.27

data, and in the same manner that GSK uses to generate financial information for GSK’s public reporting obligations; and
1.1.16GSK shall pay Codexis’ costs relating to the prosecution of the [***] Patents in accordance with Section 7.8 up to a maximum amount of [***] dollars ($[***]) per Calendar Year. 
1.21Additional Covenant of Codexis.  Codexis hereby covenants to GSK that:  
1.1.20with respect to each In-License Agreement, Codexis shall maintain and keep such In-License Agreement in full force and effect under each In-License Agreement’s respective terms for the term of the In-Licensed IP licensed pursuant to such In-License Agreement; 
1.1.21Codexis shall not amend any such In-License Agreement in a manner that adversely affects GSK’s rights under Section 3.2 and/or imposes any additional obligations upon GSK not disclosed to GSK under the In-License Agreements; and 
1.1.22except in respect of Section 8.4.4, Codexis, pursuant to the terms of the In-License Agreements, shall be responsible for any and all annual maintenance fees due to all Third Party licensors during the Term required to maintain each In-License Agreement; provided, however, that (i) GSK shall be responsible for any and all milestones and royalties due to such Third Party licensors during the Term as a consequence of GSK’s activities under the terms of this Agreement and (ii) nothing contained herein shall require Codexis to be responsible for Losses arising from the breach of such In-License Agreements by GSK as a sublicensee.  
1.1.23In the event of the termination of any of the In-License Agreements set forth on Exhibit 8.5.4, Codexis shall, at GSK’s sole discretion, either: 
(a)[***]; or 
(b)[***].  
Notwithstanding anything to the contrary, Codexis shall have no obligation under this Section 8.5.4 in the event of (i) expiration of any of the In-License Agreements set forth on Exhibit 8.5.4 in accordance with the terms of such In-License Agreement or (ii) a decision by the relevant 
    - 59 -

SV\1263057.27

Third Party licensor to abandon the Patents licensed under any of the In-License Agreements set forth on Exhibit 8.5.4 and dedicate the subject matter of such abandoned Patents to the public domain.  
1.2DISCLAIMERS.
1.1.1CODEXIS DISCLAIMER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 THROUGH 8.5, CODEXIS MAKES NO REPRESENTATIONS, WARRANTIES OR COVENANTS OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY CODEXIS CONFIDENTIAL INFORMATION, CODEXIS PATENTS, CODEXIS CORE TECHNOLOGY, CODEXIS CORE TECHNOLOGY IMPROVEMENTS, ARISING CODEXIS ENZYME TECHNOLOGY OR ARISING CODEXIS PROCESS TECHNOLOGY OR ANY LICENSE GRANTED BY CODEXIS HEREUNDER, OR WITH RESPECT TO THE PRODUCTS.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 THROUGH 8.5, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE CODEXIS PATENTS ARE VALID OR ENFORCEABLE OR THAT USE OF THE CODEXIS PATENTS, CODEXIS CORE TECHNOLOGY, CODEXIS CORE TECHNOLOGY IMPROVEMENTS, ARISING CODEXIS ENZYME TECHNOLOGY AND ARISING CODEXIS PROCESS TECHNOLOGY CONTEMPLATED HEREUNDER [***].
1.1.2GSK DISCLAIMER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 AND 8.4, GSK MAKES NO REPRESENTATIONS, WARRANTIES OR COVENANTS OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY GSK CONFIDENTIAL INFORMATION OR ANY LICENSE GRANTED BY GSK HEREUNDER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 AND 8.5, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE GSK BACKGROUND IP, ARISING GSK ENZYME TECHNOLOGY OR ARISING GSK PROCESS TECHNOLOGY ARE VALID OR ENFORCEABLE OR THAT THE USE OF THE GSK BACKGROUND IP, ARISING GSK ENZYME TECHNOLOGY OR ARISING GSK PROCESS TECHNOLOGY CONTEMPLATED HEREUNDER [***].
1.1LIMITATION OF LIABILITY.  EXCEPT FOR A BREACH OF [***], OR CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO 
    - 60 -

SV\1263057.27

INDEMNIFICATION UNDER ARTICLE 10, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL OR LOSS OF BUSINESS.
9.CONFIDENTIALITY
1.7Nondisclosure.  Each Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the “Receiving Party”) receiving Confidential Information from the other Party (the “Disclosing Party”) (or that has received any such Confidential Information from the other Party prior to the Effective Date) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than reasonable efforts, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to Section 9.3, and (c) not use such Confidential Information for any purpose, except as permitted by this Agreement (it being understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement).  
1.8Exceptions.  The obligations in Section 9.1 shall not apply with respect to any portion of the Confidential Information received from the Disclosing Party that the Receiving Party can show by competent written proof:
1.1.1was publicly disclosed by the Disclosing Party, either before or after disclosure to the Receiving Party hereunder; 
1.1.2was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party, as evidenced by contemporaneous written records; 
1.1.3was subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 
1.1.4was published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party; or 
1.1.5was developed independently by or for the Receiving Party or its Affiliates, as evidenced by written records, without reference to or reliance upon the Disclosing Party’s Confidential Information.  
1.2
    - 61 -

SV\1263057.27

Authorized Disclosure.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party, and Confidential Information deemed to belong to both Parties under the terms of this Agreement, to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:
1.1.6Prosecuting Patents;
1.1.7Regulatory Filings;
1.1.8Prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation;
1.1.9subject to Section 9.5, complying with Applicable Law (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; and
1.1.10disclosure, solely on a “need to know basis,” to Affiliates, potential and future collaborators (including sublicensees), potential or actual acquirers, merger partners, or assignees permitted under Section 13.5, potential or actual research and development collaborators, permitted subcontractors, investment bankers, investors, lenders or other potential financial partners, and their and each of the Parties’ respective directors, employees, consultants, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 9; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 9.3.5 to treat such Confidential Information as required under this Article 9.
If and whenever any Confidential Information is disclosed in accordance with this Section 9.3, such disclosure shall not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).  Where reasonably possible and subject to Section 9.5 and other than pursuant to Section 9.3.5, the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make such disclosure pursuant to this Section 9.3 sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance to the Disclosing Party with respect thereto; provided that, in any event, the Receiving Party will use reasonable measures to ensure confidential treatment of such information.
1.2Terms of this Agreement.  The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of both Parties. 
1.3
    - 62 -

SV\1263057.27

Securities Filings.  In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to the terms and conditions of this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other securities Applicable Law, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to the terms and conditions of this Agreement, and shall use reasonable efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party reasonably requests be kept confidential, and shall only disclose Confidential Information that it is advised by counsel is legally required to be disclosed.  No such notice shall be required under this Section 9.5 if the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party.
1.4Publicity.  
1.1.11Upon execution of this Agreement, Codexis shall issue the press release mutually agreed upon by the Parties and set forth in Exhibit 9.6.  [***].  Notwithstanding the foregoing, any disclosure that is required by Applicable Law (including the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended), or the rules of a securities exchange or the Securities and Exchange Commission or the securities regulations of any state or other jurisdiction, may be made by Codexis or GSK; provided that any such required disclosure will not contain any Confidential Information of, respectively, GSK or Codexis and, if disclosure of such information is required by Applicable Law or such rules or regulations, the Parties will comply with Sections 9.3.4 and 9.5, as applicable, and will use reasonable efforts to minimize such disclosure and obtain confidential treatment for any such information that is disclosed to a governmental agency.  Notwithstanding the foregoing, Codexis may publicly disclose any information that has previously been disclosed in accordance with this Section 9.6 without any requirement to receive GSK’s approval thereof or to provide GSK with an opportunity to review such disclosure.
1.1.12Codexis agrees to provide to GSK a copy of any public announcement regarding this Agreement or the subject matter thereof within a reasonable period of time under the circumstances prior to its scheduled release, which period of time shall not be less than fifteen (15) Business Days where practicable, for GSK’s review.  Except as otherwise required by Applicable Law, Codexis shall remove any Confidential Information of GSK that GSK deems to be inappropriate for disclosure.  Codexis agrees not to use the name or trademark 
    - 63 -

SV\1263057.27

of GSK, its Affiliates, or its employees, without the prior written consent of GSK, except that Codexis may disclose that GSK is a licensee of Codexis hereunder. 
1.1.13GSK may make public announcements and publications regarding any Pharmaceutical Product in its sole discretion, and such announcement or publication shall not be subject to this Section 9.6.  In addition, GSK may publish scientific papers and make scientific presentations; provided, however, that such publications and presentations do not include the Confidential Information of Codexis. 
10.INDEMNITY AND INSURANCE
1.1GSK Indemnity. GSK shall indemnify, defend, and hold harmless Codexis and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns, and representatives (the “Codexis Indemnitees”), from and against any and all Losses from Third Party claims to the extent arising out of or relating to, directly or indirectly:  (a) the negligence, recklessness or wrongful intentional acts or omissions of GSK, its Affiliates, and sublicensees and its or their respective directors, officers, employees and agents, in connection with GSK’s performance of its obligations or exercise of its rights under this Agreement, including without limitation under any Project; (b) any breach by GSK of any representation, warranty or covenant set forth in this Agreement; (c) research, development, synthesis, transfer, handling, storage, sale, use, optimization, modification, isolation, engineering, identification, selection, making, having made, importation, exportation or other disposition of any Licensed Product by or on behalf of GSK or any of its Affiliates, sublicensees, agents and contractors (other than Codexis) , including for each of clauses (a), (b), and (c) above, claims and threatened claims based on (i) product liability, bodily injury, risk of bodily injury, death or property damage or (ii) the failure to comply with Applicable Law; except (A) in any such case for Losses from Third Party claims to the extent reasonably attributable to any Codexis Indemnitee having committed an act or acts of negligence, recklessness or willful misconduct, (B) any breach by Codexis of any representation, warranty or covenant; or (C) for which Codexis is required to indemnify GSK pursuant to Section 10.2. 
1.2Codexis Indemnity. Codexis shall indemnify, defend and hold harmless GSK and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns, and representatives (the “GSK Indemnitees”), from and against any and all Losses from Third Party claims, to the extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness or wrongful intentional acts or omissions of Codexis, its Affiliates, and sublicensees (excluding GSK) and its or their respective directors, officers, employees and agents, in connection with Codexis’ performance of its obligations or exercise of its rights under this Agreement, including without limitation under any Project; and (b) any breach by Codexis of any representation, warranty or covenant set forth in this Agreement; including for each of clauses (a) and (b), claims and threatened claims based on (i) product liability, bodily injury, risk of bodily injury, death or property damage or (ii) the 
    - 64 -

SV\1263057.27

failure to comply with Applicable Law; except (A) in any such case for Losses from Third Party claims to the extent reasonably attributable to any GSK Indemnitee having committed an act or acts of negligence, recklessness or willful misconduct, (B) any breach by GSK of any representation, warranty or covenant; or (C) for which GSK is required to indemnify Codexis pursuant to Section 10.1.  
1.3Indemnification Procedure.  A claim to which indemnification applies under Section 10.1 or Section 10.2 shall be referred to herein as an “Indemnification Claim.”  If any Person or Persons (collectively, the “Indemnitee”) intends to claim indemnification under this Article 10, the Indemnitee shall notify the other Party (the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement, except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice).  The Indemnitor shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential conflicting interests between such Indemnitee and the Indemnitor; provided that the Indemnitor shall not be obligated to pay the fees of more than one counsel retained by all Indemnitees.  If the Indemnitor does not assume the defense of the Indemnification Claim as described in this Section 10.3 above, the Indemnitee may defend the Indemnification Claim, but shall have no obligation to do so.  The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an adverse effect on the Indemnitee’s interests (including any rights under this Agreement, or the scope or enforceability of any Patent within the Codexis Patent Rights or of the Codexis Know-How), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld or delayed.  The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s reasonable expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 9. 
1.4Insurance.  Each Party shall maintain at all times during the Term commercial general liability insurance and product liability insurance in respect of any Third Party claim, the subject of Section 10.1 and Section 10.2, from a recognized, creditworthy insurance company, with coverage limits of at least [***] Dollars ($[***]) per Third Party claim.  With respect to GSK, such product liability insurance shall include coverage for any Third Party claim subject to Section 10.1 in respect of any Licensed Product undergoing clinical trials.  The minimum level of insurance set forth herein shall not be construed to create a limit on either Party’s liability hereunder.  Within ten (10) days following reasonable written request from either Party, the other Party shall furnish to such Party a certificate of insurance 
    - 65 -

SV\1263057.27

evidencing such coverage.  In the case of a material modification or cancellation of such coverage, the covered Party shall notify the other Party as soon as reasonably practicable and provide such other Party with a new certificate of insurance evidencing that the covered Party’s coverage meets the requirements of this Section 10.4.  Notwithstanding the aforementioned, each Party may elect to self-insure or re-insure all or parts of the limits described above and, in such event, this Section 10.4 shall apply to such self-insurance or re-insurance arrangements mutatis mutandis. 
11.TERM AND TERMINATION.
1.5Term; Expiration.  This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 11, or by mutual agreement of the Parties, shall remain in effect until the expiration on a country-by-country basis of all payment obligations under this Agreement.  The period from the Effective Date until the date of expiration of this Agreement, or termination of this Agreement pursuant to this Article 11, shall be the “Term”.
1.6Termination for Material Breach.  Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement, in its entirety, in the Non-Breaching Party’s sole discretion in the event the other Party (the “Breaching Party”) has materially breached this Agreement, and such material breach has continued for sixty (60) days (the “Cure Period”) after written notice thereof is provided to the Breaching Party by the Non-Breaching Party, such notice describing the alleged material breach in sufficient detail to put the Breaching Party on notice.  If at the end of the Cure Period, the Breaching Party can demonstrate that it is actively seeking to remedy such material breach, then at the Breaching Party’s request and with the consent of the Non-Breaching Party (not to be unreasonably withheld), the Non-Breaching Party shall grant an additional forty-five (45) days for the Breaching Party to remedy such breach.
1.7Insolvency or Bankruptcy.  To the extent permitted under Applicable Law, either Party may terminate this Agreement, (a) if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or (b) if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within ninety (90) days after the filing thereof, or (c) if the other Party shall propose or be a party to any dissolution or liquidation, or (d) if the other Party shall make an assignment of substantially all of its assets for the benefit of creditors.  Each Party agrees to give the other Party prompt notice of the foregoing events giving rise to termination under this Section 11.3.  All rights and licenses granted under or pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, United States Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code.  The Parties shall retain and may fully 
    - 66 -

SV\1263057.27

exercise all of their respective rights and elections under the Bankruptcy Code.  All materials required to be delivered by the non-bankrupt Party under this Agreement (including all manufacturing information) shall be considered to be “embodiments” of such intellectual property for purposes of Section 365(n) of the Bankruptcy Code.  Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to, any intellectual property licensed to the non-bankrupt Party, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.  All written agreements entered into in connection with the Parties’ performance under this Agreement from time to time shall be considered agreements “supplementary” to this Agreement for purposes of Section 365(n) of the Bankruptcy Code.
1.8Termination for Challenge of any Codexis Patent.  If GSK or any of its Affiliates (the “Challenging Party”) challenges the validity, scope or enforceability of or otherwise opposes any Codexis Patent in any country (each, a “Patent Challenge”), Codexis has the right to give notice to the Challenging Party that this Agreement will terminate in its entirety forty-five (45) days after such notice, and, unless the Challenging Party withdraws or causes to be withdrawn such Patent Challenge within such forty-five (45) day period, this Agreement will so terminate.  
1.9Consequences of Expiration or Termination.  
1.1.1In General.  Expiration or termination of this Agreement for any reason shall not (a) release either Party from any obligation that has accrued prior to the effective date of such expiration or termination; (b) preclude either Party from claiming any other damages, compensation, or relief that it may be entitled to upon such expiration or termination; or (c) terminate any right to obtain performance of any obligation provided for in this Agreement that shall survive expiration or termination.  Upon any expiration or termination of this Agreement, each Party shall return to the other Party and cease using all Confidential Information of such other Party; provided that the legal department of each Party may retain one (1) copy of such Confidential Information.  Upon expiration (but not earlier termination) of this Agreement, the licenses granted to GSK pursuant to Sections 3.5.2 (if GSK exercised the Option) and 3.2.2 shall become perpetual and non-exclusive in the Field; provided that GSK shall remain responsible for any payments due to Codexis after the effective date of such expiration in accordance with Section 7.11. In the event of termination of this Agreement in accordance with this Article 11, [***] GSK shall have no rights to practice the Platform Technology.
1.1.2Partial Termination of Licenses.  All licenses granted to GSK under this Agreement shall terminate on a country-by-country basis to the extent that they relate to a country in the Territory that GSK has selected for termination in accordance with Section 11.7.  Upon termination of this Agreement by GSK with respect to a country in the Territory (a 
    - 67 -

SV\1263057.27

“Terminated Country”), Codexis’ rights and GSK’s obligations under Section 11.5.3 shall apply as to the Terminated Country.  In addition, the certification signed by [***], or a successor, provided to Codexis pursuant to Section 11.5.3 shall certify that all use of Platform Technology by GSK, its Affiliates or sublicensees, either alone or with a Third party, in the Terminated Country(ies) has ceased as of the date of such certification.  For the avoidance of doubt, partial termination of this Agreement with respect to any Terminated Country(ies) does not relieve GSK of obligations under Article 7 that arise from GSK’s exercise of rights or obligations under this Agreement within such Terminated Country(ies) existing as of the effective date of such partial termination.  For clarity, in the event that GSK, on a country-by-country basis, terminates this Agreement with respect to all countries in the Territory, this Agreement will be deemed to be terminated in its entirety.  
1.1.3Codexis Audit Right on GSK Breach or Termination. In the event of termination of this Agreement by Codexis as a result of GSK’s material breach under Section 11.2, or by GSK pursuant to Section 11.7, GSK shall provide to Codexis, within ninety (90) days after the effective date of such termination, a certification signed by [***] certifying that all Codexis proprietary materials, information, and technology in custody or control of GSK or sublicensee of GSK has been destroyed.  In addition, Codexis shall have a right to conduct an audit to determine that all Codexis materials, information, and/or technology have been destroyed and that such destruction is complete (the “Termination Audit Right”).  Under the Termination Audit Right, GSK shall allow a designee chosen by Codexis and reasonably acceptable to GSK to review documentation, materials, and facilities of GSK as reasonably necessary for such designee to determine whether all Codexis materials, information, and/or technology has been destroyed.  Results of such investigation shall be made available to both GSK and Codexis; provided that such designee shall disclose to Codexis only its determination of whether all Codexis materials, information, and/or technology has been destroyed.  GSK may require such designee to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are comparable to the obligations set forth in Article 9.  The Termination Audit Right shall continue until the earlier of (a) ten (10) years after the effective date of termination of this Agreement by Codexis as a result of GSK’s material breach under Section 11.2, or by GSK pursuant to Section 11.7 or (b) until a designee determines, pursuant to the Codexis’ exercise of the Termination Audit Right, that all Codexis materials, information, and/or technology has been destroyed.  All reasonable expenses arising from the first audit shall be at Codexis’ expense, and all subsequent audits, if any, shall be at GSK’s expense.
1.10GSK Continuing Rights.  Upon termination of this Agreement by GSK pursuant to Section 11.2 and 11.3, GSK shall continue to have the rights to research, develop, use, optimize, modify, isolate, engineer, identify, select, make, have made, import and/or export Enzymes and their derivatives under the licenses granted to GSK pursuant to Section 3.2, which 
    - 68 -

SV\1263057.27

shall remain in effect to the fullest extent possible subject only to the payment by GSK of the applicable amounts set out in Article 7.   
1.11GSK Termination at Will.  At any time following Completion of Wave 1, GSK may terminate this Agreement in its entirety, or on a country-by-country basis, upon providing ninety (90) days’ written notice to Codexis at any time and for any reason or for no reason at all.  In such event, GSK shall pay to Codexis all reasonable non-cancellable and non-terminable costs incurred by Codexis upon such event of termination.  If GSK terminates this Agreement in its entirety pursuant to this Section 11.7 during the TT Term, GSK shall pay to Codexis the applicable termination payment set forth in this Section 11.7. 

						
	Termination at Will During TT Term	Termination At Will Payment
	During Technology Transfer Project 1, as defined in the Technology Transfer Plan	$[***]
	During Technology Transfer Project 2, as defined in the Technology Transfer Plan	$[***]
	During Technology Transfer Project 3, as defined in the Technology Transfer Plan	$[***]
	During Technology Transfer Project 4, as defined in the Technology Transfer Plan	$[***]

1.12Additional Consequence of Certain Terminations.  If Codexis terminates this Agreement pursuant to Section 11.2, or if GSK terminates this Agreement in its entirety, then, in addition to the consequences set forth in Sections 11.5 - 11.7, [***]. 
1.13Survival.  Notwithstanding anything to the contrary in this Agreement, the following provisions shall survive, as well as any other provision which by its terms or by the context thereof, is intended to survive expiration or termination of this Agreement:  Articles 1 (Definitions), 6 (Intellectual Property), 7 (Financial Terms) (in accordance with Section 7.11), 9 (Confidentiality) (for the period of time set forth in Section 9.1), 12 (Dispute Resolution), and 13 (Miscellaneous), and Sections 3.1.2, 3.1.3, 3.4.1 and 3.4.2 (for the remaining term of the relevant Patents), 3.7.2, 8.6, 8.7, 10.1, 10.2, 10.3, 11.5, 11.8 and 11.9. Except as otherwise expressly 
    - 69 -

SV\1263057.27

provided, all other rights, licenses and obligations shall terminate upon expiration or termination of this Agreement.  
12.DISPUTE RESOLUTION.
1.14Resolution by Executive Officers.  The Parties agree that the procedures set forth in this Article 12 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (each, a “Dispute”) between the Parties that may arise from time to time pursuant to this Agreement relating to any Party’s rights and/or obligations.  Except as otherwise provided in this Agreement, in the event of any Dispute between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves.  In the event that such Dispute is not resolved on an informal basis within ten (10) Business Days, either Party may, by written notice to the other Party, refer the Dispute to the executive officers designated by the Parties for attempted resolution.  Such officers, or their designees, shall attempt in good faith to promptly resolve such Dispute within thirty (30) Business Days thereafter.  In the event that any matter is not resolved under the foregoing provisions, each Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2.  
1.15Mediation.  If a Dispute arises out of or relating to this Agreement, or the breach thereof, and if said Dispute is not resolved through negotiation by the Parties under Section 12.1, the Parties agree that they shall try in good faith to resolve the Dispute by referring it for confidential mediation under the CPR Mediation Procedure in effect at the start of mediation.  Unless otherwise agreed, the Parties shall select a mediator from the CPR Panels of Distinguished Neutrals.  If the Parties cannot agree, they will defer to the CPR to select a mediator.  The cost of the mediator shall be borne equally by the Parties.  The place of mediation shall be New York, New York, United States of America.  Any Dispute not resolved within forty-five (45) days (or within such other time period as may be agreed to by the Parties in writing) after appointment of the mediator shall be finally resolved by arbitration pursuant to Section 12.3.
1.16Arbitration.  Subject to Section 12.4, any Dispute referred for arbitration shall be finally resolved by binding arbitration before a panel of three (3) arbitrators in accordance with the rules of the American Arbitration Association (“AAA”) in effect at the time the proceeding is initiated. If the issues in Dispute involve scientific, technical or commercial matters, then any arbitrator chosen under this Agreement shall have educational training and industry experience sufficient to demonstrate a reasonable level of relevant scientific, technical and commercial knowledge relevant to the subject matter of the Dispute.  All proceedings and communications as part of the arbitration shall be in English.  Following selection of the third arbitrator, the arbitrators shall use all reasonable efforts to complete the arbitration proceedings and render an award within six (6) months after the last arbitrator is appointed. In any such arbitration, the following additional procedures shall apply: 
1.1.4
    - 70 -

SV\1263057.27

Rules.  The arbitration shall be conducted pursuant to the then-current AAA rules in effect for disputes between U.S. parties on the date of commencement of the arbitration; provided, however, that discovery in any arbitration shall be conducted in accordance with the AAA Commercial Arbitration Rules in effect immediately prior to October 1, 2013, for large complex commercial disputes between U.S. based entities. 
1.1.5Panel.  Within thirty (30) days after a Party demands arbitration, each Party shall select one (1) arbitrator and the third chosen by the two (2) Party-chosen arbitrators.  If either, or both, of GSK or Codexis fails to choose an arbitrator within thirty (30) days after receiving notice of commencement of arbitration or if the two arbitrators fail to choose a third arbitrator within thirty (30) days after their appointment, then either or both Parties shall immediately request that the AAA select the remaining number of arbitrators to be selected, which arbitrator(s) shall have an appropriate background, experience and expertise in the subject matter at issue in the Dispute.  The place of arbitration shall be San Francisco, California, United States of America.  The seat of arbitration shall be the State of New York, United States of America (for clarity, the Parties intend this to mean that the procedural rules of the State of New York, United States of America, will apply to any arbitration).
1.1.6Injunctive Relief; Costs and Expenses.  Either Party may apply to the arbitrators for interim injunctive relief until the arbitration decision is rendered or the Dispute is otherwise resolved.  Either Party may, without waiving any right or remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending resolution of the Dispute pursuant to this Article 12.  The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages.  Each Party will share equally the cost and expenses of the panel selected in Section 12.3.2 and any administrative fees unless in each case the arbitrators agree otherwise, which they are hereby empowered, authorized and instructed to do if they determine that to be fair and appropriate.  Each Party shall bear its own costs and expenses and attorneys’ fees in connection with any such arbitration; provided, however, that the prevailing Party in any such arbitration shall be entitled to recover from the other Party the reasonable attorneys’ fees, costs and expenses incurred by such prevailing Party in connection with such arbitration. 
1.1.7Confidentiality.  Except to the extent necessary to confirm an award or decision or as may be required by Applicable Law, or the requirement of any exchange on which a Party’s shares are traded, neither Party nor any arbitrator may disclose the existence or results of any arbitration without the prior written consent of both Parties. In no event shall any arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the Dispute would be barred by the applicable Delaware statute of limitations.
1.1.8Breach of the Agreement.  In the event of a Dispute involving the alleged breach of this Agreement (including, without limitation, whether a Party has satisfied its diligence obligations hereunder), (a) neither Party may terminate this Agreement under 
    - 71 -

SV\1263057.27

Article 11 until resolution of the Dispute pursuant to this Article 12 and (b) if the arbitrators render a decision that a breach of this Agreement has occurred, the arbitrators shall have no authority to modify the right of the non-breaching Party to terminate this Agreement in accordance with Section 11.2.
1.1.9Performance. Any disputed performance or suspended performance pending the resolution of a Dispute that the arbitrators determine to be required to be performed by a Party shall be completed within a reasonable time period following the final decision of the arbitrators.
1.1.10Binding Decision.  The decision of the arbitrators shall be the sole, exclusive and binding remedy between the Parties regarding the determination of all Disputes presented.  The arbitrators shall prepare and deliver to the Parties a written, reasoned opinion conferring their decision.  Judgment on the award so rendered may be entered in any court having competent jurisdiction thereof.  Any monetary payment to be made by a Party pursuant to a decision of the arbitrators shall be made in Dollars, free of any tax or other deduction.
1.17Confidentiality and Patent Disputes.  Notwithstanding anything in this Agreement to the contrary, any and all issues regarding (a) breach or threatened breach of a Party's confidentiality obligations under this Agreement or (b) the ownership, scope, construction, validity and enforceability of any Patent shall be determined in a court of competent jurisdiction under the local Patent laws of the jurisdictions having issued the Patent in question.
13.MISCELLANEOUS.
1.18Non-Solicitation.  During the period beginning on the Effective Date and ending on the date that is [***], (the “Non-Solicitation Period”), GSK and its Affiliates shall not, directly or indirectly, solicit, hire, employ or attempt to solicit, hire or employ any person acting in a scientific role who is or was an employee or contractor of Codexis or any Codexis Affiliate during the Non-Solicitation Period, or in any other way directly or indirectly seek to solicit, induce, bring about, influence, promote, facilitate, or encourage any such individual to work for GSK or any party other than GSK; provided that the foregoing shall not restrict GSK or its Affiliates from advertising employment opportunities in any manner that does not directly target Codexis or its Affiliates or from hiring or employing any person who responds to such generalized public advertisements.
1.19Severability.  If one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one 
    - 72 -

SV\1263057.27

such that the objectives contemplated by the Parties when entering this Agreement may be realized.
1.20Notices.  Any notice required or permitted to be given by this Agreement shall be in writing and shall be (a) delivered by hand or by overnight courier with tracking capabilities, (b) mailed postage prepaid by first class, registered or certified mail, or (c) delivered by facsimile or e-mail followed by delivery via either of the methods set forth in (a) or (b), in each case, addressed as set forth below unless changed by notice so given:
If to GSK: 
GlaxoSmithKline
709 Swedeland Road
P.O. Box 1539, Mail Code UW2318
King of Prussia, PA 19406-0939
United States

Attention:    [***]
Email:    [***]

With a copy to:

GlaxoSmithKline
2301 Renaissance Boulevard 
Mailcode RN0220
King of Prussia, PA 19406-2772
United States

Attention:     [***]
Email:    [***]
If to Codexis:
Codexis, Inc.
200 Penobscot Drive
Redwood City, CA  94063
Attention:  Chief Executive Officer 
Telephone:  [***]
Fax:  [***]
Email:    [***] 

    - 73 -

SV\1263057.27

With a copy to:

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA  94063
Attention:  General Counsel
Telephone:  [***]
Fax:  [***]
Email:    [***]

Any such notice shall be deemed given on the date received.  A Party may add, delete or change the Person or address to which notices should be sent at any time upon written notice delivered to the Party’s notices in accordance with this Section 13.3. 
1.21Force Majeure.  Except for the payment of money, neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, earthquakes, acts of war, terrorism, or civil unrest (“Force Majeure”); provided, however, that the affected Party promptly notifies the other Party; provided further that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with the utmost dispatch whenever such causes are removed.  When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.
1.22Assignment.  Neither Party may, without the consent of the other Party, assign or transfer any of its rights and obligations hereunder; provided that no such consent is required for an assignment or transfer to an Affiliate of such Party or to a successor in interest to such Party by reason of merger or consolidation or sale of all or substantially all of the business of such Party relating to the subject matter of this Agreement, whether by merger, sale of stock, sale of assets or otherwise.  This Agreement shall inure to the benefit of and be binding on the Parties’ successors and assigns.  Any assignment or transfer in violation of the foregoing shall be null and void. 
1.23Change of Control [***].  [***] 
    - 74 -

SV\1263057.27

[***].
1.24GSK Divestments.  If GSK sells, leases, loans, provides or otherwise transfers to any Third Party any asset, facility, business unit or personnel that practice or otherwise use any Codexis Core Technology, Codexis Core Technology Improvements or Enzyme Technology, GSK shall provide a certification to Codexis and Codexis shall have an audit right as set forth in Section 11.5.3. 
1.25Waivers and Modifications.  The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.  Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion.  No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by both Parties.
1.26Choice of Law.  This Agreement shall be governed by, enforced and construed in accordance with the laws of the State of Delaware, United States of America, excluding: (a) any conflicts of law principles that would result in the application of the laws of any state other than the State of Delaware; (b) the United Nations Convention on Contracts for the International Sales of Goods; (c) the 1974 Convention on the Limitation Period in the International Sale of Goods (the “1974 Convention”); and (d) the Protocol amending the 1974 Convention, done at Vienna April 11, 1980; provided, however, that with respect to matters involving the enforcement, validity or scope of Intellectual Property rights, the laws of the applicable country shall apply.
1.27Relationship of the Parties.  Each Party is an independent contractor under this Agreement.  Nothing contained herein is intended or is to be construed so as to constitute Codexis and GSK as partners, agents or joint venturers.  Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party.  
1.28Entire Agreement.  This Agreement, together with the attached exhibits and schedules, constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior and contemporaneous negotiations, representations, agreements and understandings regarding the same.
1.29Counterparts.  This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.  
    - 75 -

SV\1263057.27

Signatures to this Agreement transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature.  Notwithstanding the aforementioned, the Parties shall as soon as reasonably practicable exchange original signed counterparts to this Agreement. 
1.30Interpretation.  
1.1.11Drafting Party.  Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties and their counsel.  Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
1.1.12Singular and Plural; Gender.  The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The word “will” shall be construed to have the same meaning and effect as the word “shall.”  The word “any” means “any and all” unless otherwise clearly indicated by context.  The word “including” will be construed as “including without limitation.”  The word “or” is disjunctive but not necessarily exclusive.
1.1.13References.  Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to Applicable Law herein shall be construed as referring to such Applicable Law as from time to time enacted, repealed or amended, (c) any reference herein to any Person shall be construed to include the Person’s successors and assigns, and (d) all references herein to Articles, Sections or Exhibits, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Exhibits of this Agreement.
1.1.14Headings and Captions.  Headings and captions are for convenience only and are not to be used in the interpretation of this Agreement.
1.31
    - 76 -

SV\1263057.27

Anti-Bribery and Corruption.
1.1.1Codexis acknowledges that it has read GSK’s ‘Prevention of Corruption – Third Party Guidelines’ attached at Exhibit 13.14 and agrees to perform its obligations under the Agreement in accordance with the principles set out therein.
1.1.2Codexis shall comply fully at all time with all applicable laws and regulations, including but not limited to applicable anti-corruption laws, of the territory in which Codexis conducts business with GSK.
1.1.3GSK shall be entitled to terminate this Agreement immediately on written notice to Codexis, if Codexis fails to perform its obligations in accordance with this Section 13.14. [***].
1.32Ethical Standards and Human Rights.  Codexis represents and warrants, to the best of its knowledge, that in connection with this Agreement, it respects the human rights of its staff and does not employ child labor, forced labor, unsafe working conditions, discrimination on the basis of race, religion, disability or gender, or cruel or abusive disciplinary practices in the workplace; and that it pays each employee at least the minimum wage, provides each employee with all legally mandated benefits, and complies with the laws on working hours and employment rights in the countries in which it operates.  Codexis shall encourage compliance with these standards by any supplier of goods or services that it uses in performing its obligations under this Agreement.
1.33Good Data Management.  During the Technology Transfer or under any Collaborative Project conducted pursuant to this Agreement, each Party shall, and shall cause any Third Party acting for and on behalf of such Party to, carry out its obligations under the Agreement, and collect and record any data generated therefrom, in accordance with the following good data management practices:
1.1.15Data are being generated using sound scientific techniques and processes;
1.1.16Data are being accurately recorded in accordance with good scientific practices; 
1.1.17Data are being analyzed appropriately without bias in accordance with good scientific practices;
1.1.18
    - 77 -

SV\1263057.27

Data and results are being stored securely and can be retrieved, and
1.1.19Data trails exist to demonstrate and/or reconstruct key decisions.

[Signature Page Follows]
    - 78 -

SV\1263057.27

IN WITNESS WHEREOF, the Parties have caused this Platform Technology Transfer, Collaboration and License Agreement to be executed by their respective duly authorized officers as of the Effective Date.

						
	Codexis, Inc.	GlaxoSmithKline Intellectual Property Development Limited
	By: /s/ John J. Nicols    
	By: /s/ Paul Williamson    

	Name: John J. Nicols    
	Name: Paul Williamson    
For and on behalf of
Edinburgh Pharmaceutical Industries Limited

	Title: President & CEO    
	Title: Corporate Director    

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.18

Codexis Core Patents

																								
	CODEXIS CORE PATENTS
	Country	Application Title	Application Status	Application Number	Filing Date	Publication Number	Patent
Number
	Issue
Date

	US	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Granted	12/562988	09/18/2009	2010/0093560	8,383,346	02/26/2013
	CN	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS	Granted	200980122093.2	12/13/2010	102066561	200980122093.2	09/25/2013
	CA	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS	Published	2,726,850	12/02/2010	2726850	 	 
	EP	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS	Published	09763625.2	11/29/2010	2285958	 	 
	IN	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS	Published	8090/CHEN/2010	12/13/2010	8090/CHENP/2010	 	 
	SG	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS	Granted	201009215-3	12/13/2010	 	167342	05/31/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	CA	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Published	2763017	11/21/2011	2763017	 	 
	CN	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Published	200980159766.1	12/08/2011	102803489	 	 
	EP	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Published	09845944.9	12/05/2011	2451951	 	 
	IN	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Published	9101/CHENP/2011	12/07/2011	9101/CHENP/2011	 	 
	US	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS	Published	13/756778	02/01/2013	2013/0143767	 	 
	US	METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS	Granted	12/867429	08/12/2010	2011/0029468	8,504,498	08/06/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS	Published	09710859.1	02/12/2009	2250595	 	 
	EP	METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS	Published	09710490.5	02/12/2009	2250594	 	 
	US	METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS	Granted	12/867433	10/21/2010	2011/0034342	8,768,871	07/01/2014
	[***]	[***]	[***]	[***]	[***]	 	 	 
	EP	REDUCED CODON MUTAGENESIS	Published	10817881.5	03/30/2012	2478137	 	 
	US	PROTEIN VARIANT GENERATION BY REGION SHUFFLING	Published	13/577651	08/07/2012	2014/0005057	 	 
	EP	PROTEIN VARIANT GENERATION BY REGION SHUFFLING	Published	12803889.0	12/12/2013	2726651	 	 
	WO	GENE SHUFFLING METHODS	Published	PCT/US2013/030526	03/12/2013	WO2013138339	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.19 

Codexis Core Technology

The enzyme optimization process starts by identifying genes that code for enzymes known to have the general type of catalytic reactivity for a desired chemical reaction. Typically, we identify gene sequences in published databases and then synthesize candidate genes having those sequences. Using a variety of biotechnology tools, we diversify these genes by introducing mutations, giving rise to changes in the enzymes for which they encode. The methods for diversifying these genes, and types of diversity being tested, often vary over the course of an enzyme optimization program. For finding initial diversity, methods typically include random mutagenesis and site-directed (included structure-guided) mutagenesis. We also test mutational variations that distinguish related enzymes among different organisms. Once we have identified potentially beneficial mutations, we test combinations of these mutations in libraries made using our proprietary gene recombination methodologies, gene shuffling and multiplexed gene SOEing, or Splicing by Overlap Extension.
With our proprietary gene shuffling methodology, we generate libraries of genes that have random combinations of the mutations we are testing. The pool of genes is used to transform host cells, which entails introducing the various genes, one by one, into host cells. These cells are then segregated and grown into colonies. Cells from individual colonies are cultured in high throughput to produce the enzyme encoded by the shuffled gene in those cells. The enzymes are then screened in high throughput using test conditions relevant to the desired process. The screening results identify individual shuffled genes that produce improved enzymes having combinations of beneficial mutations and weed out enzymes having detrimental ones. Using different test conditions and/or different analytical methods, we can identify variant enzymes that exhibit various improved performance characteristics, such as stability, activity and selectivity, under conditions relevant to the desired chemical process.
In the next step in our optimization process, we use our proprietary software tool, ProSARTM, to analyze protein sequence-activity relationships. ProSARTM aids in identifying specific gene and enzyme mutations that are beneficial, neutral or detrimental with respect to the desired performance characteristics. Earlier directed evolution methods did not separately evaluate individual mutations in libraries of variants which carry multiple mutations, where beneficial and detrimental performance characteristics may be mixed in an individual gene or enzyme. Capitalizing on the advent of inexpensive gene sequencing, we are able to determine which particular mutations are present in the genes and proteins we have screened. Our ProSARTM bioinformatics software relates the screening results to the mutations and ranks the individual mutations with regard to their degree of benefit or detriment, relative to whichever process parameter(s) the screening tested. Using that information, we can bias the pool of mutational diversity in the next iteration to further the accumulation of beneficial diversity and cancel out detrimental diversity in the individual genes in the resulting shuffled library. The ProSARTM results also help us develop ideas about new diversity to test. ProSARTM, combined with efficient gene synthesis and high quality library generation methods, has led to a significant increase in the efficiency and speed of enzyme improvement and optimization.
In another step of our optimization process, we take the best variants we have identified and prepare enough of each to test in the desired chemical process at laboratory scale, for in-process confirmation. This optimization routine is done iteratively, typically adding new diversity to the 
[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

pool in each iteration. The gene that codes for the best performing enzyme in one iteration is used as the starting gene for the next iteration of shuffling and screening. As the enzymes improve over these iterations, the screening conditions are made increasingly more stringent. In this way, enzymes are rapidly optimized until all in-process performance requirements have been achieved and the economic objectives for the desired process have been met.
Multiplexed gene SOEing is our proprietary methodology for rapidly generating gene variants. Using multiplexed gene SOEing, we rapidly generate collections of individual gene variants that have predetermined, as opposed to random, combinations of mutations we are testing. It is based on a biotechnology technique, which we refer to as SOEing, generally used to make a hybrid, or spliced, gene from fragments of two genes and/or to introduce a specific mutation into a splice between fragments of one gene. We have automated the process to make robotically, in parallel, one hundred to several hundred variants, each with a predetermined combination of the mutations we are testing. The variants are introduced into host cells, and the encoded enzyme is produced and screened in high throughput, as described above.
Using multiplexed gene SOEing, we can test many mutations and combinations thereof in parallel, and because the mutation incorporation is controlled and predetermined before screening, as opposed to random incorporation and selection after screening, the resulting data set can be more optimal for ProSARTM analysis.
We believe using multiplexed gene SOEing to survey many mutations quickly, followed by ProSARTM-driven shuffling of beneficial mutations, is a particularly effective approach, providing rapid gains in enzyme performance

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.24

Codexis Enzyme Patents

																								
	CODEXIS ENZYME PATENTS
	Country	Application Title	Application Status	Application
Number
	Filing
Date
	Publication Number	Patent
Number
	Issue
Date

	US	TRANSAMINASE POLYPEPTIDES	Granted	12/684864	01/08/2010	2010/0209981	8,470,564	06/25/2013
	EP	TRANSAMINASE POLYPEPTIDES	Published	10729606.3	01/08/2010	2385983	 	 
	SG	TRANSAMINASE POLYPEPTIDES	Published	201104947-5	07/06/2011	0172891	 	 
	IN	TRANSAMINASE POLYPEPTIDES	Published	5648/CHENP/2011	08/04/2011	5648/CHENP/2011	 	 
	IL	TRANSAMINASE POLYPEPTIDES	Pending	213950	07/06/2011	 	 	 
	CN	TRANSAMINASE POLYPEPTIDES	Published	201080010926.9	01/08/2010	102341494	 	 
	US	TRANSAMINASE POLYPEPTIDES	Published	13/920,902	06/18/2013	2013/0266994	 	 
	US	TRANSAMINASE BIOCATALYSTS	Granted	12/714397	02/26/2010	2010/0285541	8,293,507	10/23/2012
	CN	TRANSAMINASE BIOCATALYSTS	Published	201080017312.3	10/19/2011	102405281	 	 
	EP	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	IN	TRANSAMINASE BIOCATALYSTS	Published	6857/CHENP/2011	09/22/2011	6857/CHENP/2011	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	TRANSAMINASE BIOCATALYSTS	Granted	201106064-7	02/26/2010	0173815	173815	11/15/2013
	JP	TRANSAMINASE BIOCATALYSTS	Published	2011-552209	08/23/2011	2012-519004	 	 
	US	TRANSAMINASE BIOCATALYSTS	Published	13/604,323	09/05/2012	2012/0329108	 	 
	DE	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	202010012539.4	12/18/2013
	FR	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	ES	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	CH	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	GB	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	IE	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	IT	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	NL	TRANSAMINASE BIOCATALYSTS	Granted	10746948.8	09/26/2011	2401366	2401366	12/18/2013
	CN	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS	Published	201080027481.5	12/20/2011	102482648	 	 
	EP	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS	Published	10797576.5	12/22/2011	2446025	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS	Pending	9363/CHENP/2011	12/21/2011	 	 	 
	SG	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS	Allowed	201109538-7	12/21/2011	0177331	 	 
	US	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS	Allowed	13/378618	12/15/2011	2012/0190086	 	 
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE	Published	10810597.4	03/15/2012	2467473	 	 
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE	Published	 	03/15/2012	2372/CHENP/2012	 	 
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE	Published	13/390677	02/15/2012	2012/0149073	 	 
	SG	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE	Published	201201086-4	02/16/2012	0178456	 	 
	CN	TRANSAMINASE REACTIONS	Published	201080027740.4	12/21/2011	102597226	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	TRANSAMINASE REACTIONS	Published	10797544.3	12/22/2011	2446026	 	 
	IN	TRANSAMINASE REACTIONS	Published	9683/CHENP/2011	12/22/2011	9683/CHENP/2011	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	TRANSAMINASE REACTIONS	Published	201109536-1	12/21/2011	0177329	 	 
	US	TRANSAMINASE REACTIONS	Published	13/378963	04/09/2012	2012/0190085	 	 
	IL	TRANSAMINASE REACTIONS	Pending	216099	11/02/2011	 	 	 
	US	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	12/490190	06/23/2009	2010/0063300	8,178,333	05/15/2012
	CN	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Allowed	200980133157.9	06/24/2008	102131813	 	 
	SG	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	201009300-3	06/23/2009	 	167392	08/15/2013
	EP	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Published	397/CHENP/2011	01/19/2011	397/CHENP/2011	 	 
	US	STEREOMERICALLY PURE FUSED BICYLIC PROLINE COMPOUNDS USEFUL FOR PREPARING HEPATITIS C PROTEASE INHIBITORS	Allowed	13/294930	11/11/2011	2012/0130087	 	 
	US	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	13/436506	03/30/2012	2012/0244581	8,574,876	11/05/2013
	FR	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013
	DE	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	602009019988.9	11/06/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IE	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013
	IT	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013
	NL	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	ES	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013
	CH	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	GB	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS	Granted	09798485.0	06/23/2009	2307419	2307419	11/06/2013
	US	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	12/545761	08/21/2009	2010/0055751	8,288,131	10/16/2012
	US	POLYNUCLEOTIEDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES	Granted	13/610723	09/11/2012	2013/0005018	8,455,230	06/04/2013
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE	Granted	12/549154	08/27/2009	2010/0151534	8,426,178	04/23/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE	Published	09810573.7	08/27/2009	2329013	 	 
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE	Published	2014/CHENP/2011	03/22/2011	2014/CHENP/2011	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE	Granted	13/796985	03/12/2013	2013/0177962	8,673,607	03/18/2014
	US	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE	Granted	12/545034	08/20/2009	2010/0062499	8,273,554	09/25/2012
	CN	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE	Published	200980141486.8	04/19/2011	102186972	 	 
	SG	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE	Pending	201101090-7	02/16/2011	 	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE	Published	09810477.1	03/29/2011	2329014	 	 
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE	Published	2000/CHENP/2011	03/22/2011	2000/CHENP/2011	 	 
	US	POLYNUCLEOTIDES ENCODING RECOMBINANT KETOREDUCTASE POLYPEPTIDES	Granted	13/590882	08/21/2012	2012/0322136A1	8,415,126	04/09/2013
	US	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE	Published	13/764596	02/11/2013	2013/0210098	 	 
	US	ENONE REDUCTASES	Granted	12/646907	12/23/2009	2010/0190218	8,329,438	12/11/2012

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	ENONE REDUCTASES	Published	09835878.1	12/23/2009	2382308	 	 
	IN	ENONE REDUCTASES	Published	4505/CHENP/2011	12/23/2009	4505/CHENP/2011	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	ENONE REDUCTASES	Published	201104630-7	12/23/2009	0172783	 	 
	US	ENONE REDUCTASES	Published	13/658582	10/23/2012	2013/0115663	 	 
	US	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES	Granted	12/642586	12/18/2009	2010/0173372	8,187,856	05/29/2012
	IN	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES	Published	5068/CHENP/2011	12/18/2009	5068/CHENP/2011	 	 
	US	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES	Granted	13/452328	04/20/2012	2012/0220002	8,580,555	11/12/2013
	US	PENICILLIN G ACYLASES	Granted	12/615139	11/09/2009	2010/0143968	8,247,192	08/21/2012
	US	PENICILLIN G ACYLASES	Granted	13/542835	07/06/2012	2012/0270282	8,569,013	10/29/2013
	US	NITRILASE BIOCATALYSTS	Granted	13/381155	12/28/2011	2012/0142063	8,614,081	12/24/2013
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE	Granted	12/549293	08/27/2009	2010/0173369	8,288,141	10/16/2012
	US	POLYNUCLEOTIDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES	Published	13/610166	09/11/2012	2013/0005017	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	CN	SYNTHESIS OF PRAZOLE COMPOUNDS	Published	201080054980.3	06/04/2012	102884178	 	 
	EP	SYNTHESIS OF PRAZOLE COMPOUNDS	Published	10836590.9	07/05/2012	2510089	 	 
	IN	SYNTHESIS OF PRAZOLE COMPOUNDS	Published	5934/CHENP/2012	07/05/2012	5934/CHENP/2012	 	 
	SG	SYNTHESIS OF PRAZOLE COMPOUNDS	Published	201204152-1	06/06/2012	0181535	 	 
	US	SYNTHESIS OF PRAZOLE COMPOUNDS	Published	13/514750	06/08/2012	2013/0017580	 	 
	EP	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS	Published	11778262.3	12/03/2012	2566497	 	 
	IN	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS	Published	10077/CHENP/2012	11/30/2012	10077/CHENP/2012	 	 
	US	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS	Published	13/695856	11/02/2012	2013/0052699	 	 
	US	PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM	Published	13/577772	10/16/2012	2013/0029385	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM	Published	7740/CHENP/2012	09/07/2012	7740/CHENP/2012	 	 
	SG	STRUCTURE-ACTIVITY RELATIONSHIPS	Published	201200817-3	02/12/2001	178753	 	 
	US	STRUCTURE-ACTIVITY RELATIONSHIPS	Published	13/757554	02/01/2013	2013/0165341	 	 
	US	STRUCTURE-ACTIVITY RELATIONSHIPS	Published	13/764252	02/11/2013	2013/0157900	 	 
	CN	KETOREDUCTASES AND USES THEREOF	Granted	200880004582.3	02/08/2008	CN 101627116A	ZL2008 8 0004582.3	07/10/2013
	SG	KETOREDUCTASES AND USES THEREOF	Granted	200904674-9	02/08/2008	 	154045	03/30/2012
	KR	KETOREDUCTASES AND USES THEREOF	Pending	10-2009-7016084	02/08/2008	 	 	 
	US	KETOREDUCTASES AND USES THEREOF	Granted	12/028,780	02/08/2008	2008/0318295	7,820,421	10/26/2010
	EP	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	IL	KETOREDUCTASES AND USES THEREOF	Pending	199399	02/08/2008	 	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	JP	KETOREDUCTASES AND USES THEREOF	Published	2009-549110	02/08/2008	2010-517574	 	 
	US	KETOREDUCTASES AND USES THEREOF	Granted	12/881734	09/14/2010	2011/0165670	8,071,347	12/06/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	CH	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	DE	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	FR	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	GB	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	IE	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	NL	KETOREDUCTASES AND USES THEREOF	Granted	08725329.0	02/08/2008	2115130	2115130	08/03/2011
	US	KETOREDUCTASES AND USES THEREOF	Granted	13/290773	11/07/2011	2012/0178142	8,415,127	04/09/2013
	US	KETOREDUCTASES AND USES THEREOF	Published	13/793158	03/11/2013	2013/0196408	 	 
	JP	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Allowed	2007-526267	06/04/2005	 	5042831	 
	DE	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	102004029112.8	06/11/2004	 	1763577	10/06/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	05756002.1	06/04/2005	1763577	1763577	10/06/2010
	US	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	11/629000	12/08/2006	2009/0162893	7,943,356	05/17/2011
	GB	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	05756002.1	06/04/2005	1763577	1763577	10/06/2010
	IT	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	05756002.1	06/04/2005	1763577	1763577	10/06/2010
	AT	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	05756002.1	06/04/2005	1763577	1763577	10/06/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	FR	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS	Granted	05756002.1	06/04/2005	1763577	1763577	10/06/2010
	SG	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE	Granted	201000745-8	08/24/2008	 	159008	09/14/2012
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE	Pending	1624/CHENP/2010	08/24/2008	 	 	 
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE	Published	08798570.1	08/24/2008	2195443	 	 
	CN	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE	Published	200880104011.7	08/24/2008	101784669	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE	Granted	12/197286	08/24/2008	2009/0093031	7,977,078	07/12/2011
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (r)-3-HYDROXYTHIOLANE	Granted	13/110789	05/18/2011	2011/0217754	8,227,229	07/24/2012
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (r)-3-HYDROXYTHIOLANE	Published	13/525048	06/15/2012	2012/0276599	 	 
	CN	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	200880115770.3	09/13/2008	101855342	ZL 2008 8 0115770.3	07/10/2013
	JP	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Published	2010-525057	09/13/2008	2010-538657	 	 
	US	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	12/210195	09/13/2008	2009/0191605	8,748,143	06/10/2014

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Pending	2039/CHENP/2010	09/13/2008	 	 	 
	SG	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	201001576-6	09/13/2008	 	159828	04/13/2012

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013
	KR	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Pending	10-2010-7007675	09/13/2008	 	 	 
	US	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	13/682600	11/20/2012	2013/0078692	8,512,973	08/20/2013
	US	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Allowed	13/970284	08/19/2013	2013/0344552	 	 
	DE	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	602008028883.8	11/20/2013
	FR	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013
	CH	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	GB	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013
	IE	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	NL	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES	Granted	08830789.7	09/13/2008	2198018	2198018	11/20/2013
	SG	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	201001902-4	09/28/2008	 	160022	07/31/2013
	US	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	12/240986	09/29/2008	2009/0155863	8,088,610	01/03/2012
	CN	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Allowed	200880118039.6	09/28/2008	101889081	ZL200880118039.6	06/18/2014
	EP	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012
	IN	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Pending	2378/CHENP/2010	09/28/2008	 	 	 
	IL	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	204331	09/28/2008	 	204331	07/31/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,3)-METHYL2-(3-(3-(2(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE	Granted	13/329986	12/19/2011	2012/0184000	8,617,853	12/31/2013
	DE	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IE	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012
	NL	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012
	CH	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012
	GB	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF	Granted	08833139.2	09/28/2008	2203557	2203557	02/29/2012
	EP	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL	Published	EP11846568.1	06/14/2013	2649187	 	 
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 
	US	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL	Published	13/992138	06/06/2013	2013/0260426	 	 
	EP	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL	Published	11796441.1	12/17/2012	2582799	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL	Pending	267/CHENP/2013	01/11/2013	 	 	 
	US	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL	Allowed	13/704507	12/14/2012	2013/0089898	 	 
	EP	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE	Published	11818555.2	04/29/2013	2606139	 	 
	[***]	[***]	[***]	[***]	[***]	 	 	 
	US	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE	Published	13/817295	03/12/2013	2013/0164794	 	 
	SG	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Granted	201001989-1	10/01/2008	 	160517	05/05/2014
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Granted	12/243,968	10/01/2008	2009/0162909	7,883,879	02/08/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Published	08836133.2	10/01/2008	2205727	 	 
	IL	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Pending	204379	10/01/2008	 	 	 
	JP	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Pending	2010-527257	10/01/2008	 	 	 
	IN	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Pending	2450/CHENP/2010	10/01/2008	 	 	 
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Granted	12/977,825	12/23/2010	2011/0159567	8,257,952	09/04/2012
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Granted	13/569900	08/08/2012	2013/0034895	8,470,572	06/25/2013
	US	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE	Published	13/925096	06/24/2013	2014/0057330	 	 
	[***]	[***]	[***]	[***]	[***]	 	 	 
	EP	BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF	Published	12771861.7	11/06/2013	2697662	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	 	 	 
	[***]	[***]	[***]	[***]	[***]	 	 	 
	WO	BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS	Published	PCT/US13/039874	05/07/2013	WO2013/169725	 	 
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 
	WO	BIOCATALYSTS FOR THE PREPARATION OF HYDROXY SUBSTITUTED CARBAMATES	Published	PCT/US2012/065046	11/14/2012	WO2013/074650	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	 	 	 	 	 
	[***]	[***]	[***]	[***]	[***]	 	 	 
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 
	[***]	[***]	[***]	[***]	[***]	[***] 
		

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]		
	[***]	[***]	[***]	[***]	[***]	[***]	 	 
	[***]	[***]	[***]	[***]	[***]	[***]		
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	 	 	 
	IN	IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	514/CHENP/2006	08/11/2004	 	239120	03/09/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	200600860-1	08/11/2004	 	119648	12/31/2008
	US	KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	10/916311	08/11/2004	2006/0195947	7,629,157	12/08/2009
	US	KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	12/576195	10/08/2009	2010/0028972	7,833,767	11/16/2010
	EP	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011
	US	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	11/502745	08/10/2006	2007/0161094	7,807,423	10/05/2010
	US	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS	Granted	10/782258	02/18/2004	2004/0214297 A1	7,132,267	11/07/2006

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	10/639159	08/11/2003	2004/0137585	7,125,693	10/24/2006
	IN	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYR1C ACID DERIVATIVES	Granted	158/CHENP/2005	08/11/2003	 	220964	06/11/2008
	SG	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	2005007634-8	08/11/2003	 	109875	08/31/2007
	SG	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-RYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS	Granted	200600847-8	02/18/2004	 	119636	02/29/2008

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	JP	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	2004-528083	08/11/2003	2005-535330	4578240	09/03/2010
	HK	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	05108017.7	08/11/2003	 	HK1074059	09/09/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	FR	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011
	DE	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011
	IE	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011
	NL	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011
	GB	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES	Granted	03785237.3	08/11/2003	1537222	1537222	03/09/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	200600859-3	08/11/2004	 	119647	02/27/2009
	US	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	12/790784	05/28/2010	2010/0304459	7,939,309	05/10/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	IN	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	521/CHENP/2006	08/11/2004	 	239922	04/09/2010
	AU	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	2004288134	08/11/2004	 	2004288134	04/01/2010
	US	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	10/915927	08/11/2004	2005/0095619A1	7,816,111	10/19/2010
	EP	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013
	FR	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	DE	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	602004043547.3	10/09/2013
	IE	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	NL	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013
	CH	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013
	GB	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES	Granted	04816807.4	08/11/2004	1660648	1660648	10/09/2013
	US	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	12/573824	10/05/2009	2010/0167345	8,101,395	01/24/2012
	US	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	10/917179	08/11/2004	2005/0153417	7,824,898	11/02/2010
	IN	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	519/CHENP/2006	08/11/2004	 	239852	04/06/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	SG	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	200808477-4	11/14/2008	0148180	148180	01/30/2014
	US	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	11/266747	11/02/2005	2006/0099700	7,588,928	09/15/2009

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	11/067323	02/23/2005	2005/0272064	7,541,171	06/02/2009
	US	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	12/505374	07/17/2009	2009/0298125	8,252,554	08/28/2012
	US	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES	Granted	13/349514	01/12/2012	2012/0208259	8,535,910	09/17/2013
	US	ALANINE 2,3-AMINOMUTASES AND RELATED POLYNUCLEOTIDES	Granted	11/919271	03/20/2009	2010/0099143	7,790,432	09/07/2010
	IN	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Pending	2322/CHENP/2009	10/01/2007	 	 	 
	SG	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Granted	200901677-5	10/01/2010	 	150849	01/30/2014

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Allowed	07843631.8	10/01/2007	2066788	 	 
	CN	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Published	200780036841.6	10/01/2007	101528917	 	 
	US	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Granted	11/865696	10/01/2007	2004/0248539	7,879,585	02/01/2011
	US	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Granted	12/978022	12/23/2010	2011/0195465	8,273,547	09/25/2012
	US	POLYNUCLEOTIDES ENCODING KETOREDUCTASES FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR	Granted	13/571,248	08/09/2012	2013/0040364	8,617,864	12/31/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	CH	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	US	ENZYMATIC CONVERSION OF EPDXIDES	Granted	11/833933	08/03/2007	2008/0220485	7,695,942	04/13/2010
	FR	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	DE	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	60122505.8	08/23/2006
	GB	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	IE	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	NL	ENZYMATIC CONVERSION OF EPOXIDES	Granted	01934641.0	05/23/2001	1287155	1287155	08/23/2006
	[***]	[***]	[***]	[***]	[***]			

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]			

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.30

Codexis Mayflower Patents

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	CODEXIS MAYFLOWER PATENTS
	Country	Application Title	Application Status	Application Number	Filing Date	Publication Number	Patent Number	Issue
Date

	GB	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	US	METHOD FOR IN VITRO RECOMBINATION	Granted	09/075511	05/08/1998	 	6,165,793	12/26/2000
	AU	METHOD FOR IN VITRO RECOMBINATION	Granted	2005202165	12/02/1996	 	2005202165	06/26/2008
	CA	METHOD FOR IN VITRO RECOMBINATION	Granted	2239099	12/02/1996	2239099	2239099	11/30/2004
	EP	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	BE	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	NL	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	DK	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	FR	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	DE	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	KR	METHOD FOR IN VITRO RECOMBINATION	Granted	96-0704465	02/17/1995	 	491810	05/19/2005
	CH	METHOD FOR IN VITRO RECOMBINATION	Granted	96940934.1	12/02/1996	0876509	0876509	09/19/2001
	US	END-COMPLEMENTARY POLYMERASE REACTION	Granted	08/425684	04/18/1995	 	5,834,252	11/10/1998
	US	END-COMPLEMENTARY POLYMERASE REACTION	Granted	08/675502	07/03/1996	 	5,928,905	07/27/1999
	US	END-COMPLEMENTARY POLYMERASE REACTION	Granted	09/245802	02/05/1999		6,489,146	12/03/2002
	US	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION	Granted	09/724067	11/28/2000	 	6,482,647	11/19/2002
	US	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION	Granted	08/792409	02/03/1997	 	6,096,548	08/01/2000

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION	Granted	09/430927	11/01/1999	 	6,358,742	03/19/2002
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10/646221	08/22/2003		7,534,564	05/19/2009
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	09/954692	09/12/2001		6,946,296	09/20/2005
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	08/769062	12/18/1996	 	6,335,160	01/01/2002
	GB	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	09/693389	10/20/2000	 	6,586,182	07/01/2003
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	09/693350	10/20/2000	 	6,579,678	06/17/2003

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	09/339913	06/24/1999	 	6,303,344	10/16/2001
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	09/339926	06/24/1999	 	6,653,072	11/25/2003

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	12/069011	02/05/2008		7,776,598	08/17/2010
	CA	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	2274319	12/17/1997		2274319	04/09/2013
	BE	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	CA	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Published	2589337	12/17/1997	2589337	 	 
	MC	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	CH	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	EP	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	DK	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	JP	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10-528054	12/17/1997	 	5008784	06/08/2012
	FR	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	LU	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	FI	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	DE	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997	1149905	69739996.6-08	09/15/2010
	GR	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010
	NL	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	01202350.3	12/17/1997		1149905	09/15/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	BE	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	DE	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	GB	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	CH	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	DK	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	FR	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	NL	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING	Granted	10075154.4	12/17/1997		2202308	02/13/2013
	US	METHOD FOR PRODUCING POLYNUCLEOTIDES WITH DESIRED PROPERTIES	Granted	09/333762	06/15/1999	 	6,337,186	01/08/2002
	US	OPTIMIZATION OF INSECT RESISTANCE GENES USING DNA SHUFFLING	Granted	09/296886	04/22/1999	 	6500617	12/31/2002
	US	DNA SHUFFLING OF MONOOXYENASE GENES FOR PRODUCTION OF INDUSTRIAL CHEMICALS	Granted	09/373,928	08/12/1999	 	6,605,430	08/12/2003

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	HIGH THROUGHPUT MASS SPECTROMETRY	Granted	09/502,283	02/11/2000	 	7,384,387	06/10/2008
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	11/339090	01/24/2006		7,620,502	11/17/2009
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	11/975638	10/18/2007		7,853,410	12/14/2010
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	12/557463	09/10/2009		7,957,912	06/07/2011
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	11/982405	10/31/2007		7,904,249	03/08/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	09/618579	07/18/2000	 	7,024,312	04/04/2006
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	09/539486	03/30/2000	 	7,058,515	06/06/2006
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	09/494282	01/18/2000		6,917,882	07/12/2005
	US	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS	Granted	11/075231	03/07/2005		7,421,347	09/02/2008
	US	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	09/626929	07/27/2000	 	6,319,714	11/20/2001
	GB	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	09/694863	10/23/2000	 	6,521,453	02/18/2003
	US	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	11/987555	11/30/2007		8,029,988	10/04/2011
	US	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	12/557829	09/11/2009		8,058,001	11/15/2011
	CA	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Published	2320697	01/18/2000	2320697	 	 
	CH	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	EP	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	EP	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Published	10075153.6	01/18/2000	2253704	 	 
	BE	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	DK	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	FR	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	DE	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	NL	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	00909923.5	01/18/2000		1072010	04/21/2010
	US	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION	Granted	09/626595	07/27/2000	 	6,479,652	11/12/2002
	US	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS	Granted	09/723520	11/27/2000	 	6,413,745	07/02/2002
	US	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS	Granted	09/723473	11/27/2000	 	6,358,740	03/19/2002
	US	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS	Granted	09/517933	03/03/2000	 	6,365,377	04/02/2002
	US	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION	Granted	12/557434	09/10/2009		8,108,150	01/31/2012
	US	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION	Granted	11/818237	06/12/2007		8,224,580	07/17/2012

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION	Granted	10/386903	03/10/2003	0198988	7620500	11/17/2009
	JP	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION	Granted	2003-576577	03/10/2003	 	4851687	 
	EP	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION	Published	03711540.9	03/10/2003	1488335	 	 
	US	INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING	Granted	11/677505	02/21/2007		8,014,961	09/06/2011
	US	INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING	Granted	10/154936	05/23/2002		7,462,469	12/09/2008
	US	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	12/557746	09/11/2009		8,170,806	05/01/2012
	US	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	11/973805	10/09/2007		7,873,499	01/18/2011

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	11/210239	08/22/2005		7,430,477	09/30/2008
	US	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	13/434261	03/29/2012		8,589,085	11/19/2013
	US	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	09/495668	02/01/2000		6,961,664	11/01/2005
	CA	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS	Granted	2337949	01/18/2000		2337949	03/15/2011
	US	METHOD AND SYSTEM USING SYSTEMATICALLY VARIED DATA LIBRARIES	Granted	10/225564	08/20/2002	 	7,873,477	01/18/2011
	US	METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS	Granted	10/232770	08/30/2002	 	7,702,464	04/20/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	US	METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS	Granted	13/229228	09/09/2011	 	8,457,903	06/04/2013
	EP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Published	12/979,637	12/28/2010	2011/0161265	 	 
	BE	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	FR	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	GB	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	DE	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	DK	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	BE	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	GB	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	DE	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	NL	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	 	 	 
	FR	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	CH	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	DK	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10181057.0	09/28/2010		2390803	11/20/2013
	CH	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	NL	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	JP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	2003-573522	03/03/2003	 	5,319,865	07/19/2013
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	11/981577	10/30/2007		7,751,986	07/06/2010
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	11/706034	02/12/2007		7,747,393	06/29/2010
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Allowed	11/429628	05/05/2006	2006/0205003	 	 
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10/629351	07/29/2003		7,747,391	06/29/2010
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	10/379378	03/03/2003		7,783,428	08/24/2010

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	EP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	05779687.2	06/21/2005		1761879	08/14/2013
	EP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Allowed	03743748.0	03/03/2003	1493027	 	 
	EP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Published	10181000.0	09/28/2010	2278509	 	 
	US	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Granted	11/981578	10/30/2007		8,762,066	06/24/2014
	EP	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES	Published	10181159.4	09/28/2010	2315145	 	 

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.74

In-License Agreements
[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.77

In-Licensed Patents

																								
	Country	Application Title	Application Status	Application No.	Filing Date	Publication No.	Pat. No.	Issue Date
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]	[***]		

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]			
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]
[***]
	[***]	[***]
[***]
		
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

																								
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.80

Invoice Requirements

All payments subsequent to the Upfront Payment to Codexis due under this Agreement shall be paid within [***] days after the date of receipt of the relevant Invoice by GSK, and as according to Article 7 of this Agreement. The Upfront Payment to Codexis shall be paid within [***] after receipt of the relevant Invoice from Codexis by GSK in accordance with Section 7.1.
The invoice should include the following details:
(a)    “INVOICE” stated at the top and addressed to 
GlaxoSmithKline Intellectual Property Development Limited
980 Great West Road, 
Brentford, 
Middlesex, 
TW8 9GS 
United Kingdom
(b)    Bank details
(c)    Codexis letterhead. 
(d)    Invoice Number, Currency and Date
(e)    Complete Name, Address, Contact name and number
(f)    Amount being invoiced
(g)    VAT Registration number where VAT is being charged
(i)    Following GSK Information: 
• GSK Contact for Invoices : [***]

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.112

Restricted Enzymes

To be provided in accordance with Section 3.7.1

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.117

Technology Transfer Plan

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Technology Transfer Plan
Establishment of Codexis CodeEvolver®
Directed Evolution Technology
at GSK’s site in Upper Merion, PA

			
	

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

1.    EXECUTIVE SUMMARY
The scope of this Plan is the full implementation of Codexis’ biocatalyst screening and CodeEvolver® directed evolution technology within GlaxoSmithKline (GSK), in order to augment GSK’s capabilities in cost efficient development and manufacture of pharmaceutical compounds (also referred to within the plan as API’s). The complete transfer of Codexis technology to one GSK site (Upper Merion, PA (UM)) will be accomplished across the following three Waves:

1)    Transfer of the Codexis [***]. 
2)    Enabling GSK to practice CodeEvolver® comprising: 
a. GSK laboratory set-up; including transfer of the Codexis informatics [***].
b. Training in Codexis labs with Technology Transfer Evolution [***]
c. Training in GSK labs with Technology Transfer Evolution [***]
3)    Demonstration of proficiency of the GSK team with Technology Transfer Evolution [***]. 

Codexis and GSK will establish dedicated Training Teams to facilitate the Technology Transfer.  Codexis Team (as defined in Section 2.2.5 (b) in the Platform Technology Transfer, Collaboration, and License Agreement) will include personnel for [***]. Based on the work plan, [***]. 
Likewise, dedicated GSK personnel will shadow Codexis Team and then conduct evolution programs at GSK, to set up and deploy equipment, and provide general program management support.  [***].

2.  TECHNOLOGY TRANSFER PROGRAM SCOPE
2.1  WAVE 1: TRANSFER OF CODEXIS SCREENING CAPABILITIES TO GSK
[***]
[***] 
[***]
CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

[***] 
[***]  

[***]

															
	Step	Inputs	Process	Output
	Materials
		[***] 
[***]
	[***]	[***]
		[***]	[***]	[***]
		[***]	[***] 
	[***]
		[***]	[***] 
	[***]
	Methods
		[***]	[***]	[***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

												
		[***]	[***]	[***]
		[***]
[***]
	[***] 
	[***]
		[***]  
[***]
	[***]	[***] 

    Wave 1 Milestone Success Criteria
1.    [***]
2.    [***]
3.    [***]
4.    [***]

[***]

2.2  WAVE 2: ENABLING GSK TO PRACTICE CODEEVOLVER®
[***]
[***]
1)    [***]
2)    [***]
CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

3)    [***]
[***]
[***]

															
	Step	Inputs	Process	Output
	Materials
		[***]	[***] 
	[***]
	Methods
		[***]	    [***]
	[***]
		[***]	    [***]
	[***]
		[***]	    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
	[***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

												
		[***]	    [***]
    [***]
	[***]
		[***]	    [***] 
    [***]
	[***]
		[***]	    [***]
    [***]
	[***]
		[***]	    [***]
    [***]
	[***]
		[***]	    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
	[***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

												
		[***]	    [***]
    [***]
	[***]
		[***]	    [***] 
    [***] 
	[***]
		[***]	    [***]
    [***]
	[***]
		[***]	    [***]
    [***]
	[***]
		[***]	[***]	[***]
    [***]
    [***]

		[***]	[***]	[***]
    [***]
    [***]

[***]
CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

[***]

[***]

    Wave 2 Milestone Success Criteria
1.    [***]
2.    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
3.    [***]

2.3  WAVE 3: DEMONSTRATED PROFICIENCY OF GSK TEAM ACROSS TWO INDEPENDENT PROJECTS
[***]
[***]
[***]
    [***]
    [***]
    [***] 
    [***]
    [***]
    [***]

[***]

    Wave 3 Milestone Success Criteria
4.    [***]
    [***]
    [***]
CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

    [***]
    [***]
5.    [***]
    [***]
    [***]
    [***]
    [***]  
2.4 INDICATIVE GANTT CHART
[***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

3.  PERSONNEL COMPETENCY REQUIREMENTS
Codexis will provide the following competencies to support successful technology transfer:
    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
    [***]    
    [***]
    [***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

APPENDIX I - TRANSFER OF MATERIALS (WAVE 1)

[***]
1)    [***]
A)    [***]
																		
	Platform	Short
Name
	# of 96-well
Plates
per Panel
	# of Enzymes
per Kit
	Format	Quantity
Provided

	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]

[***]
[***]
[***]
[***] [***]

B) [***]
    [***]
    [***]
    [***]
CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

2)    [***]
															
	Platform	Short Name	Format	Number of Enzymes	Quantity
Provided

	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]		[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]

3)    [***]
									
	Platform	Short
Name
	Format
	[***]	[***]	[***]

[***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

APPENDIX II – EQUIPMENT LIST
			
	Principal Equipment
	[***]
	[***]
	[***]  

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***] 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***] 

	[***]
	[***]
	[***] 

	[***]
	[***] 

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

APPENDIX III - SOFTWARE LIST

    [***]
    [***]
    [***]
    [***]
    [***]
    [***]
    [***]

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

APPENDIX IV- PROTOCOLS AND SOP LIST

[***]

    
[***]
[***] 
[***]
[***]
[***]

*************************************************************************

[***]

[***] 
[***]
[***]
[***] 
    
*************************************************************************

[***]

[***]
[***]
[***]

*************************************************************************

[***]

[***]
[***]
[***]
[***]

*************************************************************************

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 17

[***]
[***]
[***]
[***]

*************************************************************************

[***]

[***]
[***]
[***]

*************************************************************************

[***]

[***]
[***]
[***]
[***]

*************************************************************************

CODEXIS CONFIDENTIAL INFORMATION

Exhibit 2.5

Material Transfer Record Form

GSK and Codexis

Capitalized terms used herein that are not defined herein shall have the meanings set forth in the Platform Technology Transfer and License Agreement dated 10 July 2014 made between GSK and Codexis.

In connection with the performance of the Agreement and pursuant to the terms of the Agreement: 

(i) GSK will transfer to Codexis the Materials set forth below;
 and/or 
(ii) Codexis will transfer to GSK the Materials set forth below. 

This Material Transfer Record Form shall be used as the record of all such Material transfers, whether from GSK to Codexis or from Codexis to GSK. 

Transfer Date: 

Description of Materials 

Description of Research for which the Material(s) will be Used

Signature – GSK Scientific Lead ...............................

Date

Signature – Codexis Scientific Lead ................................

Date

Note:  This MTR is to be completed and signed by the Codexis and the GSK Scientific Lead for each transfer.  A copy of each completed MTR is to be timely provided to Alliance Manager (for GSK) and to the Alliance Manager (for Codexis).  This MTR should not be used to transfer any materials in which the Transferor believes that Third Parties have rights, or which the Transferor believes infringe or misappropriate any Intellectual Property rights held by any Third Party. If there are any questions about the appropriateness of a transfer, please contact the GSK Scientific Lead or the Codexis Scientific Lead, as appropriate, identified herein before making the transfer. 

CODEXIS CONFIDENTIAL INFORMATION

CODEXIS CONFIDENTIAL INFORMATION

Exhibit 3.3.1

Codexis Strain-Related Protocols

[***]

[***]

[***]

[***]

CODEXIS CONFIDENTIAL INFORMATION

Exhibit 8.5.4

Third Party In-License Agreements

[***]

CODEXIS CONFIDENTIAL INFORMATION

Exhibit 9.6

Press Release

    - 1 -

SV\1263057.27

Exhibit 13.14

Prevention of Corruption – Third Party Guidelines

PREVENTION OF CORRUPTION – THIRD PARTY GUIDELINES
The GSK Anti-Bribery and Corruption Policy (POL-GSK-007) requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which GSK (whether through a third party or otherwise) conducts business.  POL-GSK-007 requires all GSK employees and any third party acting for or on behalf of GSK to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all GSK business.  GSK values integrity and transparency and has zero tolerance for corrupt activities of any kind, whether committed by GSK employees, officers, or third-parties acting for or on behalf of the GSK. 
Corrupt Payments – GSK employees and any third party acting for or on behalf of GSK, shall not, directly or indirectly, promise, authorize, ratify or offer to make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual (or at the request of any individual) including a “government official” (as defined in the glossary section) for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage or to improperly assist the company in obtaining or retaining business.  
Government Officials – Although GSK ́s policy prohibits payments by GSK or third parties acting for or on its behalf to any individual, private or public, as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate, this policy is particularly applicable to “payments” of “anything of value” (as defined in the glossary section), or at the request of, “government officials” (as defined in the glossary section).
Facilitating Payments – For the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as payments to an individual to secure or expedite the performance of a routine government action by government officials) are no exception to the general rule and therefore prohibited.
GLOSSARY
The terms defined herein should be construed broadly to give effect to the letter and spirit of the ABAC Policy.  GSK is committed to the highest ethical standards of business dealings and any acts that create the appearance of promising, offering, giving or authorizing payments prohibited by this policy will not be tolerated.  
Anything of Value: this term includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses, entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value.  
Payments: this term refers to and includes any direct or indirect offers to pay, promises to pay, authorizations of or payments of anything of value.  
    - 1 -

SV\1263057.27

Government Official shall mean:
Any officer or employee of a government or any department, agency or instrument of a government;
Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government;
Any officer or employee of a company or business owned in whole or part by a government;
Any officer or employee of a public international organization such as the World Bank or United Nations;
Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or
Any candidate for political office

    - 2 -

SV\1263057.27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]